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 Tumor vascularization is an important control point in cancer progression and its 
inhibition is a promising approach to cancer therapy. Stromal-derived factor-1α (SDF-1α or 
CXCL12) is a chemoattractant for lymphocytes, hematopoietic progenitor cells, and vascular 
endothelial cells.  SDF-1α binds to the CXCR4 receptor on cell surfaces and to heparan sulfate in 
cell membranes and the extracellular matrix.  We hypothesized that SDF-1α is an important 
mediator of tumor vasculogenesis, recruiting bone marrow-derived endothelial progenitor cells 
to tumors.  We evaluated the role of SDF-1α in the adhesion of bone marrow-derived lineage-
negative cells (Lin¯  BMC) to the murine Lewis lung adenocarcinoma (LLCaB subclone), both in 
vitro and in vivo.  LLCaB lung and liver metastases expressed significantly elevated levels of 
SDF-1α compared to normal tissue from naïve controls and primary tumors.  SDF-1α expression 
inversely correlated with tumor size, implicating involvement in early tumor development. SDF-
1α was detected on ~30% of blood vessels in primary and metastatic tumors by double 
immunocytochemistry staining and on endothelial cells within primary cultures of dissociated 
LLCaB tumors (DTC).  Lin¯  BMC enriched for Sca1+cKit+ (LSK) cells, including endothelial 
progenitors and CXCR4+ cells, were used for subsequent adhesion studies.  LSK cells 
preferentially adhered in vitro to DTC, compared to other target cell types.  Pre-incubation with 
anti-CXCR4 antibody or the CXCR4 antagonist AMD3100 decreased adhesion of LSK cells by 
50%.  Biolocalization of adoptively-transferred EGFP-Lin¯  BMC in tumor-bearing wild-type 
mice was evaluated by qPCR for the egfp-transgene.  A significantly greater number of Lin¯  
BMC localized to metastases 2-3 days after intravenous injection than to adjacent healthy tissue, 
normal organs, or primary tumors.  Control CXCR4¯  EGFP-dermal fibroblasts showed 
significantly less tumor localization.  One-week post-injection, Lin¯  BMC were still detected in 
every metastasis, suggesting that BMC were retained and/or had replicated.  These data support 
the hypothesis that the biolocalization of circulating Lin¯  BMC to tumors is SDF-1α-mediated.  
We have also put forth the novel proposal that SDF-1α promotes early tumor vasculogenesis as a 
tumor endothelium-associated adhesion molecule for circulating CXCR4+ Lin¯  BMC.  These 
findings may aid our understanding of the mechanism of tumor vascularization and the design of 
tumor-targeted therapy. 
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CHAPTER I:  INTRODUCTION 
Cancer is a disease in which cells undergo uncontrolled proliferation, leading to invasion 
into adjacent tissues and metastasis to other organs in the body via the circulatory system (1-3;3). 
In the 1970’s Dr. Judah Folkman pioneered the idea that angiogenesis was an important point in 
the control of cancer progression and that its inhibition would be a valuable new approach in 
cancer therapy (4;5). This is now a widely accepted theory and there has been considerable focus 
on designing therapies that could potentially target developing blood vessels. Despite significant 
advances in cancer research, the mechanism by which tumor cells metastasize and acquire 
angiogenic phenotypes is not fully understood. Although there has been substantial progress in 
the field of cancer treatment and improvement in survival and quality of life for some patients, 
cancer can remain a devastating diagnosis. Hence, it is important to enhance our understanding 
about the important mediators involved in the process of tumor vascularization and growth that 
may aid in the design of superior therapy. 
 
General Properties of Tumors 
All cancers arise gradually as the cells are unable to correct mutations that arise.  These 
errors could be due to several factors including, but not limited to, exposure to chemical 
carcinogens, ionizing radiation, viral or bacterial infection, genetic mutations, hormonal 
imbalance, immune-system dysfunction, and/or hereditary factors. Such factors could lead to 
mutations in tumor suppressor genes, proto-oncogenes and DNA repair genes and cause the cells 
to undergo uncontrolled cell division and lose their capacity for apoptosis and senescence. 
Tumorous cell clusters rely on the diffusion of oxygen and other essential nutrients for growth; 
this process is inadequate once tumors become 1-2 mm2 in size (4;5).  The growth of these 
  
 
2
micro-tumors is restored if they undergo angiogenesis i.e. formation of new vasculature. Thus, 
tumor vascularization constitutes an important control point in cancer progression and its 
inhibition has been suggested to be a valuable approach to cancer therapy.  
Many groups have reported that tumor blood vessels are morphologically and 
physiologically heterogeneous; with abnormal arterio-venous architecture, irregular diameter and 
aberrant branching (6;7).  Tumor blood vessels are devoid of a complete basement membrane, 
smooth muscle cells, and pericytes, and are leaky.  This abnormal vascular architecture is 
thought to be responsible for the high intra-tumor pressure, erratic blood shunting, and hypoxia 
present in tumors (7). Several hypoxia-induced genes and proteins that are expressed or 
upregulated in tumors have also been identified.  
Most tumors are hypoxic in nature (7-9). Tumors rapidly outgrow their blood supply, 
creating regions where the oxygen concentration is significantly lower than in healthy tissues. 
Hypoxia is likely a result of the uncontrolled cell proliferation, creating a higher cell density, and 
thus taxing the local oxygen supply. Hypoxic zones within tumors are usually resistant to 
radiotherapy and chemotherapy and can ultimately contribute to recurrence (7;9). Hypoxia and 
hypoxia-regulating proteins have been demonstrated to be associated with a worse prognosis (10-
12), making it a determining factor of cancer progression and therapeutic response (7;9;13;14) .  
Hypoxia-induced factor (HIF) is a dimer of α and β subunits, each of which has three 
isoforms. HIF-1 is the best studied among these. In normoxic conditions the enzyme prolyl-
hydroxylase (PH) is active and causes hydroxylation of HIF-1α. A component of E3 ubiquitin 
ligase complex binds the hydroxylated HIF-1α and earmarks it for degradation. In contrast, under 
hypoxic conditions PH is inactive, which leads to the accumulation of HIF-1α. This leads to the 
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dimerization of HIF-1β with HIF-1α and the active dimer binds to the hypoxia-response element 
(DNA binding site) resulting in the transcription and synthesis of downstream proteins (7).   
HIF-1 is reported to be over expressed in numerous human tumors (7;15) and is 
recognized as an important regulator of tumor proliferation. Its expression influences several 
downstream signaling pathways that affect cell proliferation, survival and migration, matrix 
physiology, and angiogenesis. Vascular endothelial growth factor (VEGF), stromal-derived 
factor (SDF-1), matrix metalloproteinase (MMP), insulin growth factor (IGF-2), and tumor 
growth factor (TGF) are among the well-studied target genes of HIF-1 and influence 
angiogenesis, anaerobic metabolism, vasodilatation, respiration, erythropoesis and apoptosis. 
These events ultimately lead to malignant progression and increased tumor aggressiveness 
(Review in (7).  
Hypoxia is the most potent stimulator of VEGF, which is a well studied growth factor in 
tumor biology (8).  VEGF is an important regulator of blood vessel growth and permeability, and 
is upregulated in many human and experimental tumors. Many anti-VEGF and anti-VEGF 
receptor (VEGFR) monoclonal antibodies and small-molecule inhibitors are in clinical 
development for use as cancer therapeutic agents (16). VEGF in turn induces the expression of 
SDF-1α (14;17); SDF-1α and its receptor CXCR4, have been implicated in tumor angiogenesis 
and organ-specific metastasis. Low oxygen tension also regulates angiopoietins (ANG-1 and 
ANG-2) and their receptor (Tie-2), which have wide-ranging effects on tumor angiogenesis, 
inflammation, and vascular extravasation of cells. Although the role of angiopoietins in tumor 
angiogenesis is controversial, ANG-2 is reported to be pro-angiogenic and ANG-1 is thought to 
be a stabilizing factor for tumor vasculature (18;19). ANG-1 has also been demonstrated to bind 
integrins, which are strongly implicated in cancer progression. Integrin α5β1 is expressed mainly 
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on vascular endothelial cells and is upregulated along with fibronectin in tumor neovasculature. 
Integrins αvβ3 and αvβ5 are involved in angiogenesis, and are expressed in malignancies such as 
melanomas, gliomas, and breast, prostate, and colon cancers (16). VEGF and hypoxia also 
directly influence the expression of integrins on endothelial cells (20). The expression of certain 
ephrins by endothelial cells is also influenced by hypoxia (21-23). It has been shown that HIF-2α 
plays an important role in vascular remodeling during tumor vascularization through activation 
of ephrin A1 on endothelial cells (21). The receptors for ephrins (Eph receptors) have been 
correlated with the growth of solid tumors. Eph receptors have been shown to be overexpressed 
in a wide range of cancers including melanoma, breast, prostate, pancreatic, gastric, and 
esophageal and colon cancer as well as hematopoietic tumors (24). E-selectin (25) and its 
carbohydrate ligands (Sialyl Lewis-a, and Sialyl Lewis-x) have also been shown to be induced 
by hypoxia. Expression of Sialyl Lewis-a/x is reported to be elevated during hypoxia-induced 
cancer progression in locally advanced cancers (26;27).  Thus, hypoxia contributes significantly 
to the invasive, metastatic and angiogenic phenotypes of aggressive cancers.  
 
Tumor Vascularization 
 It is generally accepted that there are two main processes by which new blood vessels are 
created in tumors: 1) angiogenesis and 2) vasculogenesis. Several researchers are of the opinion 
that the two processes occur either concomitantly or sequentially (28;29). Vascular co-option and 
vasculogenic mimicry have also been suggested to give rise to tumor vasculature (30). 
 Tumor Angiogenesis 
Angiogenesis is defined as the physiological process involving the formation of new 
blood vessels from pre-existing vessels (19;31-33). It is a normal process in embryonic growth 
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and development, wound healing, and the menstrual cycle. As aforementioned, it is now well-
established that tumors require angiogenesis to grow and metastasize to secondary sites in the 
body (5). The basic process involved in angiogenesis is proliferation of existing, activated 
vascular endothelial cells (VEC) culminating in the formation of tube-like structures for blood 
flow. 
Tumors secrete angiogenic factors that activate VEC in the blood vessels in adjacent 
tissue. The activated VEC proliferate and release proteases and other enzymes, which modify the 
basement membrane and extracellular matrix (ECM). Integrins on the surface of VEC interact 
with their respective ligands in the ECM, which leads to their assisted and directional migration 
towards the tumor-derived chemotactic signal. Additional enzymes, such as matrix 
metalloproteinase, remodel the surrounding ECM for the “sprouting” vessel.  The developing 
blood vessels roll up to form tube-like structures and finally the individual conduits connect to 
form blood vessel loops. These blood vessels are stabilized by smooth muscle cells (SMC) or 
pericytes, and the blood flow begins (34). 
Many proteins like acidic and basic fibroblast growth factors (aFGF, bFGF), 
transforming growth factor (TGF-β), hepatocyte growth factor (HGF), VEGF, angiogenin, 
angiopoietins, interleukin-8 (IL-8), SDF-1α, integrins, selectins, and ephrins have been 
implicated as positive regulators of angiogenesis in tumors (35-37). These proteins are produced 
by various cell types including fibroblasts, endothelial cells, tumor cells, and immune cells in the 
microenvironment, and cause proliferation and recruitment of VEC from adjacent blood vessels 
towards neo-vasculature in tumors (38). 
The major signaling pathway in tumor angiogenesis is thought to involve VEGF and its 
receptors. Suppression of tumor growth and angiogenesis have been demonstrated clinically by 
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blocking VEGF and VEGFR2 in approaches including an anti-VEGF antibody (Avastin®), 
VEGFR2 mutant, anti-VEGFR2 antibodies, small molecule inhibitors of VEGF receptor tyrosine 
kinase (RTK), and soluble VEGF receptors (39-41).   
The CXC chemokine family consists of ligands and receptors that interact to produce 
pro-angiogenic and angiostatic effects (42). Activation of the chemokine receptor CXCR2 by 
pro-angiogenic ligands or triggering of CXCR4 by ligand CXCL12/SDF-1 has been reported to 
promote angiogenesis. Blocking the function of CXCR2 by specific antibodies has been shown 
to inhibit pancreatic cancer cell-induced angiogenesis (43). In contrast, engagement of CXCR3 
by angiostatic chemokines has been demonstrated to inhibit vascularization.  
Inhibitor of differentiation-1 (Id-1) gene has been demonstrated to confer angiogenic 
property like migration and capillary-like tube/cord formation on fully differentiated human 
umbilical vein endothelial cells (HUVEC). In the in vivo experiments in ischemic limb injury 
model, Id1-overexpressing HUVEC increased capillary density and improved limb salvage 
compared to control HUVEC. Thus Id-1 has been shown to contribute to therapeutic 
angiogenesis (44). Id-1 has also been reported to regulate angiogenesis through the 
transcriptional repression of thrombospondin-1, a potent inhibitor of angiogenesis (45). 
Several investigators have demonstrated that sprouting angiogenesis in tumors could also 
be negatively regulated to restrict tumor growth by using naturally occurring angiostatic agents 
like thrombospondin-1, prolactin, platelet factor-4, interferon-α, interferon-γ inducible protein-
10, angiostatin, endostatin, tumstatin, etc. Although the receptors for several of these angiostatic 
proteins have been indentified, their mode of action is not clearly understood (Reviewed in (45-
47). Sprouting angiogenesis in tumors remains an attractive point of control in tumor 
progression.  
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 Tumor Vasculogenesis 
Vasculogenesis is defined as the process by which the primary vascular network 
(primitive plexus) is created by hematopoietic stem cells (HSC) and endothelial progenitor cells 
(EPC) in the developing embryo. The process is initiated by the formation of blood islands 
containing precursors called hemangioblasts. The fusion of these blood islands forms the primary 
capillary plexus and their elongation leads to generation of blood vessels.  The role of post-natal 
vasculogenesis has been recently recognized and is a topic of much debate. 
Asahara’s group was the first to isolate endothelial progenitor cells (EPC) from bone 
marrow (BM) and demonstrate the mobilization and contribution of EPC to neo-vascularization 
in an ischemic injury model (48;49). This initiated the exploration of the involvement of BM-
derived EPC in tumor vascularization via post-natal vasculogenesis. When this project was 
started in 2006, there were 3 out of a total of 9 reports that demonstrated the incorporation of 
BM-EPC in developing vasculature. Tumor-localization of EPC was shown to be mediated by 
VEGFR-1/2 and Selectins (50-52). Since then many investigators have implicated the 
importance of hypoxia-induced proteins in localization of BMC to tumors (Table 1).  There are 
conflicting reports about the contribution of BM-derived EPC to tumor vascularization: only 
12/28 (43%) reports have demonstrated BMC-mediated vasculogenesis, (Table 1). In addition, 
the mechanism by which BM-derived cells might be mobilized from bone marrow, recruited, and 
retained in tumors is not clearly understood. Recently Nolan et al. demonstrated that BM-derived 
cells contributed to tumor vascularization in early tumors, but as tumors progressed these cells 
were gradually replaced by tissue-derived EC (53). Other reports indicate that the BM-derived 
EPC acted as the angiogenic switch and were responsible for the advancement of micro-
metastases (28;54).  Nevertheless, several other reports have indicated that although bone  
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Table 1: Literature Summary of the Contribution of Bone marrow-derived Endothelial 
Progenitor Cells in Tumor Vasculogenesis 
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BMC (Bone Marrow Cells), EPC (Endothelial Progenitor Cells), BV (Blood Vessels); B6RV2 lymphoma , C6 glioma, MCA/120 fibrosarcoma,B16F1 murine melanoma, TS/A 
mammary carcinoma, N202.1A mammary carcinoma, B15/BL melanoma, LLC/3LL Lewis lung carcinoma, Namalwa, Granta 519, B6RV2 Lymphoma, RT-2 Rat glioblastoma, 
KR158 astrocytoma, GL261 glioma,N202 breast carcinoma, B16F10 murine melanoma, PyMT spontaneous tumor, SMA-560 glioma, hNB Human neuroblastoma, MPNST 
Malignant peripheral nerve sheath tumor, TG1-1 mammary tumor, B16F10 murine melanoma, MT1A2 mammary carcinoma, SK-N-BE Human neuroblastoma, TMA 1202 
human prostate adenocarcinoma, Pan-O2 pancreatic, EL4 lymphoma, U251 and U87MG glioblastoma; PHD2 prolyl hydroxylases 
 
YEAR AUTHOR REF TUMOR RESULTS BMC in tumors 
EPC in 
tumor BV 
2001 Lyden (50) B6RV2, LLC Anti-VEGFR1 and VEGFR2 antibodies ablated tumor growth + + 
2003 Vajkoczy (51) C6 Selectins and PSGL-1-mediated localization of  embryonic EPC + + 
2003 De Palma (55) 
TS/A, N202.1A, 
B15/BL, 
LLC/3LL 
BM-EPC not detected in tumor vasculature + – 
2003 Capillo (56) Namalwa, Granta 519 EPC were mobilized in tumor bearing mice ? – 
2004 Göthert (57) LLC, B6RV2 BMC did not contribute to tumor endothelium –/+ – 
2004 Li (52) TMA 1202 BMC-mediated vascularization in poorly differentiated 
adenocarcinoma + + 
2005 Bagley (58) MDA-MB-231 EPC and pericytes stabilized tumor vasculature but did not initiate vasculogenesis + ? 
2005 Jodele (59) SK-N-BE MMP9-mediated recruitment of BMC to tumors + ? 
2005 Patil (60) LLC LSK localized to tumors did not incorporate into tumor BV + – 
2006 Santarelli (61) RT-2 GFP+CD34+Flk1+ cells incorporated into tumor vasculature + + 
2006 Aghi (62) KR158, GL261 SDF-1α-mediated localization of EPC to glioma + + 
2006 Li (63) N202, LLC α4β1-mediated homing to Lin¯  cells to tumor vasculature + + 
2006 Emerson (64) B16F10 VEGF and PlGF mediated vasculogenesis + + 
2007 Nolan (53) B6RV2, LLC, B16F0, PyMT 
 
BM-EPC recruited to the periphery of tumors 
 
+ + 
2008 Tabatabai (65) SMA-560 Anti-Eselectin antibody the number of LSK cells in tumor decreased by 85% + ? 
2008 Gao (28) LLC, PyMT BM-EPC recruited to micro-metastases and acted as angiogenic 
switch for tumor progression + + 
2008 Mahler (66) hNB, MPNST Decrease in BM-EPC in HSV-treated tumors + ? 
2008 Suriano (67) TG1-1 BM-EPC detected in tumors in presence of estrogen + ? 
2008 Purhonen (68) B16F10 VEGFR2+ cells not mobilized from BM in presence of tumor + – 
2008 Ahn (69) MT1A2, TG1-1, B16F1, LLC BMC infiltrating tumors were not EPC + – 
2008 Reddy (70) Ewings Sarcoma SDF-1 stimulated migration of CD34+ to functional vessels + – 
2008 Du (71) Glioblastoma HIF1 recruited BMC to tumors + ? 
2009 Chan (72) 
HCT1116, 
SU.86.86, HT29, 
RKO 
PHD2-mediated infiltration of BM-derived CD11b+ and CD45+ 
cells + ? 
2009 Wickersheim (73) LLC, B16, TRAMP C1 BMC recruitment in poorly differentiated tumors + + 
2009 Folkins (74) C6 VEGF and SDF-1 dependent localization of BMC + ? 
2009 Murakami (75) 3LL Chemotherapy increased circulating EPC + ? 
2009 Madlambayan (76) LLC, B16, Pan-02,  EL4 CD31
+
 BM-derived cells in tumor-associated vasculature + + 
2010 Kioi (77) U251, U87MG Inhibition of HIF-1 and SDF-1/CXCR4 prevented influx of CD11b+ BMC and post irradiation tumor vascularization + + 
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marrow-derived cells localized to tumors they did not contribute to tumor vasculature (Table 1).  
Overall, based on current literature, the detection of EPC in tumor blood vessels ranges 
from < 1% to ~33% of tumor vasculature (51;61;73;78). This disagreement is thought to be due 
to the lack of universal consensus for EPC phenotype. Tumor type, and the stage and location of 
tumor have also been suggested to contribute to this debate  (Reviewed in (54;79;80). 
Nonetheless, several growth factors, chemokines, protein receptors, proteases, and signaling 
pathways have been demonstrated to be instrumental in mobilizing EPC into circulation and 
mediated their tumor-localization. In particular, key modulators of angiogenesis such as 
VEGF/VEGFR, SDF-1/CXCR4, selectin/selectin ligands and hypoxia-regulating proteins have 
been implicated in tumor vasculogenesis.  
Inhibitor of differentiation-1 (Id-1) is thought to be important in modulating the role of 
EPC in tumor development. Id-1 is reported to be a repressor of thrombospondin, regulator of 
ECM remodeling, angiogenesis and vasculogenesis (81). It was recently reported that angiogenic 
defects in Id mutant mice inhibited the growth of tumor xenografts (82). Inducible ribonucleic 
interference (RNAi)-mediated suppression of Id-1 in BM was reported to reduce the level of 
circulating EPC (ckit+VEGFR2+CD11b–) and impair the formation of pulmonary macro-
metastases (28).  
Despite the controversy, bone marrow-derived cells and post-natal vasculogenesis appear 
to be important in certain aspects of tumor growth and progression of the metastatic disease.  
 Vascular Co-Option 
 Co-opt vascularization is thought to occur when tumor cells localize to a well-
vascularized host organ and progress by co-opting with the host blood vessel. Hence, these 
tumors develop as blood vessel-dependent tumors as opposed to initiating tumor angiogenesis 
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(46;83).  Vascular co-option was first observed in C6 glioma in rat brains, where small tumors 
were well vascularized and the vasculature displayed characteristics of normal brain vessels. 
Vascular co-option has now been reported in several tumor types like murine Lewis lung 
carcinoma and ovarian cancer, human melanoma and Kaposi Sarcoma (46). The vessel that 
initially supported tumor growth later regressed in the glioma model. This was thought to be due 
to VEC apoptosis. Finally, the expression of Angiopoietin-2 and VEGF-mediated angiogenesis 
at the periphery of tumor mass was demonstrated to rescue tumor growth (46;83). Anti-VEGF 
therapies, that target developing tumor vasculature, are believed to inhibit maturation of vessels 
in the process of vessel co-option. 
 Vascular Mimicry 
 Vascular mimicry is defined as the formation of fluid-channels lined with tumor cells 
without the participation of VEC, BMC and independent of vascularization (6;46;84).  This is 
also referred to as ‘pseudo-vasculogenesis’ (6;46;84).  This has been observed in several 
aggressive tumors like melanoma, ovarian, prostatic and breast carcinomas (6;46;84).  Although 
the detailed mechanism of vascular mimicry is not known, it was suggested that special 
microenvironments caused tumor cells to dedifferentiate into a pluripotent embryonic phenotype 
and transdifferentiate into an endothelial cell-like phenotype. These tumor cells have been shown 
to express endothelial cell markers like CD34, CD105 and VE-Cadherin (85). 
 
Anti-angiogenic Strategies 
 As discussed earlier, tumor vascularization is a critical point of control in tumor 
proliferation and numerous clinically translatable anti-angiogenic therapies that target specific 
steps in tumor vascularization are under investigation. Anti-angiogenic therapies hold great 
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therapeutic potential for several reasons: 1) easy accessibility, 2) specificity, 3) low toxicity, 4) 
tumor cells drug resistance surmountability, and 5) applicability to a wide array of tumors 
(47;86;87).  
One possibility for vascular targeting is the use of antibodies and immunotoxins to kill 
tumor endothelial cells (TEC). Tumor endothelium is more easily accessible to targeting 
antibodies than tumor antigens, which require antibody extravasation.  However, this approach is 
constrained by the incomplete knowledge of antigens specific to TEC. Nonetheless, several small 
molecules and monoclonal antibodies that target various steps involved in tumor vascularization. 
Some of these therapeutic inhibitors include epidermal growth factor inhibitors (Cetuximab, 
Erlotinib), anti-HER-2 antibody (Herceptin), receptor tyrosine kinase inhibitors (Sunitinib, 
Sorafenib, Axitinib, Pazopanib, Lapatinib), TNF-α inhibitors (Lenaliomide, Thalidomide) and 
inhibitors of VEGF/VEGFR (Bevacizumab, Aflibercept, Cediranib, Apatinib), are being 
currently tested in combination with radiotherapy and/or chemotherapy in Phase III clinical trials 
for different types of cancers. Tumors can also be targeted by the local or systemic introduction 
of genetically modified cells that specifically localize to tumors and continually release anti-
angiogenic factors. Lal et al. were the first to report the implantation and survival of systemically 
injected endothelial cells (EC) within mouse gliomas in 1994 (31). Later, in a mouse 4T1 
mammary tumor model Zweibel et al. intravenously administrated EC that were genetically 
modified for recombinant human IL-2. These EC were reported to incorporate into tumor 
vasculature and significantly reduced the metastatic burden (88;89). Thus, the use of genetically 
modified EC was an attractive potential treatment strategy for delivering therapeutic agents to 
tumors. This approach has not been vigorously pursued in part because of the set backs in 
clinical gene therapy and limited availability of syngeneic human endothelial cells.  
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Bone marrow-derived hematopoietic stem cells (HSC) or endothelial precursors / 
progenitor cells (EPC) may offer an alternate option for tumor targeting using gene therapy 
(87;90). Wei et al. systemically injected embryonic EPC that were transfected with a suicide 
construct to convert the prodrug 5-fluorocytosine (5-FC) to its active form 5-fluorouracil (5-FU) 
into mice with tumors.  They saw an improvement in survival in the mice that also received 5-FC 
fusion protein, the substrate for the suicide gene (78). Thus, understanding the mechanism by 
which EPC localize to tumors and contribute to tumor vascularization could be exploited to 1) 
control vasculogenesis by arresting tumor growth, and 2) use genetically-modified autologus 
EPC as a therapeutic Trojan horse(91).   
 
Endothelial Cells  
 The innermost layer of all blood and lymphatic vessels consists of a single layer of 
specialized squamous epithelial cells called endothelial cells (EC)(92). They are typically flat, 
with a cobblestone morphology, and their long axes are oriented parallel to the direction of blood 
flow. The tight junctions and gap junctions help EC cells form epithelial sheets that restrict the 
extravasation of fluid, proteins, and cells from vasculature.  Yamashita summarized molecular 
markers that distinguished the murine vascular (i.e. arterial and venous) and lymphatic 
endothelial cells (93). This group also showed that all EC differentiate from common 
progenitors. VEGF is thought to guide the differentiation of VEGFR2+ progenitors into CD31+ 
VE-Cadherin+ endothelial cells. VEGF is also implicated in the maturation of ephrinB2-EphB4+ 
venous EC. On the other hand, Notch signaling in the presence of VEGF, TGF-β, mechano-
chemical stimuli like shear stress and high oxygen concentration in arterial blood were reported 
to be responsible for the differentiation of arterial EC. CXCR4 and ephrinB2 were two of the 
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markers shown to be expressed by arterial EC. VEGF-C and angiopoietins have been reported to 
be important for the generation of lymphatic EC (Prox1+LYVE1+VEGFR3+) (93). 
 Vascular Endothelial Cells  
 Vascular endothelial cells (VEC) line the lumen of all blood vessels in the circulatory 
system and are quiescent under normal physiological conditions. They function in maintenance 
of the selective barrier between circulating molecules and tissue, thrombosis, vasodilatation and 
vasoconstriction, and in inflammation and angiogenesis. This heterogeneity in function is due to 
the variation in morphology and protein expression in VEC in different organs and vascular 
beds. Additionally, this disparity is suggested to be due to cellular functions like nutrient uptake, 
waste removal, blood pressure regulation and neighboring cells arising under physiological and 
pathological conditions (92). Small molecules, water, and soluble proteins are transported across 
the endothelium by pinocytosis, while VEC in organs such as kidney and brain have  
fenestrations to perform functions like filtration and transportation of larger molecules (92).  The 
anti-coagulants and anti-thrombogenic substances, like von Willebrand factor (vWF also called 
coagulating factor VIII), produced by VEC maintain a non-thrombogenic barrier between 
platelets and sub-endothelial tissue (92).   Damage to the endothelium causes the release of pro-
thrombic agents that result in platelet aggregation and clot formation. Blood flow in vasculature 
is modulated by secretion of vasoconstrictors (endothelin, angiotensin, etc.) and vasodilators 
(nitric oxide, prostacyclin, etc.). Immune responses are controlled by regulating the interaction of 
lymphocytes with cell adhesion molecules on VEC. Several cytokines, chemokines, interleukins 
(IL-6, IL-8), and cell adhesion molecules (integrins, ICAM-1, ICAM-2, VCAM, L-selectin, E-
selectin, etc) have been established as important immune-modulators. It has also been reported 
that VEC uptake Ulex europaeus lectin 1(UEA-1) and acetylated low density lipoprotein (Ac-
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LDL) (94-96). Finally, when endothelium is damaged in response to tissue injury or during neo-
vascularization, as in embryonic development, menstruation, and tumor growth, the activated 
VEC enable and participate in formation of new blood vessels. Several unique proteins have 
been shown to be expressed by VEC in vivo and in ex vivo cultures. Some markers that are 
routinely used to identify VEC are listed in Table 2 (97).  
 Circulating Endothelial Cells 
 Circulating endothelial cells (CEC) were first detected in 1970 in blood smears based on 
their morphology from patients with vascular injury. On average, 99% of EC are quiescent and 
very few (~5 cells / mL) are detected in healthy individuals (98-100). Although the mechanism 
by which VEC detach from blood vessels is poorly understood, it is thought to be mediated by 
neutrophil attack, cytokines, and proteases activated by vascular injury. Thus, it is generally 
agreed that the number of CEC is correlated with the degree of endothelial injury (98-100). Cell 
adhesion proteins such as cadherins, integrins, and their ligands are also thought to be involved 
in this process. Although there is a lack of consensus on phenotypic identification, CEC are 
suggested to express vWF, CD146, and VE-Cadherin in the absence of CD45, CD14, and 
CD133.  Similar to vascular endothelial cells, CEC uptake Ulex europaeus lectin 1(UEA-1) and 
acetylated low-density lipoprotein (Ac-LDL). 
 Elevated numbers of CEC have been described in patients diagnosed with several 
different types of cancers. In this scenario it is not clear whether CEC are simply markers of 
altered vascular integrity or actually contribute to neoplastic progression (Reviewed by (99). In 
addition to VEC shed from activated tumor vessels, the increase in CEC could also be attributed 
to bone marrow-derived circulating endothelial progenitors (CEP) differentiating into CEC. It is 
suggested that CEC can be distinguished from CEP, by the expression CD133 (primitive stem  
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Table 2: Endothelial Cell Specific Markers 
 
Cell Surface 
Marker 
Cluster of 
Differentiation 
(CD) 
Cells that Express the 
Markers 
Endoglin CD105 EC, fibroblasts, and SMC 
E-selectin CD62E Activated EC 
PECAM-1 CD31 EC, and certain tumors 
P-selectin CD62P EC, platelets 
VCAM CD106 EC 
VE-Cadherin CD144 EC 
VEGFR1 - EC, Hematopoietic cells 
VEGFR2 CD309 EC, EPC 
vWF - EC, megakaryocytes 
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cell marker) on CEP (101). However, there is a need for further analysis of sorted and 
functionally tested CEC/CEP to identify specific markers recognizing individual cell types.   
 
Endothelial Progenitor Cells  
 Endothelial progenitor cells (EPC) are a sub-population of BM-derived cells that have the 
potential to differentiate into mature EC and contribute to the process of re-endothelialization 
and neo-vascularization (Figure 1) (48;63;64;83;90;102-110). These cells have generated much 
interest since they were proposed to have the potential for treating human vascular disease and to 
be a possible target to restrict tumor vascularization. However, there have been conflicting 
reports about the accurate identity, characteristics, and function of EPC.  The majority of EPC 
are thought to reside in bone marrow in close association with HSC and BM stromal cells. This 
association is hypothesized to provide the optimal environment for survival and growth of 
progenitor cells. Several cell surface proteins on HSC have been identified as putative markers to 
define progenitor cells that have the capability to differentiate into EC. Some of these proteins 
have been reported to be expressed by other cell populations (Table 3). The EPC and HSC have 
been suggested to arise from common precursor as they share common markers like CD34, 
CD133, and CD117 (Table 4). In addition, defining the identity of EPC is further complicated by 
the presence of circulating endothelial progenitors and circulating endothelial cells.  
Characteristics of Endothelial Progenitor Cells 
 The putative cell surface markers for EPC from multiple studies are shown in Table 5 
(Adapted from (105).   Several research groups have analyzed the phenotypic expression of 
endothelial cell specific markers on viable CD34+ and CD34+FGFR+ cells collected from BM, 
umbilical cord blood (UCB), and cytokine mobilized peripheral blood (PB) from human donors.  
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The CD34+ FGFR1+ cell were reported to co-express the primitive hematopoietic cell antigen, 
AC133/CD133 (aka Prominin-1 or PROM-1) and like the EC (1) grew slowly in culture, (2) 
were stimulated by fibroblast growth factor-2 (FGF-2) and VEGF, (3) gave rise to cells that 
express von Willebrand factor (vWF) and VE-Cadherin and (4) incorporated acetylated low- 
density lipoprotein (Ac-LDL).  This cell population was also reported to express EC-specific  
 proteins like CD34, FGFR, CD38, VE-Cadherin, ckit, CD31, VEGFR2, and CD133.  Thus, it 
was concluded that the CD34+FGFR+ population contained ECP (111).   Human CD34+ cells 
from different hematopoietic sources have been reported to express CD133 and VEGFR2. These 
cells when incubated with VEGF and FGF-2 on collagen were shown to differentiate into 
CD133¯  VEGFR2+ mature EC (112). CD133+ cells isolated from PB and cultured in VEGF and 
stem cell growth factor were also reported to express the markers for mature EC: CD31, CD34, 
VE-Cadherin, VEGFR2, Tie-2 and vWF (113). It has also been demonstrated that the BM-
derived EPC were CD133+, CD34+, VEGFR2+ and VE-Cadherin¯ .  EPC isolated from PB lost 
CD133 and gradually differentiated into mature EC in culture. A small sub-fraction of 
mononuclear cells of PB-derived EPC became CD133+/-, CD34+, VEGFR2+, CD14¯ , VE-
Cadherin¯ , and eNOS¯  after 4-7 days in culture. These cells, within several weeks in culture, 
acquired a mature EC phenotype: CD133¯ , CD34+/-, VEFGR2+, CD14¯ , VE-Cadherin+, eNOS+, 
and vWF+ (48;49;83;102-104;106;114).  Similar to progenitor cells from bone marrow and 
peripheral blood, tissue resident progenitor cells are also thought to be able to differentiate to EC 
(104). The most widely accepted phenotype used to define the human EPC appears to be 
CD34+CD133+VEGFR2+. These markers are used to characterize the early functional human 
angioblast and EPC. However, CD34+CD133+VEGFR2+ cells isolated from human PB and UCB  
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Figure 1: Endothelial Progenitor Cells are a Subpopulation of the Bone Marrow  
Cells not Committed to any Specific Lineage (Lin¯  BMC) (Adapted from (48;115) 
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Table 3: Endothelial Progenitor Markers Shared by Cells of other Lineages 
 
CD Number Common name and Synonyms Expression 
CD11b Integrin αM, Mac-1, CR3 Monocytes, granulocytes, 
macrophages, NK- cells 
CD13 Alanine aminopeptidase Epithelial cells, macrophages, 
granulocytes, synaptic membranes 
from the CNS 
CD14 LPS-R, Mo2 Macrophages, monocytes 
CD31 PECAM-1, GPIIa Platelets, monocytes, granulocytes, 
B-cell 
CD34 Mucosialin Hematopoietic progenitor cells, 
capillary endothelial cells, bone 
marrow stromal, mast cells 
CD38 Cyclic ADP ribose hydrolase Activated T-cells, Plasma cell, NK-
cells 
CD45 Protein tyrosine phosphatase, 
receptor type, C 
All hematopoietic cells except 
erythrocytes and plasma cells 
CD62L L-selectin, B-cells, T-cells, monocytes, 
neutrophils, eosinophils, NK- cells, 
bone marrow myeloid cells 
CD105 Endoglin Endothelial cell, bone marrow cell 
subset 
CD117 SCF-receptor, c-kit Progenitor cells 
CD133 Prominin-1, AC133 Stem cell subset 
CD144 VE-Cadherin Endothelial cell 
CD146 MUC18, P1H12 Endothelial cell 
CD309 VEGFR2, Flk-1 Endothelial cell 
CD331 FGFR1, Flt-2  
 Sca1, Ly6A/E, Ly6D HSC, liver sinusoid cells 
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Table 4: Classification of Human Hematopoietic Stem Cells (HSC), Endothelial Progenitor 
Cells (EPC), and Circulating Endothelial Cells (CEC) Based on Source of Origin and 
Protein Markers 
 
Cell type Source of origin Phenotypic marker 
HSC Bone marrow CD34, CD133, CD117 
EPC Bone marrow, peripheral blood, 
umbilical cord blood, parenchyma 
and tissue specific EPC 
CD34, CD133, CD117, VEGFR2, 
VE-Cadherin, FGFR 
CEP Bone marrow CD31, CD34, CD133, VEGFR2, VE-
Cadherin, CXCR4, CD146, vWF 
CEC Mature Endothelium CD34, VEGFR2, VE-Cadherin, 
CD146, vWF 
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did not differentiate into EC in vitro (Reviewed in (105).  Thus, the debate about EPC identity is 
far from over. 
 Currently human EPC are being isolated using 3 general approaches: 1) Peripheral 
mononuclear cells (MNC) cultured on fibronectin-coated tissue culture plates, 2) CD34+ cells 
cultured on fibronectin, reportedly giving rise to CD34+VEGFR2+ endothelial progenitor cells, 
and 3) MNC cultured in the colony forming unit-Hill (CFU-Hill) and endothelial colony forming 
cell (ECFC) assays. Although the CFU-Hill cells had characteristic properties and protein 
expression similar to EC, they neither formed capillaries nor proliferated extensively in vitro. 
The ECFC, on the other hand, have been shown to express antigens similar to endothelium and 
formed capillaries in vitro and in vivo (Reviewed in (105;116-118). 
 The bone marrow is comprised of the lineage-committed cells and the lineage-negative 
pluripotent stem / progenitor cells. The lineage-committed cells include mature blood cells like 
erythrocytes, monocytes, macrophages, dendritic cells, natural killer cells, and B- and T-cells. 
Studies in mouse models have shown that endothelial progenitors are a subset of the lineage-
negative BMC (Lin¯  BMC) (49). It is also reported that Lin¯ cKit+Flk1+ express the stem cell 
marker Sca-1 and have endothelial properties (53;119). Additionally, bone marrow-derived 
Lin¯ Sca1+cKit+ (LSK) are a good source of EPC (119) and have been reported to possess 
therapeutic potential for angiogenesis (80;115;120). The expression of CD133 on mouse EPC 
has not been absolutely confirmed, but like human EPC they have been shown to be CD34+, 
VEGFR2+, and CD45¯   (Figure 1 and Table 5). The murine EPC also express CD31 (PECAM) 
and von Willebrand Factor (vWF), and have the capacity to uptake Ac-LDL or bind lectins.  
Some of these properties are shared by HSC, CEP, and CEC. The expressions of VEGFR2 and 
VE-Cadherin have been recommended to be more specific for murine EPC (48;104;105;118). 
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Table 5: Surface Immunophenotype of Endothelial Progenitor Cells (Adapted from 105) 
 
Human Mouse 
Cell surface Markers 
Number of 
reports 
Cell surface Markers 
Number of 
reports 
CD34+ 14 VEGFR2+ 5 
CD133+ 8 cKit+ 5 
VEGFR2+ 6 Lin- BMC+ 3 
CD45+ 4 Sca1+ 2 
CD31+ 2 CD34+ 2 
CD14+ 2 CD13+ 2 
CD45¯  2 CD45¯  0 
Other markers Other markers 
CD11b+, CD62L+, FGFR1+, CD146+, 
VE-Cadherin+, CD3¯  
CD133+, CXCR4+, VE-Cadherin+ 
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 Overall, Lin¯ Sca1+cKit+ cells constitute a very minuscule proportion of total bone 
marrow cells. Their percentage in BM has been reported to range from 0.1 - 3% in wild-type 
mice (121-124). Bone marrow-derived Lin¯  cells from healthy C57Bl/6 mice were reported to 
contain 5%, 23% and 5% of Sca1+, cKit+ and Sca1+cKit+ cells respectively (125;126). Similarly, 
Koike et al. also reported that 4% of Lin¯  bone marrow cells were double-positive for Sca1 and  
cKit (120).  Friedlander demonstrated that Lin¯  BMC expressed Sca1 (4%), cKit (70%), 
VEGFR2 (2%), CD31 (81%) and Tie-1 (1%). They also showed that the Lin¯  BMC cell 
participated in neo-vascularization by incorporating into the developing blood vessel in a mouse 
cornea assay (63;108;110). Ikehara et al. described the differentiation of Lin¯  BMC into EPC.  
Lin¯  BMC  when cultured in presence of granulocyte colony stimulating factor (GCSF) and 
monocyte colony stimulating factor (MCSF) had elevated numbers of Flk1+CD45¯ , 
Sca1+CD45¯ , CD31+CD45¯   or CD146+CD45¯  cells.  When these cultured Lin¯  cells were 
intravenously injected into ischemic hind limbs of mice, the number of intramuscular capillaries 
in the ischemic leg increased substantially (120). The expression of CXCR4 on murine Lin¯  
BMC has also been reported and the presence of CXCR4 has been demonstrated to cause their 
migration in response to SDF-1α (127).  
Mobilization of Endothelial Progenitor Cells 
 Current literature indicates that coronary artery bypass surgery, myocardial infarction, 
burn injuries, hypoxia, exercise, and cancerous pathology lead to an increase in circulating 
endothelial progenitors in man (83;102;103;114). Involvement of EPC is thought to be essential 
for regeneration and repair of injured tissue and for vasculogenesis in tumors (48;83;103;128). 
EPC recruitment to the sites of neoangiogenesis is triggered by the increased availability of 
angiogenic growth factors and chemokines like VEGF, angiopoietin, and SDF-1α.  It is thought 
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that early infiltrating EPC recruit additional EPC by secreting VEGF, HGF, G-CSF and GM-
CSF (48). Furthermore, it has been shown that tumor-derived VEGF and PlGF, and possibly 
angiopoietin, activate matrix metalloproteinase-9 (MMP-9) within the bone marrow 
microenvironment. This results in the cleavage of membrane-bound kit-ligand (aka stem cell 
factor or SCF) from BM stromal cells. The increased level of soluble kit-ligand within the BM 
promoted the mobilization of stem and progenitors, including EPC and HSC. The mobilized EPC 
and HSC translocated from the osteoblastic zone to the vascular zone, where they proliferated, 
differentiated and were launched into the peripheral circulation (80;129;130). Several cytokines 
like IL-2, IL-3, IL-6, IL-8, IL-1β, erythropoietin, and stem cell factor (SCF) have been 
implicated in the mobilization of HSC and the increase in circulating EPC (38;83;90).  
 Recent evidence suggests that hypoxic environments, such as in tumors, regulate the 
angiogenic properties of BM-derived vascular progenitors. As mentioned earlier, expression of 
VEGF is regulated by hypoxia.  Recently, the hypoxia-responding integrins were shown to be 
involved in regulating the expression of SDF-1α and recruiting CXCR4+ EPC to ischemic tissue 
(131). Hordijk et al. described that in response to SDF-1α there was a loss of VE-Cadherin-
mediated endothelial cell-cell adhesion.  This loss of cell-cell adhesion was considered to be 
responsible for the increased permeability of BM endothelium and for the mobilization of human 
CD34+ cells from bone marrow (132).  In vitro, transmigration of CD34+ cells across the human 
umbilical cord vascular endothelial cells (HUVEC) and the bone marrow endothelial cell 
(BMEC) monolayer in response to all CXC, CC and CX3C chemokines, except MIP-1α, has also 
been reported.  The maximum effect was observed in response to SDF-1α (133). The CD34+ 
circulating hematopoietic progenitor cells have been shown to express CXCR4 and are 
chemoattracted to SDF-1α (110;134;135). Additionally, in vitro assays have demonstrated an 
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additive effect of VEGF on SDF-1α-mediated trans-endothelial migration of CD34+ progenitor 
cells (134). In conclusion, VEGF and SDF-1α appear to be most critical in mobilization of 
hematopoietic stem cells and endothelial progenitors in vitro and in vivo. 
Endothelial Progenitor Cells and Tumor Neo-vascularization 
Lyden published the first report in 2001 indicating that EPC localized to new blood 
vessels in tumors. They reported that Id-mutant mice had significantly fewer VEGFR2+ bone 
marrow-derived circulating endothelial progenitor cells. Additionally, compared to the wild-type 
mice, the tumor growth was demonstrated to be severely impaired in these Id-mutant mice. They 
concluded that VEGF-responsive BM-derived precursors were necessary for tumor angiogenesis 
and growth (50;53;136). Since then several conflicting reports, that either refuted or supported 
the theory of tumor vasculogenesis, have been published.   
There have been a few reports that indicated that BM-derived cells localized to tumors, 
but that these cells were not EPC and that they did not incorporate into the vasculature (Table 1) 
(56;57;60;68-70;137). Shinde-Patil et al. injected the Indium oxide-labeled Lin¯  Sca1+cKit+ 
BMC mice with heterotopic Lewis lung tumor. Biolocalization of EPC was detected by 
radioactivity. Most cells were detected in liver at both 24- and 72-hours post-injection. Less than 
2.5% of the injected cells localized to tumors. Immunohistological analysis revealed that most 
EPC detected in tumors were located perivascularly (60). Purhonen et al. did not observe an 
increase in BM-derived circulating VEGFR2+ cells in the presence of tumor. VEGFR2+ BMC 
were used as EPC in these experiments. Most BM-derived cells in tumors were once again 
observed in the perivascular space (68). Another group suggested that tumor infiltrating BM-
derived cells were predominantly CD11b+. CD11b is integrin alpha M and is routinely used as a 
marker for the macrophages-monocyte lineage. These CD11b+ cells were demonstrated as a 
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major source of MMP-9, which remodeled the ECM and assisted in the sprouting of blood 
vessels. Genetic ablation of MMP-9 was shown to significantly decrease tumor growth and 
vascularization (69). In a separate account, SDF-1α was reported to stimulate the migration of 
CD34+ BMC in vivo. Although these cells were recruited to tumors, they were found in close 
proximity of functional blood vessels and supporting pericytes (70). 
In contrast, there are about eleven reports that have shown the incorporation of EPC into 
developing tumor vasculature and their significant contribution to the process of vasculogenesis. 
Vajkocky et al. transplanted ex vivo-cultured embryonic EPC (eEPC) into tumor-bearing athymic 
mice. They observed approximately 43% of the injected eEPC to be arrested in tumors. Of these 
tumor-localized cells, approximately 55% eEPC were observed to have extravasated into the 
tumor interstitium and nearly 33% contributed to the functional tumor blood vessels. This 
homing of eEPC was shown to be mediated by selectins and PSGL-1 (one of the ligands for 
selectins, Table 7); and blocking these receptor-ligand interactions reduced the homing of eEPC 
by 77% (51). Santarelli et al. observed that 12% of CD34+VEGFR2+ cells in tumors were 
derived from BM. They also found these cells to be incorporated into the blood vessels, 
contributing 4.2% to tumor vasculature (61). Another group demonstrated that integrin α4β1 
mediated the homing to human CD34+ and murine Lin¯  BMC to tumor vasculature (63). 
Emerson et al. implicated VEGF and PlGF in mediating vasculogenesis. They reported that the 
recruitment of EPC to tumors was mediated by VEGFR1, but blocking VEGFR2 prevented EPC-
mediated vessel formation (64). Kaplan also reported a similar observation. However, they 
suggest that BM-derived VEGFR1+ cells created the ‘pre-metastatic niche’ that enabled the 
establishment of tumor cells in specific organs. VEGFR2+ BMC later infiltrated into the 
developing tumor and contributed to vascularization. Thus, blocking both VEGFR1 and 
  
   
29
VEGFR2 has been proposed to be important to prevent the BMC-mediated contribution to the 
development and vascularization of metastases (138). 
As tumors grow, the core is devoid of blood supply and becomes necrotic.  The actively 
developing tumor vasculature is described to be at the periphery of the tumors. Several 
investigators have shown that EPC were preferentially recruited to the tumor periphery (53;63).  
This was shown to be mediated by elevated expression of α4β1 ligand at the periphery (139). 
Additionally, higher numbers of BM-derived cells have been shown to be recruited to poorly 
differentiated tumors (52;73). Although, it was initially thought that EPC stabilized tumor 
vasculature rather than initiate vasculogenesis (28), newer reports suggest otherwise. It was 
recently described that tumor-localized EPC matured into endothelial cells and incorporated into 
tumor vessels, and that this contribution of BM-derived EPC to tumor vasculature was diluted as 
tumor progressed. Supporting this theory, selective ablation of EPC showed a substantial delay 
in tumor growth (140). Moreover, BM-EPC recruited to micro-metastases have been suggested 
to act as the ‘angiogenic switch’ for tumor progression (28). This report suggested that EPC 
contributed in the early phase of tumor development and were instrumental in initiation of tumor 
vascularization. 
In conclusion, a significant amount of research has been carried out to understand the 
mechanism of post-natal vasculogenesis in tumors, but much of the information remains 
controversial. Two reasons for the disagreement concerning vasculogenesis in tumors are 
inconsistency in the phenotype of endothelial progenitors and the type, stage, and location of 
tumors under investigation. 
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Endothelial Cell Adhesion Molecules  
 The cell adhesion molecules (CAM) are cell surface proteins that are involved in cell-cell 
and cell-ECM interactions. They are composed of an intracellular domain that interacts with the 
cytoskeleton, a transmembrane domain, and an extracellular domain that binds to ligands. They 
are broadly classified into calcium-independent (Integrin and Immunoglobulin super family) and 
calcium-dependent (Cadherin and Selectins) CAMs. Endothelial cells use cell adhesion 
molecules, such as integrins and cadherins to attach themselves to each other and to the vascular 
ECM, and selectins to arrest circulating leukocytes.  
 Integrins 
 Integrins are a group cell-surface heterodimeric proteins, composed of α and β subunits 
that interact with the ECM and play important role in signal transduction. In mammals, 19 α and 
8 β subunits have been characterized; these subunits combine to generate 24 unique integrins 
(141). Endothelial cells express a subset of integrins including vitronectin receptors (αvβ3 and 
αvβ5), fibronectin receptors (α4β1, α5β1), collagen receptors (α1β1, α2β1), laminin receptors 
(α3β1, α6β1, and α6β4), and osteopontin receptor (α9β1). Reports from several laboratories have 
shown that genetic ablation or blocking of certain integrin subunits resulted in defective 
vasculature development, embryonic lethality, and reduced tumor angiogenesis (Reviewed in 
(33;141-144). Integrins αvβ3, αvβ5, and α4β1 have been implicated in tumor growth, 
vascularization, and metastasis. Several integrin-targeted therapeutic agents are currently in 
clinical trials for cancer therapy (16;143).   
 Immunoglobulin Super Family (IgSF) 
The immunoglobulin super family (IgSF) is a large family of proteins that is involved in 
numerous functions including ligand recognition, binding, and adhesion. Members of this family 
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primarily involved in adhesion are ICAM-1 (intracellular cell adhesion molecule aka CD54), 
VCAM-1 (vascular cell adhesion molecule aka CD106), PECAM-1 (Platelet-endothelial cell 
adhesion molecule aka CD31), and NCAM (neural cell adhesion molecule aka CD56). Both 
ICAM-1 and VCAM-1 have been shown to be upregulated in EC in response to TNF-α and IL-1 
(145). VCAM-1, on endothelial cells, is reported to be a ligand for integrin VLA-4 (very late 
antigen-4 or α4β1).  The overexpression of VCAM-1 has been associated with oncogenesis, 
tumor angiogenesis, and metastasis in gastric carcinoma (146). PECAM-1 or CD31 is expressed 
by EC and is routinely used as a marker for endothelial cells.  
Cadherin 
Cadherins mediate calcium-dependent interactions between neighboring cells. Different 
members of the cadherin family are found in different organs. E-cadherins are found in epithelial 
tissue, N-cadherins are found in neurons, and P-cadherins are found in the placenta. VE-
Cadherin is expressed on EC and is believed to provide the mechanical barrier to inter-
endothelial leakage. VE-Cadherin was reported to be expressed on non-endothelial cells in vitro 
and on blood conduits made of tumor cells implicated in vascular mimicry (85). Recent reports 
have revealed that BM-derived EPC participating in tumor vascularization expressed VE-
Cadherin (28;53) and has been suggested to be a superior marker for identifying EPC and EC. 
Additionally, there are few studies implicating VE-cadherin as a possible target for inhibiting 
angiogenesis in tumors, although mostly in combination with other chemo- and anti-angiogenic 
therapy (147).  
 Selectins 
Selectins are a group of calcium-dependent type I single-chain transmembrane proteins. 
There are three selectins based on the cell type in which they are predominantly expressed: E-
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selectin (endothelial cells), L-selectin (leukocytes), and P-selectin (platelets and endothelial 
cells). All selectins consist of an N-terminal lectin-like domain, an epidermal growth factor like 
domain, six consensus repeats, a single transmembrane domain, and a short cytoplasmic domain. 
Selectins bind sialylated and fucosylated oligosaccharides such as Sialyl Lewis-x (sLe-x); these 
sugar moieties make up the terminal components of glycans attached to glycoproteins and 
glycolipids (148;149). 
L-selectin and Tumor Biology 
L-selectin also known as CD62L, leukocyte adhesion molecule (LAM-1), lectin adhesion 
molecule (LECAM-1), is expressed by leukocytes, and is responsible for leukocyte trafficking. 
Several activating factors including GM-CSF, interferon-α, IL-8, adrenalin, and shear stress 
influence L-selectin expression. Soluble L-selectin (sL-selectin) is reported to be functionally 
active and thought to be involved in obstructing the adhesion of leukocytes to endothelium (149). 
L-selectin and sL-selectin have been reported to be elevated in several diseases including 
meningeal leukemia and lymphoma (149;150). Furthermore, L-selectin has also been reported to 
be involved in metastasis of tumor cell (151). 
Some ligands that bind L-selectin include GlyCAM-1, MadCAM-1, CD34, PSGL-1, 
Sialyl Lewis-x and sulfated molecules like 6-sulfo-sLe-x, heparin, and sulfatides. Some of these 
ligands have been found to be expressed on certain tumor cells and implicated in the metastatic 
process (151). 
P-selectin and Tumor Biology 
Platelets and endothelial cells express P-selectin (CD62P, LECAM-3). It is constitutively 
expressed in α-granules in platelets and Weibel-Palade bodies in endothelial cells. Histamine, 
thrombin, activated complement, and certain viruses lead to the rapid mobilization of P-selectin 
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to the cell surface, and cytokines like IL-4, IL-13, and oncostatin M cause an upregulation in P-
selectin mRNA and protein synthesis. Some of the ligands that bind P-selectin include PSGL-1, 
sLe-x, heparin, and sulfatides.  In two independent studies, Borsig and Garcia demonstrated that 
metastasis of colon cancer cells was mediated by binding of sulfatides on colon cancer cells to P-
selectin on endothelium. In the presence of sulfatase or heparin the metastatic burden was 
significantly reduced (151;152).  
E-selectin  
E-selectin (CD62E, LECAM-2) is a well-studied endothelial leukocyte adhesion 
molecule (ELAM) that is selectively expressed on activated endothelium during inflammatory 
responses and during tumor development. E-selectin is usually absent from resting endothelium 
(34;145;149;153-155). It has a molecular weight of 64 kDa, but has detected between 107-115 
kDa by western blotting. This disparity in molecular weight is most likely due to variable 
glycosylation of E-selectin. It was reported to be transiently expressed in endothelial cells in 
response to TNFα, IL-1β, NF-κB, and activator protein. E-selectin mRNA has been reported to 
have a short half-life of 2 hours (156).  The synthesized protein was shown to be directly 
delivered to plasma membrane (157). In response to IL-1β treatment, E-selectin was detected on 
cell surface of human umbilical vein endothelial cells as early as 30 minutes, peaked by 4 hours, 
and subsequently declined to basal levels by 24 hours (158). Surface E-selectin is slowly 
endocytosed and degraded by lysosomes. A VEGF-mediated induction of E-selectin on 
endothelial cells has also been reported (159). In addition, Tabatabai et al. demonstrated that 
upregulation of E-selectin in tumors was mediated by VEGF (65). E-selectin has been reported 
to bind to several glycoproteins and glycolipids. Some of the E-selectin ligands are sLe-x, Sialyl 
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Lewis- a (sLe-a), E-selectin ligand (ESL-1), Leukosialin/CD43, CD44, LAMP-1, P-selectin 
glycoprotein (PSGL-1) and even L-selectin (Table 6).   
  E-selectin and tumor biology 
The contribution of E-selectin to tumor growth and metastasis was recognized in early 
the 1990’s. In an early experiment, murine endothelial cells (EC) expressing E-selectin were co-
transplanted with tumor cells that expressed sLe-x and sLe-a. It was demonstrated that the initial 
adhesion of tumor cells and EC was mediated by the interaction of E-selectin on endothelium 
and sLe-x and sLe-a on tumor cells. These results indicated that the interaction of tumor cells 
and EC was highly dependent on the interaction of the cell adhesion molecule mediating the 
adhesion of cancer cells to EC.  Blocking sLe-x and sLe-a remarkably retarded tumor growth and 
angiogenesis (32).  In a separate report, E-selectin mRNA was shown to be induced in the lungs 
of B16 tumor bearing wild-type mice. E-selectin expression was significantly reduced in B16 
tumors in p38a+/- mice, suggesting that expression of E-selectin was mediated by p38a (160;161). 
Other studies, similar to the ones mentioned above, have suggested the involvement of E-selectin 
in adhesion and growth of metastatic tumor cells. 
 E-selectin and Metastasis 
There is strong evidence for the involvement of E-selectin in tumor development. 
However, the precise relationship between E-selectin expression, cell adhesion, tumor invasion, 
and metastasis remains unclear. Several metastatic tumors isolated from human subjects with 
cancers of the colon, prostrate, breast, pancreases, and lung were reported to express functional 
ligands of E-selectin and adhered to an endothelial cell monolayer expressing E-selectin. It is 
believed that tumor cells might harness and exploit the selectin-dependent mechanism, 
commonly used by leukocytes, for metastasis (162). The efficiency of E-selectin-mediated  
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Table 6: E-selectin Ligands 
 
CD number Common Name Cell Type 
CD208 CLA 
Cutaneous 
lymphocyte antigen 
(modification of 
PSGL-1) 
T-cells, endothelial cells, B cells, NK , 
DC, Langerhans cells in the skin 
- ESL-1 E-selectin Ligand Endothelial cell, fibroblast, neutrophil, 
colon carcinoma, lymphoma, 
CD107a LAMP-1 Lysosomal-associated 
membrane protein 
Keratinocytes, Melanocytes, Microglial 
cells, Platelets 
CD147 Basigin  
EC, Pericytes, T-cells,  follicular 
dendritic cells, Mesenchymal stem cell, 
Keratinocytes, 
CD15s sLe-x Sialyl Lewis x Tumor cells 
CD162 PSGL-1 P-selectin glycoprotein ligand-1 WBC, EC 
CD43 Leukosialin Sialophorin 
Basophils, B-cells, DC, Enterocytes, 
Macrophage, Mast cells, Microglial 
cells, Mast Cells, Neutrophils, 
Osteoblast, Platelets, T-cells, HSC 
CD44 HCELL 
Phagocytic 
Glycoprotein 1  
(pgp 1) and HCAM 
Adipocytes, Astrocytes, Basophils, B-
cells, Chondrocytes, DC, EC, 
Enterocytes, Eosinophils, Fibroblasts, 
Keratinocytes, Mast cells, Macrophage, 
Melanocytes, Monocytes, Osteoblasts, 
Osteoclasts, Schwann cells, T-cells, 
Thyrocytes, 
CD62-L L-selectin  
Basophils, DC, Eosinophils, 
Keratinocytes, Macrophages, 
Megakaryocytes, Monocytes, 
Neutrophils 
CD65 VIM-2 Ceramide Dodecasaccharide Myeloid cells, Monocytes 
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binding of colon carcinoma cells to endothelial cells has been demonstrated to correlate with 
their metastatic potential. It was thus proposed that soluble forms of E-selectin ligand, LAMP-1 
and leukosialin (CD43), would be useful therapeutic agent to prevent metastases (163). Elevated 
levels of E-selectin have been often reported on blood vessels close to or within tumor 
metastasis. This notion that E-selectin on activated endothelium facilitated tumor cell seeding 
was validated by Uotani’s report. They observed an elevation in E-selectin in livers after partial 
hepatectomy. They observed an increase in the incidences of liver metastases when tumor cells 
were injected after hepatectomy. Furthermore, a significant decrease in metastatic burden was 
reported in the presence of E-selectin neutralizing antibodies. This experiment confirmed the role 
of E-selectin in establishing metastases in their model (164).  Insug et al. intravenously 
administered the Sialy Lewis-a expressing B16 tumor cells mixed with Sialy Lewis-a-mimicking 
antagonizing peptide or unrelated peptide into healthy mice or E-selectin-/- mice. They observed 
that colonization of tumor cells was blocked by the antagonizing peptide in wild-type mice and 
was completely abolished in E-selectin knockout mice (165;165). Another group of investigators 
showed that the metastatic process in the lung was almost completely abrogated in the 
genetically manipulated mice that lacked the expression of E-selectin, regardless of sLe-x/a 
expression on tumor cells (165-168). Consequently, Thurin et al. proposed that the interaction of 
tumor cells, via the carbohydrate determinant, and E-selectin constituted an important step in the 
metastatic process, and that carbohydrate antigen mimetic could potentially be used for anti-
adhesive tumor therapeutics (165;168;169). Our laboratory has obtained similar results 
supporting the function of E-selectin in colonization and growth of Lewis lung tumor cells. 
Besides contributing to tumor cell metastasis, E-selectin appears to be involved in tumor 
vascularization (170;171) (Verbanac laboratory, manuscript in preparation). 
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  E-selectin and Tumor Vascularization 
There are over seven hundred reports on the subject of ‘E-selectin and Cancer’, found in 
a PubMed search, but less than a handful of these have fully explored the role of E-selectin in 
tumor vascularization. Nonetheless, E-selectin expression in tumor endothelium is theorized to 
be important and soluble E-selectin is thought to be an important angiogenic growth factor. E-
selectin expression was reported to be elevated in proliferating EC in blood vessels in 
hemangiomas. It was concluded that E-selectin was instrumental in angiogenesis and a plausible 
marker for proliferating endothelium (172). Compared to benign mucosa, the in situ E-selectin 
expression in tumor-associated vessels in gastric carcinomas was reported to be 34% higher. In 
addition, E-selectin positive vessels were more frequently observed in regions that were densely 
vascularized and this overexpression of E-selectin was shown not to be associated with the 
inflammatory infiltrate (173). These studies suggest that E-selectin expression is in all 
probability elevated in tumors that acquire actively proliferating vasculature. Our laboratory has 
observed expression of E-selectin on tumor-derived EC. Additionally, results from in vivo 
biolocalization studies showed a 70% decrease in adhesion of adoptively-transferred vascular 
endothelial cells to tumor endothelium in the presence of E-selectin blocking antibody (170) 
(Verbanac laboratory, manuscript in preparation). These reports suggest that E-selectin might be 
involved in tumor vascularization.  
 Soluble E-selectin 
Circulating soluble E-selectin (sE-selectin) is thought to be released by enzymatic 
degradation or due to shedding from damaged endothelial cells. It is considered to be evidence of 
endothelial activation. Similar to patients with inflammatory conditions, sE-selectin has been 
reported to be elevated in serum and plasma of patients with breast, ovarian, gastrointestinal 
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cancers as well as multiple myelomas compared to healthy controls (162;174;175). Level of 
circulating E-selectin has been correlated with the severity of certain cancers (176;177) and is 
suggested to have a role in pathogenesis and prognosis of cancer patients (178;179).   
  Selectin Ligands in Tumor Biology and Metastasis 
The ligands that bind E-selectin are listed in Table 6. Some of these glycoproteins have 
also been shown to bind L- and P-selectin, and have been implicated in tumor biology. Tumor 
cells, in particular carcinoma and leukemic cells have been reported to express sLe-x structures 
in abundance. Carcinoma cells are also enriched with sLe-a structure, which is the isomer of sLe-
x. This supports the hypothesis that blood-borne disseminated tumor cells use the selectin-
carbohydrate interaction to adhere to endothelial cells at metastatic sites (180). 
 Lysosomal-associated membrane protein (LAMP-1, CD107a) is expressed on the 
luminal side of the lysosomal membrane of most normal cells. It is glycosylated with N- and O-
linked carbohydrate chains. Sialyl Lewis-x (sLe-x) is most abundantly present on N-glycans of 
LAMP-1 and constitutes 12% of the total terminal structure; LAMP-1 contains around 12 N-
glycans. In comparison to LAMP-1, sialophorin (Leukosialin, gpL115, CD43) is a major 
sialoglycoprotein on the surface of human T cells, monocytes, granulocytes, some B cells, 
pluripotent hematopoietic stem cells and bone marrow derived-Lin¯ Sca1+cKit+ cells. Sialyl 
Lewis-x is present in O-glycans on CD43 and constitutes 1% of total terminal structure but 
leukosialin contains  about 80 O-glycans. Thus, despite the differential glycosylation on LAMP-
1 and CD43, both bind E-selectin with equal affinity and have been proposed as potential 
inhibitors for E-selectin-mediated adhesion (163).  
Elevated expression of LAMP-1 and sLe-x has been reported on colon carcinoma cells 
with high metastatic potential compared to carcinoma cells that are poorly metastatic (180-182). 
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LAMP-1 was also shown to be important for the adhesion of human ovarian cancer cells to the 
extracellular matrix (183). Expression of LAMP-1 was demonstrated in human melanoma, 
fibrosarcoma, and colon-adenocarcinoma cells. The authors strongly proposed the LAMPs as a 
family of adhesive glycoproteins that participated in the complex process of tumor invasion and 
metastasis (184). Similarly, CD43 has been shown to be important in the growth of melanoma 
tumors.  A significant retardation in the growth of B16F10 melanomas and development of 
metastatic foci was observed in CD43-/- mice compared with wild-type control mice (185). Other 
E-selectin ligands, PSGL-1 and ESL-1, have been reported to be expressed on human prostate 
tumor cells and in prostate tumor cells in bone metastases (186). 
The glycosyl residues, like sLe-x and sLe-a, on the terminals of glycoproteins that bind 
selectins are most likely responsible for mediating the adhesion of tumor cells to activated EC, 
platelets, and ECM. The synthesis of these sialylated glycosyl residues requires specialized 
enzymes – glycosyltransferases. Thus, several investigators are evaluating the expression of 
specific glycosyltransferases in different metastatic cancer cells.   Recently it was demonstrated 
that fucosyltransferase-3, -6, and/or -7 were important in synthesis of Sialyl Lewis-x and ESL-1 
on metastatic prostate cancer cells (162). Thus, selectin ligands, specific glycosyl residues, and 
glycosyltransferases play a very important role in tumor biology and metastasis. 
  Pharmacological Targeting of Selectin  
Currently no clinical trials investigating selectin or selectin-targeting agents are being 
conducted. However, theoretically anti-E-selectin, anti-PSGL-1, soluble PSGL-1-Ig, and 
glycosylation inhibitors like 4-fluoro-N-acetyl-glucosamine (4-F-GlcNAc) are thought to be 
promising candidates. Antibodies against E-selectin or PSGL-1 are hypothesized to block the 
interaction between tumor cells and endothelial cells. Similarly, soluble PSGL-1 could quench 
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PSGL-1 on tumor cells, leukocytes, and platelets and prevent them from binding to activated 
endothelium. Glycosylation inhibitors like 4-F-GlcNAc have been shown to be incorporated into 
glycan structures and truncated their branching and elongation on PSGL-1, thereby preventing 
synthesis of sLe-x or sLe-a by fucosyltransferases. The above-mentioned selectin-targeting 
strategies have been applied with some success in treating diseases like psoriasis and offer 
attractive modes of interventions in cancer therapy (162).  
 
Vascular Endothelial Growth Factor and Receptor Family 
 The vascular endothelial growth factor (VEGF) family consists of VEGF-A, VEGF-B, 
VEGF-C, VEGF-D, VEGF-E (viral), and placental growth factor (PlGF) (39;187). The term 
VEGF, by convention refers solely to VEGF-A, which is the predominant vascular endothelial 
growth factor. VEGF family members bind to four receptors with high affinity.  Three of these 
receptors belong to the receptor tyrosine kinase (RTK) family: VEGFR1 (fms-like tyrosine 
kinase-1 / Flt-1), VEGFR2 (murine homologues of kinase insert domain-containing receptor 
(KDR) / fetal liver kinase (Flk-1)) and VEGFR3 (Flt-4). Neuropilin is the fourth receptor for the 
VEGF family.  These receptors have seven extracellular immunoglobulin homology domains and 
two intracellular tyrosine kinase domains in their cytoplasmic tail region.  VEGF initiates a 
cascade of events upon binding with their receptors: receptor dimerization and auto-
phosphorylation of tyrosine domains followed by activation of numerous downstream proteins 
including phospholipase C-γ/protein (40;40;62;188-192). 
 Vascular Endothelial Growth Factor-A  
VEGF-A or VEGF was first characterized as a vascular permeability factor (VPF) in 
1983.  Senger et al. reported that VPF / VEGF promoted extravasation of proteins from tumor-
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associated blood vessels, and appeared to affect vessel permeability. Normal cell types, including 
macrophages, lung epithelial cells, kidney epithelial cells, follicular cells in the pituitary, corpus 
luteum cells, aortic smooth muscle cells and a numerous tumor cells and tumors, produce VEGF.  
Other functions of VEGF include anti-apoptosis modulation (159), lymphangiogensis, immune 
suppression, stimulation and recruitment of endothelial and hematopoietic precursor cells in 
vasculogenesis, and regulation of hematopoietic stem cell survival (40).   
 VEGF is one of the key regulators of tumor growth and metastases. It is a highly specific 
mitogen for vascular endothelial cells. Besides hypoxia, mutant ras, mutant p53 tumor 
suppressor, erbB-2/Her2, activated EGFR, and bcr-abl are associated with VEGF upregulation in 
tumors. VEGF mRNA was reported to be weakly expressed by naïve CD34+ cells.  The amount 
of VEGF released was substantially increased by incubating cells with a combination of 
cytokines IL-3, GM-CSF, and G-CSF (129). Although hypoxia is thought to be predominantly 
responsible for the expression of VEGF, it can be produced in tumor cells under normoxic 
conditions. This could explain elevated levels of VEGF at the tumor periphery, which is well 
vascularized and not devoid of oxygen (8;78). Stimulation of VEGFR1+ and VEGFR2+ 
endothelial cells by VEGF leads to their survival, proliferation, and increased mobility. More 
recently, an important role for VEGF has emerged in mobilization of endothelial progenitors 
from the bone marrow to distant sites of neo-vascularization (Table 1) (50;64;107).  
  VEGF has been strongly implicated in the progression of cancerous tumors (39). Several 
researchers have reported an increase in the systemic levels of VEGF in different types of tumors 
and cancers, namely glioma, neuroblastoma, colorectal, ovarian, breast, and prostate cancer. 
Elevation of VEGF in plasma in adult mice has been shown to mobilize VEGFR2+ circulating 
endothelial progenitors. Monoclonal antibodies against VEGFR2 have a suppressive effect on 
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solid tumor growth in mice (190).  Thus, VEGF and VEGFR2 are potential direct targets in the 
suppression of pathological angiogenesis. Avastin / Bevacizumab, anti-VEGF antibody was the 
first anti-angiogenic drug approved by the US Food and Drugs Administration (FDA) for the 
treatment of metastatic colorectal cancer.  It is now used for the treatment of breast cancer and 
non-small cell lung carcinoma and is being evaluated in clinical trials for several different types 
of cancers. 
 Vascular Endothelial Growth Factor-B  
 VEGF-B is expressed in heart, skeletal muscle, and brown fat in adults and has two 
isoforms, VEGF-B167 and VEGF-B186. The carboxy-terminal of VEGF-B167 has a heparin-
binding domain whereas VEGF-B186 lacks the ability to bind to heparin. VEGF-B specifically 
binds to the soluble and membrane-bound forms of VEGFR1. Although VEGF-B is not critical 
in development, it might be important in inflammatory angiogenesis as demonstrated by reduced 
synovial angiogenesis in the arthritis model (Reviewed by (41).  VEGF-B has been detected in 
several types of tumors; however, its role in tumor biology remains elusive (Reviewed by (193). 
Vascular Endothelial Growth Factor-C and -D  
VEGF-C is expressed prominently in heart, placenta, muscle, ovary, and small intestine; 
lower levels of VEGF-C are expressed in brain, liver and thymus. Post proteolytic maturation of 
VEGF-C generates multiple forms, which bind and activate VEGFR3 receptors. The fully 
processed form of VEGF-C can also bind and activate VEGFR2 receptor. VEGF-C plays an 
important role in lymphatic development. Deletion of vegfc in mice is reported to lead to the 
complete absence of lymph vessels and embryonic lethality, but did not affect the blood 
vasculature development (Reviewed by (41).   
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VEGF-D is structurally similar to VEGF-C, and is strongly expressed in heart, lung, 
skeletal muscle, colon, and small intestine. It is an activating ligand for the VEGFR2 and 
VEGFR3, but it does not bind to VEGFR1. VEGF-D is also a known mitogen for endothelial 
cells. It has been shown to induce tumor angiogenesis through VEGFR2 and tumor 
lymphangiogenesis through VEGFR3. VEGF-D is also reported to promote metastatic 
dissemination of tumor cells via the lymphatics. Elevated levels of VEGF-D have been detected 
in gastric tumors compared to healthy gastric mucosa (Reviewed by (41). Expression of VEGF-C 
and VEGF-D have been reported to correlate with lymph node metastasis and prognosis of 
patients with colorectal carcinoma (194). VEGF-D and VEGFR-3 are implicated in promoting 
nodal metastasis in human invasive lobular breast cancer (195).  
Placental Growth Factor  
Placental growth factor (PlGF) is expressed in placenta, heart, and lungs. Many cell types 
express PlGF, including EC, SMC, fibroblasts, leukocytes, BM progenitors, cardiomyocytes, 
epithelial, and tumor cells. It has four isoforms (PlGF1-4) in humans, of which only PlGF2 has a 
homologue in mice.  It binds to VEGFR1, but not VEGFR2. It also binds to both neuropilin 
receptors. PlGF is upregulated in pathological conditions by various stimuli like hypoxia, nitric 
oxide, interleukins, TNFα, VEGF, and TGFβ etc. It serves several functions, including 
stimulation of vessel growth, as well as growth, migration, and survival of EC. PlGF stimulates 
angiogenesis by recruiting various cells that express VEGF, SDF-1α, FGF-2, PDGF-B, MMP, 
etc.  It displaces VEGF from VEGFR1; the liberated VEGF then activates VEGFR2 and 
enhances VEGF-mediated angiogenesis (Reviewed by (41;193).  
PlGF is considered to be a prognostic marker for cancer. It is reported to be significantly 
elevated in NSCLC, gastric, colorectal, and breast cancer. It is also correlated with lymph node 
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metastasis, tumor stage, and mortality in several types of cancer. Elevated plasma PlGF levels 
have also been correlated with tumor grade and survival in renal cell carcinoma. Furthermore, 
PlGF was reported to be elevated in patients undergoing anti-VEGF therapy and was thought to 
be responsible for drug resistance. Neutralizing anti-PlGF was reported to inhibit growth and 
metastases of tumor by inhibiting tumor angiogenesis, lymphangiogenesis and intratumor 
macrophage recruitment (Review by (86;193).  
Vascular Endothelial Growth Factor Receptor 1 (VEGFR1) 
An important feature of VEGFR-1 is that, unlike other VEGFR genes, it expresses two 
types of mRNA, one for a full-length receptor and another for a soluble short protein (lacks 
transmembrane and intracellular domains known as soluble VEGFR-1 (sFlt-1). The binding-
affinity of VEGFR-1 for VEGF-A is higher than that of VEGFR-2, but the kinase activity of 
VEGFR-1 is weaker than that of VEGFR-2 (196).  VEGFR1-/- mice die by embryonic day 9 
(E8.5-9) due to excess EC and disorganized vasculature. However, mice expressing the VEGFR1 
extracellular and transmembrane domains but lacking the tyrosine kinase domain intracellular 
domains of VEGFR1 are viable and have functional vasculature. This suggests that VEGFR1 
acts as a negative regulator of angiogenesis during embryogenesis (188). Nonetheless, 50% of 
mice with homozygous deletion for both the intracellular and transmembrane domains die at 
E8.5-9 due to disorganization of blood vessels.   Thus, membrane-bound form of VEGFR1 
appears to regulate vascular development by trapping VEGF for the appropriate regulation of 
VEGF signaling in vascular endothelial cells during early embryogenesis {584, 388, 583}. 
VEGFR1 is expressed by endothelial cells, monocytes, macrophages, hematopoietic 
cells, and pericytes express. VEGFR1 homodimerizes and binds VEGF, VEGF-B, VEGF-F, and 
PlGF. VEGFR1 has also been shown to dimerize with VEGFR2. Although, the tyrosine kinase 
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activity of VEGFR1 is weak and the downstream signaling pathway is poorly understood, the 
tyrosine kinase activity is thought to be important in hematopoietic cell migration in response to 
VEGF and PlGF (Reviewed by (41).  
An increase in VEGFR1 is reported in several different cancers. Its expression is 
associated with poor prognosis, metastasis, and recurrence in breast and NSCLC (193). Recently, 
VEGFR1+ BM-derived cells were implicated in formation of the pre-metastatic niche. It was also 
demonstrated that blocking VEGFR1 significantly reduced the metastatic burden (138). Thus, 
VEGFR1 appears to be important in tumor development. 
 Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)  
Endothelial cells and endothelial progenitors predominantly express VEGFR2.  It binds 
VEGF, -C, -D and -E, however VEGF is the main ligand for VEGFR2. The mitogenic, 
angiogenic and permeabilizing effects of VEGF are mediated via VEGFR2 expressed on 
vascular, and lymphatic endothelium and has been strongly implicated in angiogenesis and 
vasculogenesis. The key role of VEGFR2 in developmental angiogenesis and hematopoiesis is 
indicated by the failure to form blood islands and develop vasculature in VEGFR2-/- mice (40).   
 VEGFR2 gene encodes only one message for the full-length receptor of 1357 amino 
acids.  Within the cell, VEGFR2 protein is produced as a 150 kDa protein without significant 
glycosylation. This molecule is further glycosylated to a mature 230 kDa form and expressed on 
the cell surface.  VEGF induces auto-phosphorylation of the 230 kDa molecule only.   
 In tumor cells, HIF-1α is stabilized which induces hypoxia-responsive genes such as 
VEGF.  VEGF binds to VEGFR2 on VEC and via phospholipase C - protein kinase C - mitogen 
activated protein kinase (PLCγ-PKC-MAPK) pathway resulting in DNA synthesis, increased 
permeability, and cells survival.  This leads to endothelial cell proliferation and tubular 
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formation (191). Significant inhibition of tumor growth, angiogenesis and vasculogenesis in 
tumors by administration of anti-VEGFR2 antibody has been reported by several groups 
(193;197).  
 
Chemokines and Chemokine Receptors 
 Chemokines are structurally related, small (8-14 kDa) signaling polypeptides that bind 
and activate the seven trans-membrane G-protein coupled receptors.  Bone marrow-derived cells, 
endothelial, smooth muscle, stromal, and epithelial cells secrete chemokines.  Chemokines are 
important in leukocyte movement.  The inducible chemokines recruit leukocytes in response to 
pathophysiological conditions, whereas the constitutively expressed chemokines are involved in 
basal leukocyte trafficking and maintenance of lymphoid organ architecture (198-201).  
Chemokines can be divided into four subgroups: CXC, CC, CX(3)C, and C chemokines, where 
C represents cysteine residues and X represents any other amino acid.  
The CXC chemokines (α group) have two cysteine residues separated by a non-conserved 
amino acid (X) and are important in maintaining the delicate balance in angiogenesis (42). There 
are 17 different CXC chemokines known in the mammalian system. CXC chemokines are further 
subdivided into Glutamic acid-Leucine-Arginine (ELR)-positive and ELR-negative chemokines 
(Table 7). The ELR+ CXC chemokines bind to chemokine receptors CXCR1 and CXCR2, are 
strong attractants for neutrophils, and are pro-anagiogenic. In contrast, most ELR¯  CXC 
chemokines bind to receptor CXCR3, chemoattract lymphocytes, and are angiostatic in nature. 
The only exception is the pro-angiogenic ELR¯  CXC chemokine stromal cell-derived factor-1 
(CXCL12/SDF-1), which binds to receptors CXCR4 and CXCR7 (43). Similar to other members  
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Table 7: CXC Chemokines and Chemokine Receptors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chemokine Receptor Chemokine Function 
 
 
 
CXCR2 
CXCL1 / Gro-α 
CXCL2 / Gro-β 
CXCL3 / Gro-γ 
CXCL5 / ENA-78 
CXCL6 / GCP-2 
CXCL7 / NAP-2 
CXCL8 / IL-8 
Angiogenic 
CXCR4 
CXCR7 CXCL12 / SDF-1 Angiogenic 
 
CXCR3 
CXCL9 / Mig 
CXCL10 / IP-10 
CXCL11 / ITAC 
Angiostatic 
CXCR3B CXCL4 / PF-4 Angiostatic 
CXCR5 CXCL13 / BCA Angiostatic 
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of the ELR¯  CXC subgroup, SDF-1α attracts lymphocytes. In addition, it directs the migration of 
hematopoietic stem cells and the formation of blood vessels. It is suggested to be essential in 
tumor angiogenesis and vasculogenesis. Chemokine receptors CXCR2, 3 and 4 have been 
reported to be expressed on endothelial cells (42) and are considered as important modulators of 
tumor vascularization and metastasis (43;202-206).  
 CXCR2 and Ligands 
 CXCR2 (IL8-beta receptor or IL8Rb, IL8R1) is one of the seven known members of the 
CXC chemokine receptor group. ELR+ chemokines, such as CXCL1,2,3/GRO-α,β,γ, 
CXCL5/ENA-78, CXCL6/GCP-2, CXCL7/NAP-2, and CXCL8/IL-8 bind specifically to 
CXCR2. It is predominantly expressed by neutrophils. However, it has also been detected in 
some endothelial and tumor cells (42). CXCR2 is shown to be responsible for mediating the 
migration of neutrophils to sites of inflammation. Knockout studies in mice suggest that CXCR2 
controlled the positioning of oligodendrocyte precursors in developing spinal cord by arresting 
their migration (43). Anti-CXCR2 antibodies were found to block CXCL8-induced stress fiber 
assembly and endothelial cell migration. The signaling pathways regulated by CXCR2 are 
essential in angiogenesis. CXCR2 has also been found to regulate angiogenesis in vivo (207).  
 The important role of CXCR2 in tumor growth and angiogenesis has been known for a 
few years (207-211). ELR+ CXC chemokine-mediated angiogenesis is inhibited in both 
CXCR2−/− mice and in mice homozygous for CXCR2 in the presence of CXCR2 neutralizing 
antibody. CXCR2 neutralizing antibody was also reported to reduce pancreatic cell supernatant-
mediated neo-vascularization. A decrease in the tumor-associated angiogenesis and metastatic 
potential has been demonstrated in murine tumor model for lung cancer in CXCR2−/− compared 
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to wild-type mice. Taken together, these studies ascertain that CXCR2 is the receptor responsible 
for the angiogenic activity of the ELR+ CXC chemokines (201). 
 Strieter et al. were the first to report that CXCR2 was the putative receptor for 
chemokine-induced angiogenesis involving ELR+ CXC chemokines. They identified CXCR2 on 
human micro vascular endothelial cells (HMVEC) at the protein and RNA level. Chemotaxis of 
HMVEC in response to the ELR+ CXC chemokines was also established; anti-CXCR2 
neutralizing polyclonal antibody was shown to inhibit this chemotaxis (203). Our laboratory has 
investigated the expression of CXCR2 on primary cultures of murine cardiac vascular 
endothelial cells (VEC). In contrast to the above mentioned report, we did not detect CXCR2 
mRNA or protein in these cultured VEC. Nonetheless, CXCR2 was detected in the endothelium 
of some blood vessels in Lewis lung tumors and bone marrow-derived neutrophils. Preliminary 
results indicate that neutrophils might be crucial for establishing a pre-metastatic niche 
(Verbanac laboratory, unpublished data). Thus, CXCR2 might be involved in vascularization in 
tumors and possibly in facilitating tumor cell metastases.  
Stromal-Derived Factor (SDF-1α) and Receptor CXCR4 
Three isoforms of SDF-1 have been identified: SDF-1α, SDF-1β, and SDF-1γ, arising 
from alternate splicing of a single gene. Among these, SDF-1α (CXCL12) is the most well 
studied isoform. SDF-1α is constitutively expressed in various organs including bone, lung, liver, 
brain, thymus, and lymph nodes (212). It is mainly produced by stromal cells, such as 
osteoblasts, fibroblasts, and endothelial cells in the bone marrow (212-215).  In vitro and in vivo 
SDF-1α is shown to be chemotactic for lymphocytes, monocytes, bone marrow derived CD34+ 
cells, but not neutrophils (135;216).  It also plays an important role in development. Mice with 
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targeted disruption of the sdf-1α gene die perinatally due to defects in B-cell and myeloid 
progenitors and defective cardiac septa.  
CXCR4, also called fusin, is an alpha-chemokine receptor specific for SDF-1α. It is 
expressed by peripheral mononuclear cells, monocytes, T-cells, B-cells, endothelial cells, 
neurons, astrocytes, tumor cells and a variety of stem cells including cancer stem cells (217). 
CXCR4-/- mice die perinatally where as CXCR4+/- mice are viable, fertile, and have normal 
vascularization, hematopoiesis and cerebral development (214). Besides the well known role of 
CXCR4 as a co-factor for human immunodeficiency virus infection of T lymphocytes (218), 
CXCL12/SDF-1α interaction with CXCR4 plays a prominent role in tumorigenesis (206;219-
222). 
Recently, there have been several reports suggesting that hematopoietic cells and T-cells 
harbor intracellular CXCR4.  Several investigators have reported the constitutive intracellular 
expression of CXCR4. Additionally, CXCR4 has been shown to be internalized on binding to its 
ligand SDF-1α (223). Kollet reported that human CD34+CXCR4¯  BMC had intracellular 
reserves of CXCR4 that could be rapidly mobilized to the cell surface in the presence of cytokine 
cocktail (SCF, FLT3-L, IL-6, IL-3, and G-CSF) or in serum-starved condition in vitro (223). The 
intracellular localization of CXCR4 has also been demonstrated in human trophoblasts and T-
cells (224). This has been hypothesized to be a mechanism to prevent the activation of CXCR4+ 
stem cells that predominantly reside in the bone marrow, which is a rich resource of SDF-1α 
(225;226). CXCR4 is also an important co-receptor in HIV infection. Thus, the predominant 
intracellular expression of CXCR4 is considered to be a natural adaptation to prevent viral 
infection (218).  
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  SDF-1α and CXCR4 in Stem Cell Homing and Mobilization 
Various research groups evaluating the mechanism of hematopoietic reconstitution (stem 
cells homing to the bone marrow post sub-lethal radiation) have indicated that SDF-1α played a 
crucial role in this phenomenon (223;227;228).  SDF-1α has been reported to chemoattract 
HUVEC and CD34+ human hematopoietic progenitor cell, and mediate trans-endothelial 
migration of HSC in vitro and in vivo (134;135).   Thus, SDF-1α is important for mobilization of 
HSC, EPC, and differentiated EC. 
  SDF-1α upregulation in HUVEC in response to VEGF and bFGF has been demonstrated 
by RT-PCR, western blot analysis, and flow cytometry. It was suggested that VEGF- and bFGF-
mediated autocrine signaling regulated the morphologic and angiogenic properties of SDF-1α 
and CXCR4 in EC (229). Gurtner et al. reported the expression of SDF-1α was regulated by 
HIF-1α in HUVEC.  They have also made known that in vivo expression of SDF-1α is directly 
proportional to reduced oxygen tension. They observed that secreted SDF-1α in HUVEC culture 
medium increased by seven to nine folds when cell culture was maintained at 1% oxygen tension 
for 6 to 12 hours (109;131). 
  SDF-1α Expression in Tumor and Other Tissue 
There is growing evidence that SDF-1α and its receptors are crucial in the growth and 
metastasis of tumors (13;205;217). It remains inconclusive whether SDF-1α is angiogenic or 
angiostatic because it has been reported to attenuate the angiogenic activity of ELR+ CXC 
chemokines, bFGF, or VEGF {585, 378}, but Wang et al. demonstrated a link between SDF-1α 
and CXCR4-mediated pathways and angiogenesis modulation. Angiogenesis was reported to be 
stimulated by two separate pathways involving differential activation of the MEK/ERK and 
PI3K/AKT pathways, which resulted in differential secretion IL-6, and IL-8, and TIMP-2 and 
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VEGF in LNCaP and PC3 prostate cancer cell lines, respectively. This cytokine-mediated 
angiogenesis was inhibited due to the expression of angiostatin (endothelial angiogenesis 
inhibitor) when CXCR4 was knocked down in tumor cells. Stimulation by SDF-1α suppressed 
angiostatin expression and enabled angiogenesis (230).  Subsequently, it was demonstrated that 
CXCR4-mediated expression of glyolytic enzyme phophoglycerate kinase 1 (PGK1) and 
angiostatin lead to a reduction in angiogenesis when SDF-1α was low. In contrast, in the 
presence of high concentrations of SDF-1, VEGF, IL-6 and IL-8 induced angiogenesis (231).  
Thus, the interaction of SDF-1α and CXCR-4 is critical in angiogenic modulation in context of 
tumorigenesis.  
 Aghi et al. reported that SDF-1α was expressed by the vasculogenic glioma cells but not 
by nonvasculogenic glioma cells, and was responsible for attracting endothelial progenitors to 
tumors. In addition they demonstrated that blocking CXCR4 reduced the homing and long-term 
engraftment of vascular progenitors by 80% in vasculogenic tumors (62).  
SDF-1α has been linked to organ-specific metastasis of some tumor-types expressing 
CXCR4 and/or CXCR7 (204;212;232-236). The organ-specific pattern of breast and melanoma 
metastasis has been correlated with the expression of chemokine receptors, including CXCR4, 
CCR7, and CCR10, on tumor cells {77, 114}.  Furthermore, the SDF-1α-mediated invasion of 
human basal carcinoma cells was reported to be influenced by the upregulation of matrix 
metalloproteinase MMP-13 (72). MMP have been suggested to play an important role in the 
invasion process because their proteolytic activities assist in degradation of the extracellular 
matrix and basement membranes. Thus, SDF-1α has been implicated in tumor vascularization 
and metastatic dissemination of tumor cells. 
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  Endothelial Cell Surface-Associated SDF-1α 
 Peled et al. were the first to demonstrate the constitutive expression of SDF-1α on 
vascular endothelium in bone marrow.  Using in vitro and in vivo assays, they showed that 
murine hematopoietic progenitors (CD34+ BMC) established efficient rolling on P-selectin+ and 
E-selectin+ EC, but developed firm adhesion on EC surfaces only in the presence of 
immobilized-SDF-1α on EC. Additionally, in the absence of selectins, SDF-1α promoted VLA-
4-mediated, G protein-dependent tethering, and VCAM-mediated adhesion under shear flow 
(227). Their results revealed that SDF-1α-activated lymphocyte function-associated antigen-1 
(LFA-1), VLA-4 and VLA-5 on immature CD34+ BMC (238).  
Most chemokines, including SDF-1α, bind to heparan sulfates (HS) in the extracellular 
matrix and on the cell surface (239-242). HS are a family of sulfated glycosaminoglycans 
(GAG). The chemokine concentration gradient in tissue is important for directional migration of 
cells and is believed to be controlled by GAGs (239). GAGs are covalently attached to core 
proteins on all animal cells and ECM. The binding of SDF-1α to HS is reported to involve the 
amino acids lysine at positions 24 and 27 and arginine at position 41; the HS-binding sites are 
distinct from those required for CXCR4. The binding affinity of SDF-1α for HS has been 
calculated and is reported to range from 39-93 nM (243;244) compared to 1.67 nM for CXCR4 
(243). The association of SDF-1α with HS is shown to prevent its inactivation by the serine 
protease CD26/DPP IV, which selectively removes the N-terminal dipeptide from SDF-1α (244-
247). The constitutive expression of SDF-1α associated with heparan sulfate in cutaneous 
capillary endothelium was reported to trigger specific arrest of Kaposi Sarcoma-associated 
herpes virus-infected cells and dictated the preferential localization of Kaposi Sarcoma in the 
skin under physiologic shear flow (248). 
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Ceradini et al. detected a significant increase in endothelial cell surface-bound SDF-1α in 
hypoxic cell cultures by flow cytometry. They reported that greater numbers of CXCR4+ EPC 
adhered to HUVEC pre-conditioned in hypoxic condition compared to HUVEC monolayers 
cultured under normoxic conditions. This effect was abolished by antibody-mediated blockage of 
SDF-1α and CXCR4 interaction. In addition, in vivo results demonstrated that CXCR4+ 
progenitor cell localization to regenerating tissue was dependent on the hypoxia-induced SDF-1α 
gradient (109;131). 
 Similarly, it is likely that extracellular matrix-associated and endothelial cell-associated 
SDF-1α not only acts as an important chemotactic factor in recruiting EPC to tumors but also 
mediates the adhesion, retention, and incorporation of bone marrow-derived cells into the tumor 
vasculature, thereby contributing to tumor vasculogenesis. 
  CXCR4 Expression in Tumors 
 Several investigators have reported the involvement of CXCR4 and SDF-1α interaction 
in cancer progression (Reviewed by (217). This receptor-ligand interaction has been shown to 
promote angiogenesis and organ-specific migration of tumor cells in many cancers, like breast 
(249), (250), lung (233;251), ovarian (252), renal (13), and prostate (230) cancer, 
neuroblastomas (253) and glioblastomas (62). CXCR4 has also been strongly implicated in 
growth of several neuroectodermal tumors and small cell lung carcinoma (Reviewed by (254).
 Muller et al. showed that the human breast cancer cell line MDA-MB-231 expressed 
CXCR4 and migrated in response to SDF-1α.  They demonstrated that these cells migrated in 
response to protein extracts from lung, liver, bone marrow, lymph nodes, skin, and muscle.  This 
chemotaxis was significantly inhibited by anti-CXCR4 antibody in the lung, liver, bone marrow, 
and lymph node protein extracts (212). Their results reinforced Paget’s theory of “seed and soil” 
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and indicated the important function of SDF-1α and CXCR4 in determining the metastatic 
destination of tumor cells (255).   
 Hypoxia is an important mechanism that alters the metastatic behavior of tumor cells in 
vivo. It is reported to favor metastasis by up-regulating CXCR4 on tumor cells via the hypoxia-
inducible factor-1α (HIF-1α) (256;257). Hypoxic conditions in the tumor mass promotes 
transcription and translation of HIF-1α, whereas under physiological conditions, the tumor 
suppressor protein von Hippel-Lindau negatively regulates CXCR4 expression by degradation of 
HIF-1α (258). A recent report by Maréchal et al. showed that CXCR4 expression in pancreatic 
tumors had a positive correlation with HIF-1α. They proposed that CXCR4 was a valuable 
prognostic factor and therapeutic target in pancreatic cancer. This study also reported the 
overexpression of CXCR4 in endometrial cancer.  In a separate study, HEC1A human 
endometrial cancer cells were reported to be able to generate diffused metastases in nude mice.  
The number and size of these metastases was demonstrated to be dramatically reduced by 
simultaneous treatment with neutralizing anti-CXCR4 antibody (259). Another group reported a 
significant reduction in the growth of both colon and pancreatic tumors in mice that received 
intra-peritoneal injections of anti-CXCR4 antibody.  Administration of anti-CXCR4 antibody 
lead to a significant reduction in capillary density but did not affect the expression of VEGF in 
tumors (215). Similarly, Aghi et al. reported that in the presence of AMD3100 (CXCR4 
antagonist) the number of bone marrow-derived cells contributing to tumor endothelium was 
significantly reduced. Thus, the interaction between CXCR4 and SDF-1α has been established to 
be important for tumor angiogenesis and metastasis, and interrupting this association could be a 
valuable anti-cancer therapy. 
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  A Second SDF-1α Receptor: CXCR7 
CXCR7/RDC1 was subsequently identified in 2005 and 2006 as a novel receptor for 
SDF-1α and CXCL11/I-TAC (260-262). CXCR7 has been reported to be expressed on malignant 
cell types and fetal liver cells. High levels of CXCR7 mRNA were detected in healthy murine 
tissues: heart, lung, brain, kidney, testes, ovary, and 14 day-old fetus; thymus and liver had 
relatively lower expression.  
Similar to the CXCR4-/- mice, mice with a homozygous deletion of CXCR7 died at birth 
with ventricular septal defects and semilunar heart valve malformation {367}. This report also 
confirmed that the principal chemokine ligand for CXCR7 was SDF-1α, but SDF-1α did not 
induce signaling through CXCR7; CXCR7 formed a functional heterodimer with CXCR4 and 
enhanced SDF-1α-induced signaling (263). Unlike many other chemokine receptors, ligand 
activation of CXCR7 did not cause calcium mobilization or cell migration. The interaction of 
SDF-1α with CXCR7 resulted in a proliferative effect, in contrast to CXCR4, which mediated 
chemotaxis (260).   
Recently, Wang et al. (235) showed that CXCR7 expression was correlated with tumor 
aggressiveness in prostate cancer. CD44 and cadherin-11 were reported to be expressed 
downstream of CXCR7, and were suggested to contribute to the invasiveness of prostate cancer 
cells. CXCR7 was also demonstrated to regulate the expression of pro-angiogenic factors IL-8 
and VEGF, which are known modulators of tumor angiogenesis.  
Burns et al. (260) reported that more CXCR7-transfected MDA-MB-435S breast cancer 
cells adhered to HUVEC cultures stimulated by TNF-α and IL-1β. In addition, when HUVEC 
were stimulated with TNF-α and IL-1β, an increase in the expression of CXCR7 was observed. 
Based on these experiments they concluded that although the expression of CXCR7 on any one 
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cell type was sufficient to promote some cell-cell interactions, CXCR7 expression on both 
activated HUVEC and tumor cells concomitantly produced maximal adherence in vitro. They 
also reported that the administration of a CXCR7 antagonist resulted in a decrease in tumor 
growth in immunodeficient and syngeneic mice engrafted with human B lymphoma, human lung 
carcinoma, or mouse lung carcinoma. Each of these tumors was shown to express CXCR7. Thus, 
they proposed that CXCR7 was a viable target for development of novel cancer therapeutics.  
Miao et al. (236) demonstrated the expression of CXCR7 on breast and lung tumor cell 
lines 4T1 and LLC, respectively. Furthermore, they reported that tumor growth was impaired 
when CXCR7 was knocked down in these tumor cells. Interestingly, they also observed specific 
expression of CXCR7 on tumor-associated blood vessels, but not on normal vasculature. They 
also reported that CXCR7 promoted the growth of breast and lung tumors and enhanced lung 
metastasis. Thus, suggesting that CXCR7 was important in promoting tumor development and 
progression (236).  This premise was consistent with the clinical observation that higher 
expression of CXCR7 was linked to early and metastatic recurrence in pathological stage I non-
small cell lung cancer (234).  
 
Synopsis of Introduction 
 Tumors arise due to genetic and epigenetic changes that lead to transformation and 
uncontrolled proliferation of cells. These tumor cell clusters rely on diffusion of oxygen and 
nutrients for expansion; these become limiting factors as tumors reach 2-3 millimeters in size. 
For further propagation and progression, tumors must undergo an ‘angiogenic switch’ to develop 
tumor vasculature. Thus, inhibition to tumor vascularization is an important control point in 
tumor development and cancer progression. Several hypoxia-induced growth factors, 
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chemokines, and cell adhesion molecules have been shown to participate in tumor angiogenesis 
that is mediated by activated mature endothelial cells. In addition, there is growing evidence that 
some of these proteins are important in mediating tumor vasculogenesis by mobilizing and 
chemoattracting the bone marrow-derived endothelial progenitor to tumors. Stromal-derived 
factor (SDF-1α) is one of the well characterized hypoxia-induced, secreted proangiogenic 
chemokines. Several cell types, including endothelial cells, produce SDF-1α. Similar to other 
chemokines, secreted SDF-1α binds to proteglycans in the extracellular matrix and on cell 
surfaces. In addition, SDF-1α-mediated chemoattraction of CXCR4+ endothelial cells and 
hematopoietic stem cells in vitro and to hypoxic regions in ischemic injuries in vivo has been 
demonstrated. SDF-1α is elevated in certain tumors, implicated in organ-specific metastasis of 
tumor cells, and involved in angiogenesis.  
The literature in the field has thus led us to propose a specific role for SDF-1α in tumor 
vasculogenesis.  These data are consistent with the proposal that tumor-derived stromal derived 
factor-1α (SDF-1α) binds to tumor endothelium and extracellular matrix and recruits and 
mediates the adhesion of circulating bone marrow-derived CXCR4+ endothelial progenitors. 
 
DISSERTATION HYPOTHESIS AND SYNOPSIS OF EXPERIMENTS 
We hypothesize that stromal derived factor-1α mediates tumor vasculogenesis, recruiting 
bone marrow-derived endothelial progenitor cells to tumors.   
 LLCaB, a subclone of the murine Lewis lung adenocarcioma tumor cell line (LLC1), was 
used in this study. First, we evaluated the development of LLCaB subcutaneous tumor and 
metastases in syngeneic immunocompetent C57Bl/6 mice. Subsequently, subcutaneous and 
metastatic tumor tissue samples from experimental mice and healthy tissue samples from naïve 
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control mice were analyzed for the expression of SDF-1α and E-selectin. The expression of 
cognate receptor/ligands for SDF-1α and E-selectin and endothelial progenitor markers were 
evaluated on Lin¯  BMC.  The use of Lin¯  BMC for in vitro and in vivo experiments was a 
practical alternative to endothelial progenitor cell purification. Dermal fibroblasts were used as a 
control cell type in both in vitro and in vivo experiments. Next, in vitro adhesion assays were 
conducted to evaluate the role of SDF-1α and E-selectin in mediating adhesion of Lin¯  BMC 
with tumor-derived cells. 
 In the initial in vivo experiments, biolocalization of vascular endothelial cells (VEC), 
isolated from EGFP-transgenic mice, in tumor-bearing mice was evaluated by microscopy. 
Although EGFP-VEC were specifically detected in metastatic lesions, quantization of VEC 
homing was compromised by tissue autofluorescence and artifactual fluorescence. This 
prompted the development and standardization of a qPCR assay to detect tissue-localized EGFP-
transgenic cells. Finally, the biolocalization of systemically administered EGFP-Lin¯  BMC and 
EGFP-dermal fibroblasts, 3 days after cell injection, in subcutaneous and metastatic tumors, and 
other organs was evaluated by qPCR. Subsequently, long-term (7-day) retention of EGFP-Lin¯  
BMC in metastatic lesions was also assessed.   
 These data from in vitro and in vivo experiments lead to the development of a model 
suggestive of several functions that SDF-1α might be involved in tumor biology.   
 
 
 
CHAPTER II:  MATERIALS AND METHODS 
Mice 
  Vascular endothelial cells (VEC) were isolated from neonatal C57Bl/6 mice that 
constitutively expressed the enhanced green fluorescent protein (EGFP) transgene (C57Bl/6-
Tg(ACTbEGFP)10sb/J, #003291 and/or C57BL/6-Tg(UBC-GFP)30Scha/J, # 004353, The 
Jackson Laboratory).  Strain #003291 is a heterozygous-bright, homozygous-lethal strain; the 
hemizygous mice used in this study were obtained by breeding transgenic male mice with 
C57Bl/6 wild-type females (#664, The Jackson Laboratory, Bar Harbor, ME). Strain #004353 is 
maintained as a homozygous strain.  The above mentioned EGFP-transgenic mice strains were 
also used for harvesting bone marrow and purifying the lineage-negative bone marrow cells 
(EGFP-Lin¯  BMC).  Two to six month-old wild-type C57BL/6 mice were used as recipients of 
syngeneic tumor cells and EGFP-VEC and EGFP-Lin¯  BMC. All mice strains were originally 
purchased from Jackson Laboratory and maintained in an in-house breeding colony. East 
Carolina University Animal Use and Care Committee approved all animal studies.   
 
Isolation and Culture of Cell from Murine Tissue 
  Cardiac Vascular Endothelial Cells (VEC) 
 VEC were isolated from 2-5 day-old mouse pups (5-30 per preparation) and maintained 
in culture for 2-3 weeks as described (Figure 2A; (94)). A minimum of 5 pups were used for 
each preparation.  The pups were euthanized using Isoflurane (Webster Veterinary, Sterling, 
MA), sterilized by a quick rinse in 70% ethanol, and followed by opening the chest cavity and 
removing the hearts using curved forceps.  The hearts were placed in a 35 mm Petri dish 
containing Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (DMEM-F12, Invitrogen, 
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Carlsbad, CA) at room temperature (RT). The hearts were minced with a sterile disposable 
scalpel with a no. 10 stainless steel blade.  The tissue was then incubated in 0.1% DNase / 2 
mg/mL Collagenase (Sigma, St. Louis, MO) in DMEM-F12 media containing 5% fetal calf 
serum (FCS) at 37°C in 5% carbon dioxide (CO2) for 1 hour (3 mL DNase-Collagenase per 5-10 
pups). The digested tissue was diluted in DMEM-F12 and collected in a 15 mL tube.  Cell 
suspension was vortexed; the larger undigested tissue chunks were allowed to settle to the 
bottom of the tube and were removed using a sterile plastic transfer pipette. The cells in the 
remaining supernatant were pelleted by centrifugation at 300 × g for 10 minutes.   The cell pellet 
was resuspended at 2 mL per 5 hearts in 38% Sterile Isotonic Percoll. Sterile Isotonic Percoll 
was a 90% Percoll (Pharmacia, Piscataway, NJ) solution in Hanks Buffered Salt Solution 
(HBSS, Gibco, Carlsbad, CA).  The cells were pelleted by centrifugation at 800 × g for 20 
minute at 25°C.  The pellet containing the enriched VEC was resuspended in 5 mL VEC media, 
plated in a 35 mm tissue culture dish and incubated at 37°C for 1 hour. The VEC media 
consisted of DMEM-F12 high glucose (Gibco) with 2.438 g/L sodium bicarbonate (pH 7.0, 
320±5 mOsm/L) supplemented with 5% FCS (Invitrogen), 15 µg/mL endothelial cell growth 
supplement (Sigma), 2 U/mL heparin (Sigma), 10 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES, Sigma), 1 mM sodium pyruvate, insulin transferrin-
selenium (25 µg/mL, 25 µg/mL, 25 ng/mL; ITS, Sigma). The final pH was adjusted to 7.0 and 
osmolarity to 320±5 mOsm/L. Non-adherent cells were gently rinsed off using a plastic transfer 
pipette and transferred to gelatin-coated 6-well plates. 
  Cells from 5 hearts were plated per well.  Next Day, the media was changed to remove 
the non-adherent red blood cells.  Three to five days later, cells were purified by selective 
trypsinization with 0.25% trypsin-0.05% ethylenediaminetetraacetic acid (ETDA, Invitrogen) 
  
   
62
after rinsing with Dulbecco’s phosphate buffered saline (DPBS) without calcium (Ca2+) and 
magnesium (Mg2+).  Cells were observed under the microscope, and at the first sign of 
detachment, cells were washed off the plate and re-plated in gelatin-coated plates or flasks.  Cells 
were subsequently passaged when cultures reached 80% confluency.  VEC were expanded in 
culture for up to 3 weeks.   
  VEC were routinely isolated from C57Bl/6-Tg(ACTbEGFP)10sb/J (Homozygous 
Actb-EGFP) transgenic mice as the homozygous Actb-EGFP mice are not viable. Nonetheless, 
the VEC isolated from both strains fluoresce with comparable brightness (Figure 2B). 
  Bone Marrow Cells (BMC) 
  Mice were euthanized by overdose of Isofluorane followed by cervical dislocation.  The 
femur and tibia from the hind limbs were removed and attached muscle tissue was removed from 
the bones using clean gauze.  The bones were placed in a 35 mm Petri dish containing 1X HBSS   
(without Ca2+ and Mg2+) containing 0.1% Bovine Serum Albumin (BSA, Sigma) or Iscoves 
media (Gibco).  The pH and osmolarilty of 1X HBSS and Iscoves were adjusted to 7.0 and 320±5 
mOsm/L respectively. The ends of the bones were cut off.  Using a 22-25 gauge needle and 10 cc 
syringe, the marrow from the bones were flushed with Iscoves or 1X HBSS with 0.1% BSA 
(HBSS/BSA).  The cell suspension was triturated using a transfer pipette to break tissue chunks.  
The suspension was then centrifuged at 300 × g at 10°C for 10 minute.  The bone marrow cell 
(BMC) pellet was resuspended in Iscoves or HBSS/BSA.  RBCs were lysed on ice for 10 minutes 
using freshly prepared RBC lysis buffer [155 mM ammonium chloride (NH4Cl) and 12 mM 
sodium bicarbonate (NaHCO3)].  The volume was increased to 50 mL and the cell suspension 
was then passed though disposable 70 µm nylon cell strainer (BD Falcon, Franklin Lakes, NJ) to 
remove pieces of bones and debris.  The cells suspension was centrifuged at 300 × g for 10  
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Figure 2: Isolation of Murine Cardiac Vascular Endothelial Cell 
A)  Protocol for isolating micro vascular endothelial cells from hearts of mouse neonates. 
B) Histogram comparing the green fluorescence intensity of VEC isolated from C57Bl/6, 
hemizygous ActbEGFP, and homozygous ActbEGFP-transgenic mice. Although, the 
homozygous ActbEGFP mice have twice the number of egfp-transgene copies compared to the 
hemizygous ActbEGFP, the green fluorescent intensity was comparable in VEC isolated from 
both strains of mice. 
  
   
64
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Purple = C57Bl/6 
Green  = Hemizygous Actb-EGFP 
Pink      = Homozygous Actb-EGFP 
 
A 
B 
2-5 day old 
mouse pups
Remove Hearts
Digest with DNase /
Collagenase
Percoll Gradient
38% Percoll
Pellet
Discard Supernatant
Plate Pelleted 
Cells
( 1hr, 37’C) 
Plate non-
adherent cells 
on Gelatin-
coated plates
Selective 
Trypsinyzation
(~1 min) 
After 3-7 days
Expand in Culture 
For 2-3 weeks
EGFP-VEC Culture (200X)
  
   
65
minutes at 10°C and cell count was done using 1% acetic acid and Trypan Blue (Gibco 
Invitrogen) on a hemocytometer.   
  Bone Marrow-derived Lineage-negative Cells (Lin¯  BMC) 
  The lineage-positive cells were immunomagnetically depleted from the BMC with 
Dynabeads (Dynal Biotech, Oslo, Norway). Biotinylated anti-mouse antibodies were added to the 
BMC suspension in 1X HBSS containing 0.1% BSA and incubated on a rotator for 30-45 minutes 
at 4°C. Two microliters of each pre-diluted antibody, namely anti-CD3 (clone 145-2C11), anti-
CD8, anti-CD11b (clone M1/70), anti-CD45R/B220 (clone RA3-6B2), anti-Gr-1 (clone RB6-
8C5), and anti-Ly-76 (clone TER-119) (Biotin Mouse Lineage Panel, BD Biosciences), were 
added per 2 × 106 BMC. After centrifugation of the labeled cells, the cell pellet was resuspended 
at 1 × 107 cells per mL. Streptavidin-coated Dynabeads (DYNAL CellectionTM Biotin Binder, 
Dynal Biotech) were added to the cell suspension at a ratio of eight beads per cell and the cell 
suspension was incubated on a rotator for 45-60 minutes at 4°C. This cell-bead suspension was 
placed on a Dynal Magnetic Particle Concentrator (Dynal Biotech, Oslo, Norway) for 5 minutes 
to allow the cells coated with antibody and magnetic beads to bind to the magnet. The 
supernatant containing the Lin¯  BMC were collected and washed with HBSS/BSA (Figure 3). 
Flow cytometric analysis of the enriched cells stained with biotinylated lineage panel antibodies 
and streptavidin-Fluorescein isothiocyanate (SAv-FITC) or SAv-Phycoerythrin (PE) confirmed 
the purity of the cell population. The Lin¯  BMC were ~95% free of lineage-committed cells. The 
Lin¯  BMC were used for in vitro and in vivo assays. 
Dermal Fibroblasts 
  Fibroblasts were isolated from the dermis of 1-2 day-old mouse pup skin as schematically 
represented in Figure 4 (method adapted from (264).  1-3 day old pups were euthanized using  
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Figure 3: Protocol for Enriching Lineage-negative Bone Marrow Cells 
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Isofluorane, sterilized with 70% ethanol, and the dorsal and ventral trunk skins were excised. 
Skins were incubated dermal side down in sterile 35 mm Petri dishes and incubated overnight at 
4°C in 0.25% trypsin (Invitrogen). The epidermis was peeled off the dermis and discarded using 
two angled fine tip forceps. The epidermis was translucent white and the dermis was light brown 
to black in color. The dermal pieces were minced using sterile scissors and incubated at 37°C in 5 
mL 0.1% Collagenase Type I (Worthington Biochemical, Freehood, NJ) per 3-5 skins. The 
dissociated dermis solution was diluted approximately 1:10 by increasing the volume to 50 mL 
with Dulbecco’s Modified Eagles Medium (DMEM) containing high glucose (4500 mg/L D-
glucose). This cell suspension was then filtered though sterile gauze and centrifuged at 200 x g 
for 7 minutes.  The supernatant was carefully aspirated and the cell pellet was resuspended in 
DMEM containing 5% FCS and incubated in a humidified incubator with 5% CO2 at 37°C.  The 
next day, non-adherent cells and debris were removed and fresh media was added to the cell 
culture. Cells were detached from culture using 0.25% trypsin-0.05% EDTA and passaged when 
cultures reached 80% confluency. The dermal fibroblasts were kept in culture for a maximum of 
10 days. 
  Dissociated Lewis Lung Subcutaneous Tumor Cell Culture  
  The protocol for culturing dissociated LLCaB subcutaneous tumor was adapted from our 
laboratory’s previously established protocol to isolate endothelial cells from human tumors (265). 
Briefly, subcutaneous tumors were surgically removed and rinsed in cold DPBS (pH 7.0, 320±5 
mOsm/L). Tumor tissue was then transferred into 20 mL of 10 mM EDTA in DPBS in 50 mL 
tubes and incubated on ice for 30 minutes. Next, the tumor tissue was minced using a scalpel and 
each 12 gm of tumor tissue was incubated in 15 mL of 0.1% DNase (Sigma) / 2 mg/mL 
Collagenase II (Sigma) in DMEM containing high glucose in 50 mL tubes.   
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Figure 4: Protocol for Isolating Dermal Fibroblasts from Mouse Neonates 
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Tumor tissue was placed on a rotating shaker (150-200 rpm) for 1.5-2 hours at 37°C.  The 
dissociated tumor tissue was then diluted 10 times in DMEM-high glucose and the suspension 
was filtered through 70 µm disposable cell strainers. The filtered cells were centrifuged at 300 x g 
for 10 minutes at 10°C.  The cell pellet was resuspended in VEC media and cells were cultured in 
gelatin-coated flask.  Cultures were rinsed to remove tissue debris and non-adherent cells and 
fresh media was added the next day.  Cultures were passaged when cells reached 80% 
confluency; 0.25% trypsin-0.05% EDTA was used to detach cells from culture flasks. 
  
Culture of Established Cell Lines 
  Lewis Lung Carcinoma Cells (LLCaB) 
  LLCaB is a subclone derived from a bone metastasis in a C57BL/6 mouse bearing a 
subcutaneous Lewis Lung Carcinoma (LLC1, ATCC #CRL-1642), and was provided to our 
laboratory by Dr. C. J. Kovacs and Mark Evans of the Department of Radiation Biology and 
Oncology at East Carolina University, Greenville, NC.  LLCaB were cultured in DMEM 
containing high glucose (4500 mg/L D-glucose), sodium bicarbonate (3.7 mg/L) with 10% fetal 
calf serum in a humidified incubator at 37°C with 5% CO2.  The LLCaB culture medium was set 
to 320±5 mOsm/L and pH of 7.0.  When the cell culture approached 80% confluency they were 
rinsed with DPBS, incubated with 500 µl of 0.25% trypsin for 2-5 minutes and collected using 
DMEM.  The cell suspension was split 1:6-1:12 and placed in new flasks.     
  Brain Endothelioma Cells (bEnd.3) 
  The mouse brain endothelioma cell line (bEnd.3) express proteins that are specifically 
expressed by activated endothelial cells found in ischemic tissue and tumor. Thus, bEnd.3 cell 
line was purchased from ATCC (#CRL-2299) to use as a surrogate for tumor-derived endothelial 
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cells.  The bEnd.3 cells were cultured in DMEM containing high glucose (4500 mg/L D-glucose), 
low sodium bicarbonate (1.5 mg/L) and 10% fetal calf serum, in a humidified incubator at 37°C 
with 5% CO2.  The bEnd.3 culture medium was set to 320±5 mOsm/L and had a pH of 7.0.  
When the cell culture approached 80% confluency they were rinsed with DPBS, incubated with 
500 µl of 0.25% trypsin - 0.05% ETDA for 2-5 minutes and collected using DMEM. 
  3T3-L1 Pre-Adipocyte Cells 
  The 3T3-L1 (ATCC# CL-173) pre-adipocyte cell line was a gift from the laboratory of 
Philip Pekala in the Department of Biochemistry and Molecular Biology at East Carolina 
University. These cells were cultured in the recommended DMEM containing high glucose (4500 
mg/L D-glucose), low sodium bicarbonate (1.5 mg/L) and 10% newborn calf serum (Invitrogen, 
Carlsbad, CA) in a humidified incubator at 37°C with 5% CO2. The 3T3-L1 culture medium was 
set to 320±5 mOsm/L and a pH 7.0. These cells are a sub-strain from 3T3 cells from Swiss albino 
mice, which undergo a pre-adipose to adipose like conversion as they progress from a rapidly 
dividing to a confluent and contact-inhibited state. 
 
Development of Lewis Lung Adenocarcinoma Tumors 
  Subcutaneous Tumors 
  Hair on the right flank of the C57Bl/6 mice was removed by shaving and application of 
Nair Hair Remover® at least two days prior to injecting tumor cells. LLCaB cells were harvested 
using 0.25% trypsin-0.01% EDTA and placed in DMEM for injection. C57Bl/6 mice were 
injected subcutaneously (s.c.) in the right flank with 5 × 105 LLCaB cells in 100 µl. Tumors 
became palpable in 7-10 days.  Tumor growth was documented by measuring tumor size using 
digital calipers.  Tumor volume was calculated as (width × width × length) / 2.  
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  Pulmonary and Hepatic Tumors 
  Lung and liver metastases were induced in C57Bl/6 mice using a previously described 
method (4). Briefly, subcutaneous tumors were developed as described above. The subcutaneous 
tumors were surgically removed when they reached a volume of 1500 mm3. Mice were closely 
monitored for weight loss and lethargy for two-three weeks following tumor removal.  During 
this period the tumor cells that had seeded in the lung and liver developed into secondary 
pulmonary and/or hepatic tumors. The weight and diameter of each macroscopically visible lung 
and liver metastases was noted. Metastatic tumor volumes were calculated (assuming spherical 
shape) by (4πr3) / 3 where r = radius. Tissue harvested were either flash frozen in liquid nitrogen 
or embedded in Tissue Tek® OCT (Optimum Cutting Temperature) compound (VWR Scientific 
Products, Suwannee, GA) and frozen using dry-ice and acetone (Sigma). 
 Hematoxylin and Eosin (H&E) Staining of Tissue Sections 
  Frozen cryostat sections were fixed by immersing slides in acetone for 20 minutes then 
rinsed with distilled water.  Slides were serially dipped in Harris’ hematoxylin (Sigma) for 1 
minute, 3-10 quick dips in acid alcohol (1% hydrochloric acid in 70% ethanol), ammonium water 
(0.2% ammonium hydroxide in distilled water) for 1 minute, Eosin Y for 30 seconds with 
intermittent rinses in water (twice for 2 minutes each). Stock Eosin was prepared by dissolving 1 
gm Eosin (Sigma) in 20 mL distilled water and 80 mL 95% Ethanol.  Working Eosin solutions 
was prepared by combining 1 part stock Eosin with 3 parts 80% Ethanol; 0.5 mL acetic acid was 
added to 100 mL of working solution before use. The sections were dehydrated by sequential 2 
minute changes in 95% ethanol (twice) and 100% ethanol (twice) to remove excess Eosin stain 
and finally in xylene.  Coverslips were mounted on slides using Permount® (Fisher Scientific, 
Pittsburg, PA).   
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Analysis of RNA Expression  
 RNA Isolation 
 Ribonucleic acid (RNA) was isolated from cell pellets or frozen tissue specimens.  
Trizol® (Invitrogen) was added to pulverized tissue or cell pellets (1 ml / 2 × 106 cell). After 
incubation at RT for 5 minutes, chloroform was added and the suspension was thoroughly mixed 
by inversion. The tubes were centrifuged at 12,000 rpm for 15 minutes at 4°C.  The aqueous 
layer was transferred into another tube and equal volume of 100% Isopropanol (Sigma) was 
added.  These tubes were mixed and incubated at -20°C overnight to precipitate RNA.  RNA was 
pelleted by centrifugation at 12,000 rpm for 15 minutes at 4°C.  The RNA pellets were rinsed 
with 75% ethanol, allowed to air dry and resuspended in nuclease-free water (Ambion, Foster 
City, CA).  RNA concentration was measured spectrophotometrically. The concentrations of all 
RNA samples were adjusted to 1 mg/mL. 
 cDNA Preparation 
 Complementary DNA (cDNA) was prepared using 5 µg RNA as previously described 
(266). Five microliters of RNA (1 µg/µl) was incubated with 0.5 µg of oligo (dT) primer at 65°C 
for 7 minutes and chilled on ice before adding a 20 µl reaction mixture containing 50 mM Tris-
HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 10 mM DTT, 0.5 mM dNTP, 5 units of cloned 
placenta RNase inhibitor and 200 units of Maloney Murine Leukemia Virus Reverse 
Transcriptase (MLV-RT). For very dilute RNA samples a maximum volume of 10.5 µl RNA was 
used. All reagents were purchased from Gibco-Invitrogen. Samples were incubated for 1 hour at 
37°C, followed by heating at 95°C for 5 minutes. cDNA samples were diluted 1:5 with water 
prior to freezing. All cDNA samples were stored at -20°C.  
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 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) 
 Reverse transcriptase PCR Gene Expression Assays (Applied Biosystems, Foster City, 
CA) were used to evaluate the expression analysis of VEGF (Mm00437308_m1), SDF-1α 
(Mm00457276_m1), VEGFR2 (Mm00440111_m1), and CXCR4 (Mm01292123_m1). Beta-2-
microglobulin (Mm00437762_m1) was used as the endogenous control. These are proprietary 
assays, detected with a FAM/MGB-labeled probe. 5 microliters of cDNA was used as the 
template in a 25 µl total reaction mixture containing 1X TaqMan® Universal Master Mix, 
nuclease free water and primer-probe. PCR was carried out under standard cycling condition: 2 
minutes at 50˚C, 10 minutes at 95˚C followed by 40 cycles of 15 seconds at 95˚C and 1 minute at 
60˚C in Applied Biosystems 7000 Thermocycler (Applied Biosystems, Inc). 
 
Analysis of Protein Expression  
  Tissue Homogenization and Protein Quantitation 
 Protein samples were prepared by sonication of pulverized frozen tissue in DPBS 
containing the tissue-culture approved Protease Inhibitor Cocktail (Sigma) and 0.05% Triton X 
(Sigma) (2 mL / gram of tissue).  Protein concentrations were determined using the Pierce Micro 
BCA Protein Assay (Thermo Scientific, Rockford, IL).  Lysates (diluted 1:100), and standards 
(provided in the kit) were added to reagents on a 96-well flat-bottomed plate and incubated as 
according to manufacturers instructions.  Plates were read at 562 nm on a Synergy HT Multi-
Mode Microplate Reader (BioTek, Winoski, VT) and concentrations determined based on 
standard curve (polynomial equation). 
 Quantitation of Chemokines by Enzyme-Linked Immunosorbant Assay (ELISA) 
 Concentration of chemokine SDF-1α in tissue homogenates was determined using 
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Quantikine® ELISA kits (R&D Systems, Minneapolis, MN). Undiluted protein samples from cell 
and tissue lysates, and serum were assayed for SDF-1α expression.  The amount of SDF-1α in 
each sample was calculated based on the standard curve (polynomial equation) from each assay. 
SDF-1α concentrations (pg/mL) in tissue homogenates were normalized to the protein 
concentration (mg/mL) of each sample; thus, the results are reported as picogram (pg) SDF-1α 
per milligram (mg) of protein.  
  Flow cytometric Analysis of Cell Surface and Intracellular Proteins 
  Flow cytometry was used to measure the cell surface and total (intracellular and cell 
surface) expression of specific proteins on cultured cell and bone marrow-derived cells. All 
adherent cell cultures were harvested using 0.25% trypsin-0.05% EDTA. Cell counts and percent 
viability was calculated using Trypan blue exclusion assay. Cells were washed with 1% bovine 
serum albumin (BSA, Sigma) and 0.05% sodium azide (Sigma) in DPBS (DPBS/BSA/Azide).  1 
× 105 cells per 10 µl DPBS/BSA/Azide were aliquoted in 5 mL polystyrene tubes and primary 
labeled antibodies were added.. To measure both intra- and extracellular protein expression the 
cells were fixed using 0.5% paraformaldehyde and permeabilized using 0.5% saponin prior to 
addition of antibodies.  Cells were washed with 4 mL DPBS/Azide, centrifuged at 300 × g for 10 
minutes.  Cell pellets were fixed using 200 µl of 1% paraformaldehyde (Electron Microscopy 
Sciences, Hatfield, PA) while vortexing. Cells were vortexed and incubated at RT for 15 minutes. 
Specific antibodies for flowcytometry from BD Pharmingen were used at 1 µg per 1 × 105 cells 
included PECAM-1 / CD31 (clone MEC13.3), CD34 (clone RAM34), VCAM-1 / CD106 (clone 
MVCAM.A), LAMP-1 / 107a (clone 1D4B), E-selectin / CD62E (clone 10E9.6), CXCR4 / 
CD184 (clone 2B11), cKit / CD117 (clone 2B8), Sca-1 (clone E13-161.7), VEGFR2 (clone 
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Avas12α1), and CD43 (clone S7).  Specific antibodies purchased from R&D Systems included 
CXCR2 (clone Fab2164), and E-selectin (MAB575 and MAB5751). 
  Immunofluorescent Staining of Cell Cultures and Tissue Sections 
  For immunofluorescent studies, tissue was surgically removed post euthanasia and frozen 
in Tissue-TEK OCT compound using dry ice and acetone.  Slides with tissue sections (10 µm for 
subcutaneous tumor and hepatic tissue and 16-18 µm for lung tissue) were prepared on a cryostat 
and stored in covered slide boxes at -70°C.  Slides were brought to RT and fixed with cold 
acetone (-20°C) for 20 minutes.  Individual sections were encircled using a PAP Pen (Invitrogen) 
prior to rinsing twice in DPBS (320±5 mOsm/L, pH 7.0). 
  For E-selectin and CD31 staining, the sections were then blocked for 1 hour at RT with 
blocking buffer: DPBS (320±5 mOsm/L, pH 7.0) containing 3% BSA (Sigma) and 10% goat 
serum (Sigma).  Purified primary rat anti-mouse antibodies diluted 1:25 in blocking buffer were 
added to each section (100 µl / section), and incubated overnight in a humidified chamber at 4°C.  
Slides were rinsed twice with DPBS, and incubated with diluted 1:300 biotinylated goat anti-rat 
secondary antibody (BD Pharmingen) for 30 minutes at RT. The slides were rinsed with DPBS 
twice and incubated with diluted 1:300 Streptavidin-PE (BD Pharmingen) for 30 minutes at RT. 
Slides were rinsed in DPBS twice before mounting coverslips.  Specific primary antibodies used 
were rat anti-mouse anti-E-selectin (clone 10E9.6, IgG2a), rat anti-mouse anti-CD31 (clone 
MEC13.3, IgG2a), and isotype control (clone R35-95, IgG2a). 
  For CD31 and SDF-1α double staining, the sections were rinsed twice with 1X Tris-
Borate-Saline (TBS) and blocked with 10% horse serum in TBS for 1 hour at RT. Equal amounts 
(2 µg / mL) of both primary antibodies (anti-CD31 and anti-SDF-1 α) and both isotype-matched 
control antibodies were diluted 1:25 in the blocking buffer; 100 µl was added to each section and 
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slides were incubated overnight in a humidified chamber at 4°C. The slides were rinsed twice 
with 1X TBS and incubated with 1:400 diluted cocktail of both secondary antibodies for 30 
minute at RT. The slides were finally rinsed in 1X TBS twice before mounting coverslips.  
Specific primary antibodies used were polyclonal goat anti-mouse anti-SDF-1α (clone C-19, 
Santa Cruz), polyclonal isotype control (Santa Cruz), rat anti-mouse anti-CD31 (clone MEC13.3, 
BD Pharmingen) and isotype control (BD Pharmingen).  The secondary antibodies were 
purchased from Jackson ImmunoResearch Laboratories Inc (West Grove, PA): PE-labeled 
donkey anti-goat and FITC-labeled goat anti-mouse. 
  Aqua-Poly Mount (Polysciences, Inc., Warrington, PA) was used to mount coverslips on 
tissue sections on all slides. The slides were observed on Olympus LPS-220 or Olympus BX5 
epifluorescence microscopes with a Texas Red and/or FITC filter. SPOTTM (SPOT Imaging 
Solutions, Sterling Heights, MI) or DP Controller (Olympus) softwares were used to collect 
photographs from respective microscopes.  
 
In Vitro Functional Assays  
 Cell Adhesion Assay 
 Confluent monolayers of primary VEC and dissociated-tumor cell (DTC) cultures were 
established in gelatin-coated 12- or 24-well plates. Confluent cultures of bEnd.3, 3T3-L1, and 
LLCaB were established in uncoated 12 or 24-well plates. Cells were plated at various 
concentrations in duplicate and allowed to grow for 3-4 days. An empty plate was used as a 
control for non-specific adhesion of EGFP-Lin¯  BMC. Media was aspirated from all adherent 
cell cultures and 5 × 104 - 1 × 105 EGFP-Lin¯  BMC were added to each well and incubated for 
30-45 minutes at RT. Non-adherent cells were removed by aspirating media using a 5 mL 
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Eppendorf pipettor.  Each well was gently rinsed with 2 mL of complete medium for each 
respective cell type and careful aspirated. This process was repeated 5 times for each well. 
Finally, 500 µl 1X HBSS (containing Ca2+ and Mg2+) was added to each well and the plates were 
observed on an inverted phase contrast fluorescent microscope under bright light and fluorescent 
lamp. Images were collected using SPOTTM imaging software. Next, the cells were harvested by 
trypsinization and fixed in 1% paraformaldehyde. The cell suspensions were enumerated using a 
hemocytometer on Olympus BX5 epifluorescent microscope and by flow cytometry (LSR II, 
Becton Dickenson, Franklin Lakes, NJ).   
 6- or 12-well plates were used to evaluate the adhesion of Lin¯  Sca1+cKit+ (LSK) cells to 
different cell types and in presence of different blocking agents. Cells were pooled from 3-6 
wells and split into 3 tubes; tube 1 was used for no staining control, cells in tube 2 were 
incubated with isotype control antibody, and cells in tube 3 were incubated with anti-Sca1-PE 
(Phycoerythrin, 488 nm-FL2) and anti-cKit-APC (Allophycocyanin, 633 nm-FL4) antibodies. 
Each tube was analyzed on the BD LSR II and 105-107 events were processed to collect 500-
10,000 fluorescent EGFP Lin¯  BMC.  The PE-APC double-labeled green-fluorescent cells were 
evaluated by three-color flow cytometry to estimate the percentage and total number of adhered 
LSK cells. In each experiment, Lin¯  BMC were stained with anti-Sca1-PE and anti-cKit-APC to 
evaluate the preparatory Sca1+cKit+ (SK) population.    
 Cell Adhesion Blocking Assay 
 The adhesion of EGFP-Lin¯  BMC was blocked using AMD3100, anti-CXCR4 (clone 
247506, R&D Systems) and/or anti-E-selectin antibodies (clone MAB5751, R & D Systems). 
For blocking CXCR4, EGFP-Lin¯  BMC were incubated in media containing AMD3100 at final 
concentration of 1, 0.1, 0.01 or 0.001 µM or blocking antibody: anti-CXCR4 antibody or isotype 
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control antibody at 12.5 or 25 µg/mL before adding to DTC, LLCaB, or bEnd.3 confluent cell 
cultures.  For blocking E-selectin, the confluent cell cultures were incubated with anti-E-selectin 
antibody 12.5 or 25 µg/mL prior to addition of EGFP-Lin¯  BMC. As stated above, non-adherent 
cells were aspirated, cell cultures were gently rinsed, harvested by trypsinization, fixed with 
paraformaldehyde, and enumerated manually on a hemocytometer and by flow cytometry.  
  
In Vivo Biolocalization of EGFP-Transgenic Cells  
 EGFP-VEC Biolocalization in Metastatic Tumor Model 
 Metastases in lung and liver tissues of C57Bl/6 mice were induced as described earlier. 
At this time, mice with metastases (n= 6) 2 × 106 EGFP-VEC were systemically administered 
via tail-vein or caudal artery. As control, healthy mice injected with 2 × 106 EGFP-VEC (n=5). 
Mice were sacrificed 24-72 hours after injection.   
 Localization of EGFP-Lin¯  BMC and EGFP Dermal Fibroblasts in Subcutaneous 
 Tumor Model 
  Mice bearing small subcutaneous tumors (approximately 100 mm3) were injected with 5 
x 105 Lin¯  BMC isolated from EGFP-transgenic mice (n=7). Mice were sacrificed at 72 hours 
post EGFP-Lin¯  BMC   injection. Subcutaneous tumors and other major organs were harvested  
and embedded in OCT compound (VWR Scientific Product) and frozen using dry-ice and 
acetone for tissue analysis. As control groups, subcutaneous tumor bearing mice were injected 
with either dermal fibroblasts (n=5) or media (n=3) that were isolated from EGFP-transgenic 
mice (Figure 6). The OCT-tissue blocks were sectioned and analyzed by qPCR, as described in 
Figure 8. 
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Figure 5: Diagrammatic Representation of the Experimental Design to Evaluate the 
Biolocalization of EGFP-Lin¯  BMC and Dermal Fibroblasts in the Subcutaneous Tumor 
Model
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  In vivo Localization of EGFP-Lin¯  BMC and EGFP Dermal Fibroblasts in   
  Metastatic Tumor Model 
 Mice with metastatic tumors were injected with injected with 5 × 105 Lin¯  BMC (n=4) or 
dermal fibroblast (n=2) isolated from EGFP-transgenic mice (Figure 7). All experimental 
animals were sacrificed at 24-72 hours post EGFP-Lin¯  BMC injection. All samples were stored 
and analyzed as stated above. Similarly, 5 × 105 EGFP-Lin¯  BMC or EGFP-dermal fibroblasts 
systemically injected into s.c. tumor bearing mice or mice with the metastatic disease. Mice were 
euthanizes 24-72 hours or 7 days later. At euthanasia, blood was collected and metastatic tissue 
and all major organs were harvested and processed as described above. 
 Immunofluorescent Microscopy 
  EGFP-VEC homing was initially determined by visual enumeration of fluorescent cells.  
Fresh frozen tissue sections were prepared from all OCT-frozen tissues (10 µm for subcutaneous  
tumors, livers, hearts, spleens and kidneys and 16-18 µm for lung tissue). All slides were brought 
to RT, fixed in cold acetone (-20°C) for 20 minutes and rehydrated in 1X TBS or DPBS.    
AquaPolymount was used to mount coverslips on tissue sections. Slides were observed on 
Olympus LPS-220 or Olympus BX5 with a wide band FITC filter to view the tissue-localized 
fluorescent (EGFP) cells.  Images were collected using digital cameras connected with the 
respective microscope and SPOTTM Imaging or DP Controller software. 
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Figure 6: Diagrammatic Representation of the Experimental Design to Evaluate the 
Biolocalization of EGFP-Lin¯  BMC and Dermal Fibroblasts in the Metastatic Tumor 
Model 
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Quantitative Real-time Polymerase Chain Reaction to Quantitate Tissue-Localized EGFP-
Transgenic Cells 
Isolation of Genomic DNA from Tissue 
 Genomic DNA was extracted from flash frozen or OCT-frozen murine tissue sections by 
the Phenol-Chloroform method (267).  For the flash frozen tissue samples, an aluminum foil 
spatula and a foil pouch with 6 layers was prepared, chilled by immersing in liquid nitrogen. The 
frozen tissue was weighed (W1) in its original foil. The tissue was then quickly and completely 
transferred, to the chilled foil pouch, using the chilled foil spatula.  The original foil was weighed 
once more (W2) and tissue weight was calculated (Wt = W1-W2).  The pouch was folded tightly 
and immersed in liquid Nitrogen for about 30 seconds.  The pouch was removed, placed on 
bench, and immediately the tissue was pulverized into powder using a hammer.  The powdered 
tissue was transferred into a tube containing tissue lysis buffer (3 mL / 50-100 mg of tissue). For 
OCT-frozen tissues 10-50 µm sections of OCT-tissue block were cut, and using pre-chilled 
plastic tongs, the sections were collected in cold polypropylene tubes (Plastic tongs and 2 mL 
microfuge tubes were placed in the -20°C cryostat unit to pre-chill). The thickness and number of 
tissue sections varied from tissue to tissue to increase the EGFP-signal to background wild-type 
(noise) ratio (Figure 8A). For lung and liver specimens 5 × 50 µm sections / tube were routinely 
collected.  These tubes were capped and stored at -70°C until ready to process.   Tubes were 
brought to RT and sections were rinsed with DPBS to remove OCT, and were digested using 
Tissue Lysis Buffer (500 µl / tube) for at least 3 hour at 50-60°C. The Tissue Lysis Buffer 
contained 100 mM NaCl (Sigma), 10 mM Tris-EDTA (pH 8.0, Sigma), 25 mM EDTA (pH 8.0), 
0.5% Sodium Dodecyle sulfate (SDS) and Proteinase K (100 µg/mL final concentration, Sigma) 
in MilliQ water. Tissue slurry was further incubated with RNase-A (Sigma, 25 µg/mL final 
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concentration) for 1 hour at RT. Equal volume of Phenol-Chloroform-Isoamly Alcohol (25:24:1) 
(Sigma) was added to tissue lysate, mixed by inversion (25 X), and centrifuged at 1500 × g for 
15 minutes to separate the DNA-containing aqueous phase.  The top aqueous phase was carefully 
transferred to a polypropylene tube, washed with equal volume of Chloroform-Isoamly Alcohol 
(49:1) (Sigma) and centrifuged at 1500 × g for 15 minute to remove phenol.  Once again the top 
aqueous phase was carefully transferred into fresh polypropylene tube and DNA was precipitated 
using 0.5 times their volume of 7.5 M ammonium acetate and 2 times the volume of 100% 
ethanol.  DNA was pelleted by centrifugation at 2000 × g for 20 minutes at 4°C.   The DNA 
pellet was rinsed once with 70% ethanol, centrifuged at 2000 × g for 5 minutes followed by air-
drying for 15 minutes.  DNA was resuspended in 1X Tris-EDTA (Sigma) and heated at 50°C for 
15 minutes to dissolve DNA. A rough estimate of DNA concentration was made by reading the 
samples spectrophotometrically on a NanoDrop®.  Accurate DNA concentrations were 
determined with a fluorescence assay using SYBR-green dye (Invitrogen), which was more 
accurate than spectrophotometric determination (OD260).   
 SYBR Green Assay for Quantitation of Genomic DNA 
 SYBR Green based fluorometric assay was the optimal method for quantitation of intact 
double-stranded DNA greater than 200 base pairs; the dye intercalates between AT-rich helices 
(268). DNA concentrations were estimated spectrophotometrically (e.g. using a NanoDrop®) to 
determine the dilution factor for the SYBR Green assay.  Each 96-well plate-based SYBR Green 
assay to quantitate genomic DNA contained a standard curve: 8-10 points (8 ng/µl to 0.06 ng/µl) 
and two-fold dilutions of 1 Kb Plus DNA ladder (Invitrogen) in 1X TE.  SYBR Green (269) was 
diluted 1:1250 in 1X TE (Tris-EDTA, Sigma) and always kept protect from light.  All DNA 
samples were diluted in 1X TE (based on the spectrophotometric concentrations) such that the 
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dilutions approximately fell within the range of the standard curve.  All samples were heated at 
50°C for 10 minutes, vortexed for a few seconds in a microfuge to make a homogeneous 
solution. Appropriately diluted standards and samples (100 µl) were placed in each well of a 96-
well plate and 100 µl diluted SYBR Green solution was added to each well with a multi-channel 
pipette.  Each plate also included a blank sample (1X TE) and a positive control (mouse genomic 
DNA, Clonetech). The plates were covered with aluminum foil and incubated at RT for 10 
minutes before reading on the automated fluorescent plate reader Synergy HT Multi-Mode 
Microplate Reader (BioTek, Winooski, VT) at 480/528 excitation/emission wavelengths. 
Fluorescent readings for standard curve dilutions were plotted on the y-axis, DNA concentrations 
were plotted on the x-axis, and a linear equation from the standard curve was obtained. Based on 
the standard curve, the concentrations of diluted DNA samples were calculated. The final 
concentrations of DNA from tissue samples were calculated by multiplying by the dilution 
factor. 
 Agarose Gel Electrophoresis of Genomic DNA 
  Agarose gel electrophoresis was performed on genomic DNA samples to determine DNA 
integrity and purity.  1X Tris-Acetate-EDTA (TAE) was used as the electrophoresis buffer; 
working buffer was prepared by diluting 10 X TAE in MilliQ water. Agarose gel (0.8-1.2%) was 
prepared by dissolving agarose powder (Pel-Freeze DNA Grade) to 1X TAE buffer. Ethidium 
bromide (0.5 µl, Sigma) was added to agarose gel solution.   After cooling the solution to about 
60°C, it was poured into a casting tray containing a sample comb and allowed to solidify at RT. 
DNA samples (200 ng DNA per well) were diluted in nuclease-free water and loading buffer 
containing glycerol (Gibco), EDTA (Gibco), Bromophenol blue (Sigma), and Xylene Cyanol FF 
(Sigma) in MilliQ water. DNA samples were carefully pipetted into each sample well in the gel, 
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the lid and power leads were placed on the apparatus, and current was applied. The voltage and 
run-time varied depending on the size of the gel: 90 volts for 45 minute for a Gibco Mini gel and 
145 volts for 2 hours and 15 minute for a Bio-Rad double gel. The distance that DNA had 
migrated in the gel was judged by visually monitoring migration of the tracking dyes. 
Bromophenol blue and xylene cyanol dyes migrate through agarose gels at roughly the same rates 
as double-stranded DNA fragments of 300 and 4000 bp respectively.  To examine DNA 
migration the gel was placed on an ultraviolet transilluminator.  Digital photographs of gels were 
obtained using a Kodak DC290 Zoom camera and edited using Adobe Photoshop 7.0 software. 
 EGFP Plasmid Standard Curve 
 pEGFP-N3 plasmid contains the egfp-transgene, which was used to develop the EGFP-
transgenic mice used as donors in the in vivo adoptive-cell transfer experiments.  pEGFP-N3 was 
a gift from Dr. Alexander Murashov (Department of Physiology, East Carolina University).  
DH5α cells transfected with pEGFP-N3 using heat-shock technique and cultured on Kanamycin 
(10 mg/mL) agar plates. A single colony of successfully transfected cells was picked and 
expanded in LB broth. Large-scale purification of plasmid was carried out using QIAGEN 
Plasmid Mega kit (Qiagen, Valencia, CA). The plasmid concentration was measured 
spectrophotometrically on the NanoDrop® spectrophotometer. The mass of one copy (or 
molecule) of the plasmid pEGFP-N3 was calculated from the following formula:  
m = mass of one copy = M / NA where 
M = the molecular weight (Dalton or gram/mole) of the plasmid (calculated using the 
 base composition of the plasmid and MW of nucleotides) = 3.09x106 
NA = Avogadro’s number = 6.02x1023 copies (or molecules) / mole.   
Number of plasmid copies / microliter = concentration (OD260) / m 
  
   
90
 Thus, it was calculated that each molecule or copy of pEGFP-N3 has a mass of ~5.1 
attograms (ag) and 1 ng of pEGFP-N3 has approximately 1.95 × 108 copies of the EGFP-gene.  
A pEGFP-N3 plasmid diluted in genomic DNA from wild-type mice was used to construct 
standard curve in each assay.   
 Quantitative Polymerase Chain Reaction (qPCR) 
  qPCR was conducted with 100 or 200 ng genomic DNA in duplicate in 20 or 25 µl 
reactions using the TaqMan® PCR Universal Master Mix (Applied Biosystems) in 96-well format 
in the Applied Biosystems 7000 Real-Time PCR System or 384-well format in the Applied 
Biosystems 7900 Real-Time PCR System.  Primer and probe sequences for the EGFP-transgene 
were from The Jackson  Laboratories and manufactured by Applied Biosystems: forward primer 
5’-ccacatgaagcagcaggactt-3’, reverse primer 5’-ggtgcgctcctggacgta-3’ and probe 6FAM-
ttcaagtccgccatgcccgaa-TAMRA.  The final concentration of primers was 400 nM each and the 
probe was 150 nM.  Gene Expression Assay Mm00607939_s1 (Applied Biosystems) was used 
for assaying β-actin (endogenous control) in separate reactions. This proprietary assay resulted in 
a 115 bp amplicon within exon 6, detected with a FAM/MGB-labeled probe.  Aproteinin B 
(ApoB) was also used as an endogenous control: forward primer 5’-cacgtgggctccagcatt-3’, 
reverse primer 5’-tcaccagtcatttctgcctttg-3’ and probe Vic–ccaatggtcgggcactgctcaa–TAMRA. 
Primer and probe sequences for ApoB were from The Jackson Laboratories and manufactured by 
Applied Biosystems. All reactions were 50 cycles using default Applied Biosystems cycling 
conditions (2 minute at 50ºC, 10 minute at 95ºC, and 50 cycles of 15 seconds denaturation at 
95ºC and 1 minute annealing and extension at 60°C).  
 The number of EGFP-transgene copies in 100 or 200 ng DNA (from EGFP-transgenic 
mice or from wild-type mice transplanted with cells from EGFP-transgenic mice) was calculated 
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from their respective Ct (cycle threshold) using the linear equation derived from the respective 
plasmid standard curve.  EGFP copy-number per diploid cell was calculated by dividing the  
number of EGFP copies in the DNA sample by the number of cells from which the DNA was 
isolated.  Each diploid cell from a C57Bl/6 male has been reported to yield 6 pg DNA (270); thus  
100 ng DNA ≈ 1.67 ×104 diploid cells.  The schematic diagram for qPCR assay is represented in 
Figure 7B. 
 Association between Manual Cell Count using Fluorescence Microscopy and qPCR 
 for Enumeration of EGFP-Transgenic Cells 
  To compare manual enumeration of tissue-localized EGFP-Transgenic Cells (EGFP-
VEC) to the qPCR method, mice bearing small subcutaneous tumors (approximately 100 mm3) 
were injected intra-tumor with EGFP-VEC. Mice were sacrificed after 2 hours and subcutaneous 
tumors were harvested.  Ten micron thin sections were prepared and alternating 10 µm sections 
were examined by fluorescence microscopy or extracted for DNA. 
  Modification in qPCR 
  To increase the signal: noise ratio of egfp-transgene: background DNA of the qPCR assay 
five 50 µm thick tissue sections were collected in multiple tubes and DNA was extracted as 
schematically shown in Figure 7A. This generated multiple DNA samples per tissue and thus the 
qPCR assay was modified for a high throughput 384-well plate format which permitted a 
maximum reaction volume of 20 µl per well. Next, to increase the amount of DNA being 
analyzed in 20 µl reactions, dose-response assays were conducted using 100, 200, 400, and 600 
nanogram of DNA. 
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Statistical Analysis 
 Data has been reported as average values and standard error means (SEM) from 
representative or all experiments. Statistical comparison between two groups in an experiment 
was performed using unpaired Student’s t-test or Mann Whitney test.  Comparison between 
multiple groups was performed using non-parametric one-way analysis of variance (ANOVA) 
with post-hoc Dunnett’s test to compare with control samples and two-way ANOVA functions. 
For statistical tests, it was assumed that the data set was unpaired (or paired where applicable), 
non-parametric and lacked Gaussian distribution. The outliers were detected by plotting data set 
in box-whiskers plot and by the use of Tukey’s analysis (GraphPad Prism 5.0 software); all 
outliers were excluded from data sets. For correlation studies, Pearson’s and Spearman’s 
coefficients were used.   Microsoft Office Excel and GraphPad Prism 5.0 statistical software 
were used for data analysis. 
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Figure 7: Genomic DNA Isolation for qPCR Assay 
A) Schematic representation of protocol used to isolate and analyze genomic DNA for egfp-
transgene. To increase the sensitivity of the qPCR assay, each tissue block was sectioned and 
five 50 micron sections were collected in individual tubes. DNA was extracted from tissue 
sections in all tubes and analyzed in 384-well qPCR plates. 
B) Schematic representation of qPCR assay to detect the tissue-localized adoptively-transferred 
EGFP-transgenic cells  
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CHAPTER III:  RESULTS 
A: Description and Characterization of the Murine Lewis lung adenocarcinoma Model 
Rationale: 
 The Lewis lung adenocarcinoma subclone LLCaB was used for developing subcutaneous 
(s.c.) tumors and subsequent metastases after surgical removal of s.c. tumors in syngeneic and 
immunocompetent C57Bl/6 mice (4). This cell line was chosen because the LLCaB tumors 
developed faster and produced greater number of metastatic lesions compared to the parental 
LLC1 line and the LLCC3 subclone (271). The s.c. tumor resection methodology produced 
robust metastatic disease and was deemed superior compared to the tail vein injection method 
(271). Nonetheless, due to substantial mortality (because of blood loss and anesthesia during the 
surgical procedure) and a wide variation in metastatic disease it was important to characterize the 
metastatic tumor model. The aim of this research project was to use this model to understand the 
role of the cell adhesion molecule E-selectin and chemokine SDF-1α in tumor biology.  
 This chapter describes the development of LLCaB tumors in a murine model, 
optimization of the conditions for development of metastatic disease and analysis of murine 
tissue for the expression of E-selectin and SDF-1α. 
Results: 
 Lewis lung Adenocarcinoma Model 
  LLCaB cells (5 × 105) were injected subcutaneously and were visible as palpable tumors 
10-14 days after injection. The average tumor growth curve from 11 separate experiments 
(n=173 mice) is shown in Figure 8A.  Following the protocol developed by Folkman (4), primary 
s.c. tumors were surgically removed to promote the development of metastases. An average of 
72% (30-95%) survived the s.c. tumor removal surgery, with death primarily due to anesthesia 
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and blood loss. Of the mice that survived through the end of the experiment (16±6 days after 
primary tumor removal) an average of 65% mice had visible metastases at euthanasia. Factors 
that influenced survival/euthanasia of mouse were s.c. tumor volume at resection, s.c. tumor 
recurrence and overall health. The majority of the mice at the end of the experiment had either 
both lung and liver metastases or had lung metastases only. A very small percentage of mice 
developed hepatic tumors only (Figure 8B). The metastatic burden varied between animals, 
which was evident on macroscopic examination of lungs and livers (Figure 8C). The metastases 
were visible as red lesions in the lungs (Figure 8C 1-3), and white lesions in the livers (Figure 8C 
4-5). No such lesions were visible in lung and liver samples from healthy control mice (data not 
shown). The microscopic evaluation of ten-micron tissue sections after hematoxylin and eosin 
staining was used to visualize micrometastases. Tissue sections from healthy control mice 
showed normal lung and liver morphology (Figure 8D, 1 and 4). Hematoxylin-stained nucleus 
and eosin-stained cytoplasm were apparent in all cells, and uniformly distributed throughout the 
tissue section. In contrast, in tissue sections with metastases (Figure 8D, 2, 3, 5 and 6), tumor 
cells and metastatic lesions were stained dark blue-black and adjacent non-tumorous regions 
appear to be similar to control tissue sections (Figure 8D). 
 As expected, metastatic burden was related to the size of the primary tumor at resection 
and the number of days elapsed after s.c. tumor removal (Figure 9A-B). At euthanasia mice with 
visible lung or liver metastases had significantly larger s.c. tumors compared to the mice that had 
‘no visible metastases’ (1618±1014 mm3 vs. 1022±814 mm3, p<0.05; Figure 9A). The mice that 
died during primary tumor removal surgery (n=18, day 0) were not included in this analysis.  
 Approximately 50% of mice with average s.c. tumor volume of 1500mm3 that were 
euthanized by 10 days after tumor-removal surgery had significant numbers of visible metastases 
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Figure 8: Summary of LLCaB Tumor Growth and Metastasis 
A) Average LLCaB subcutaneous tumor growth curve from 11 separate experiments (n=173).  
B)  Percentage of mice that developed pulmonary and/or hepatic metastases 16±6 days after 
primary tumor removal (n=173, 11 experiments). 
C) Representative photographs showing the variation in metastatic burden in each tissue. Lung 
metastases are visible as the red lesions (1-3) and liver metastases are apparent as the white 
lesions (4-6). 
D) Photomicrographs showing Hematoxylin and Eosin staining on (1) healthy lung, (2-3) lung 
metastases, (4) healthy liver, and (5-6) liver metastases (magnification 400×). The metastatic 
lesions were stained dark blue-black and are distinguishable from the adjacent relatively 
healthier tissue.  
SEM = standard error of mean
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(Figure 9B). When mice with s.c. tumor volume of 1500 mm3 were euthanized 11-20 days after 
tumor removal, about 77% of these mice had visible lung and/or liver metastases (Figure 9B). 
However, mice with tumor volume of approximately 1000 mm3 were healthy for a longer time-
period and approximately 75% of these mice had macroscopically detectable metastases (Figure 
9B). These results suggested that s.c. tumor volume of approximately 1000-1500 mm3 was 
optimal for mice to develop metastases but appear disease-free for 10-20 days post s.c. tumor 
resection. 
 At the time of euthanasia, in addition to macroscopic visualization for metastatic lesions, 
all major organs including heart, kidney, spleen, lung, and liver were weighed to estimate the 
metastatic burden. The weights of lungs from the mice with metastatic disease were significantly 
higher compared to control lungs from healthy mice. In one group (n=11), weights of the 
metastatic lungs were grouped according to number of days lapsed between tumor resection and 
euthanasia. There was no significant difference in the average s.c. tumor volume between these 
sub-groups. As reported in Figure 9C, metastatic burden, as estimated by lung weight, increased 
significantly with time. A substantial increase in the weights of spleens from mice with 
metastatic disease was also observed (data not shown). However, no metastatic lesions were 
visible on the spleens and thus the splenomegaly was most likely due to immune response.  
These results were consistent with clinical observation. In human patients, the larger the 
primary tumor, the more likely there will be metastases and greater the extent of metastatic 
disease. Metastases also increased in size with time. It was also logical that smaller primary 
tumors would lead to smaller metastases that would take more time to produce visible lesions.  
Our LLCaB tumor model thus mimicked clinically relevant metastatic disease. 
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Figure 9: Association between Primary Tumor Volume and Metastases Development 
A) Association between the average s.c. tumor volume (at resection) and metastatic burden in 
lung and/or liver was evaluated. Mice with s.c. tumors larger than 1500 mm3 volume had 
macroscopically visible metastases compared to mice with s.c. tumors ≤ 1000 mm3 at euthanasia 
(* p< 0.05, 2-tailed Student’s-test). 
B) The percentage of mice that developed macroscopically detectable metastases appeared to be 
a function of the s.c. tumor volume and the number of days after primary tumor removal. 
Metastases were apparent in 50% mice by day 10 (n=37) and 77% mice between 11-20 days 
(n=48) in mice with average tumor volume of 1500 mm3, and 21-40 days in mice with tumor 
volume of 1000 mm3 (n=22).  
C) Metastatic burden estimated by measuring the tissue-wet weight at euthanasia suggested that 
there was a significant increase in weight in metastatic lungs (n=11) compared to healthy lungs 
(n=5). In addition, the extent of significantly metastatic burden increased with increase in 
number of days after primary tumor removal. (Data from one experiment; * p< 0.05 one-way 
ANOVA, Post-hoc Dunnett’s test compared to control) 
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 E-selectin and SDF-1α Expression in LLCaB Tumors 
 The aim of this dissertation research was to understand the role of E-selectin and SDF-1α 
in tumor biology. We hypothesized that tumor endothelium expressed E-selectin and SDF-1α, 
and that the biolocalization and adhesion of bone marrow derived cells to LLCaB tumors were 
mediated by these factors. The expression of E-selectin and SDF-1α in naïve control tissues and 
in s.c. and metastatic tumors were evaluated. 
  Specific Upregulation of E-selectin on the LLCaB Tumor Endothelium  
 Our laboratory has previously shown that E-selectin was important for tumor growth and 
vascularization (170), Verbanac laboratory, unpublished data). It was also shown that E-selectin 
was expressed by the ex vivo cultured tumor-derived endothelial cells, but not by the endothelial 
cells isolated from normal healthy tissue. It was possible that E-selectin expression was simply 
being induced in vitro, after isolation and culture of tumor endothelial cells.   To investigate if 
this was an in vivo phenomenon, we proceeded to analyze E-selectin expression in LLCaB tumor 
sections by immunohistochemistry. Ten-micron adjacent sections from s.c. tumors, lung and 
liver metastases, and healthy control tissues were stained with hematoxylin and eosin (H&E) or 
immunostained with anti-E-selectin antibody or anti-CD31 antibody (marker for endothelium). 
H&E staining helped in defining metastatic lesions within lung and liver samples. CD31-stained 
blood vessels were observed in all tissues whereas E-selectin staining was specifically observed 
within the tumors. Furthermore, expression of E-selectin was restricted to the blood vessels 
within tumors. This was seen in tissue sections stained with anti-E-selectin by the red staining 
pattern, which was similar to CD31 staining in adjacent tissue sections (Figure 10).  The isotype-
matched control antibody did not show any staining.  
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Figure 10: Expression of E-selectin in Healthy Controls, Subcutaneous and Metastatic 
Tumors 
Adjacent tissue sections were stained with Hematoxylin and Eosin (H&E), isotype-matched 
control antibody, anti-CD31, or anti-E-selectin antibody. H&E staining was used to identify 
tumors and metastatic lesions in tissue sections. The blue staining pattern represents tumors. A 
rat anti-mouse CD31 antibody was used to identify blood vessels. Similarly, adjacent tissue 
sections were incubated with a rat anti-mouse anti E-selectin antibody. PE-labeled anti-rat 
secondary antibody was used to visualize antibody binding to tissue sections. E-selectin 
expression was restricted to blood vessels of tumorous tissue as noticeable by the similarity in 
staining pattern to the CD31 expression in adjacent tissue sections. The isotype-matched control 
antibody did not show any staining. Original magnification 400×, Scale 100 micron. 
  
  
 
104
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control CD31 E-selectin 
NORMAL 
LIVER
METASTATIC 
LIVER
NORMAL 
LUNG
METASTATIC 
LUNG
H & E
SUB-
CUTANEOUS 
TUMOR
  
 
105
  SDF-1α Expression in Murine Tissue 
 RNA from naïve healthy control tissues (n=7), s.c. tumors (n=11), and metastases (n=6) 
was assayed by quantitative RT-PCR for the expression of SDF-1α and an endogenous control 
gene Beta-2-microglobulin (β2M). Expression of β2M was highly consistent in all the samples 
analyzed (average Ct = 17.72±1). Sdf-1α gene transcript was detected in all tissue samples 
analyzed. The average Ct values for sdf-1α mRNA in healthy control tissues, s.c. tumors, and 
metastases were 23±2, 24.8±1 and 24.5±1, respectively. The relative gene expression between 
healthy control tissues, s.c. tumors and metastases was calculated as 2-∆∆Ct. Healthy lungs from 
naïve mice were used as ‘calibrator’tissue.  
Ct β2M(s) - Ct gene (s) =∆Ct sample 
Ct β2M(c) - Ct gene (c) =∆Ct calibrator 
∆Ct sample – ∆Ct calibrator = ∆∆Ct 
Fold difference = 2 - ∆∆Ct 
The relative sdf-1α mRNA expression in s.c. tumors and lung metastases was found to be 0.6-
fold and 0.2-fold that of healthy tissue samples (Figure 11A), respectively.  
Consistent with previous studies, utilizing ELISA methodology, a substantial SDF-1α 
expression was observed in naïve healthy control lung and liver samples (n=12). SDF-1α protein 
was not significantly different in s.c. tumors (n=59) compared to healthy control tissue samples 
(60±4 pg/mg protein in s.c. tumors vs. 80±66 pg/mg protein in healthy tissue samples; Figure 
11B). An overall three-fold increase in SDF-1α protein levels by ELISA in metastases (n=21) 
compared to healthy control samples (233±38 pg/mg vs. 80±66 pg/mg, p<0.0001; Figure 11B).  
Using the Spearman’s rank correlation test, a significant inverse correlation was 
determined between the tumor volumes of metastatic and s.c. tumors and their SDF-1α 
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concentration respectively (ρ = -0.552 and -0.36; P-value <0.01; Figure 11 C-D). To our 
knowledge, this is the first report showing a correlation between tumor size and SDF-1α protein 
expression.   
 The in situ expression of SDF-1α in tissue sections from healthy and experimental mice 
was evaluated by immunohistochemical analysis. SDF-1 was distributed evenly throughout the 
specimen in healthy and tumor tissues (Figure 12A). In the lung and liver tissue sections with 
metastatic lesions, SDF-1 was observed to be concentrated within metastases compared to 
adjacent tissue (Figure 12A). This complemented our findings from ELISA assays that the 
increase in SDF-1α in the metastatic tissue samples was due to elevated SDF-1 expression in the 
metastatic lesions.  
 Metastases and s.c. tumor sections were co-incubated with rat anti-mouse anti-CD31 and 
goat anti-mouse anti-SDF-1 antibodies. Subsequently, tissue sections were co-incubated with 
donkey anti-rat-FITC and donkey anti-goat-PE secondary F(ab’)2 fragments to examine the 
colocalization of SDF-1 was associated with the tumor endothelium (Figure 12B). In 13 slides, 
co-localization of SDF-1 and CD31 was observed in approximately one-third of tumor 
vasculature. No staining was observed with the isotype matched control antibodies. This 
supported our hypothesis that Lewis lung tumors expressed SDF-1α and that SDF-1α was 
associated with tumor endothelium. 
Blood from healthy control mice (n=9), and s.c. tumor-bearing mice (n=21), was 
collected from the inferior vena cava or retro-orbital sinus at euthanasia. By ELISA, serum from 
these samples was analyzed for circulating SDF-1α. No significant difference was observed in 
the levels of circulating SDF-1α in serum samples from s.c. tumor-bearing (Average tumor 
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Figure 11: SDF-1α Expression in Subcutaneous and Metastatic Tumors Compared to 
Healthy Tissue (RT-PCR and ELISA)  
A) RNA from healthy control tissues (n=7), s.c. tumors (n=11) and lung/liver metastases (n=6) 
was evaluated for sdf-1α gene transcript by RT-PCR. P-value <0.0001 by one-way ANOVA; 
Post-hoc Dunnett’s test compared to healthy tissue *** p <0.0001; Average data from four 
separate RT-PCR assays   
B) Protein homogenates from s.c. tumors (n=59), lung/liver metastases (n=21) and healthy 
control tissues (n=12) were evaluated for SDF-1α protein expression by ELISA. SDF-1α 
expression in lung/liver metastases was approximately 3-folds higher than naïve tissue. P-value 
<0.0001 by one-way ANOVA; Post-hoc Dunnett’s test compared to healthy tissue *** p 
<0.0001; Average data from four separate ELISA assays   
B-C) An inverse non-linear/exponential relationship was observed between SDF-1α protein 
expression in s.c. tumors (B) and in metastases (C) and their respective tumor volumes. 
Spearman rank correlation value ρ = -0.36 and -0.55 with P-value <0.01 for s.c. tumors and 
metastases respectively. 
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Figure 12: SDF-1α Expression in Subcutaneous and Metastatic Tumor Compared to 
Healthy Tissue (Immunohistochemistry) 
A) Tissue sections were stained with anti-SDF-1 (orange-yellow). SDF-1 was detected 
throughout healthy lung and liver sections, and in areas adjacent to sections from metastatic 
tissue. Metastatic lesion (T) and the edge demarking the lesion and adjacent tissue appeared to be 
more concentrated with SDF-1. Due to settings on the microscope, SDF-1 staining appears to be 
yellowish in these photomicrographs. 
B) Tissue sections were co-incubated with rat anti-mouse anti-CD31 and goat anti-mouse anti-
SDF-1. Donkey anti-rat-FITC and donkey anti-goat-PE were used to visualize primary antibody 
binding. Co-localization (yellow) of SDF-1 (red) with the endothelial marker CD31 (green) was 
observed in about one-third of the blood vessels in s.c. and metastatic tumors.  Representative of 
13 slides. Original magnification 400×.  
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volume = 2865 ± 696 mm3) and healthy mice (Figure 13A). However, it was intriguing to note a 
consistently lower amount of circulating SDF-1α in serum from female mice compared to male 
mice in both healthy and s.c. tumor-bearing mice (Figure 13B). To the best of our knowledge, 
this is a novel observation indicating a sex-based difference in circulating SDF-1α. This 
information might be relevant in treating estrogen-dependent malignancies.  
Synopsis: 
 These data have validated that the LLCaB tumor model accurately mimicked cancer 
progression in humans and was thus a clinically relevant murine model. We have also 
demonstrated that E-selectin was specifically upregulated in tumor endothelium whereas it was 
undetectable in naïve tissues from healthy mice. In contrast, tissue samples from healthy mice 
expressed basal levels of SDF-1α. SDF-1α protein levels were significantly increased in the 
metastatic tumors, but not in the s.c. tumors. In addition, these data showed a significant inverse 
relationship between SDF-1α levels and tumor size in both s.c. and metastatic tumors. This novel 
information supports the premise that SDF-1α might be important in the early stages of tumor 
development. In addition, approximately one-fifth of SDF-1α in tumors was observed to be 
colocalized with tumor endothelium, and might be important in the adhesion of bone marrow-
derived progenitors to tumors. These events could contribute to vasculogenesis and growth of 
tumors. E-selectin may be important in retarding the circulating bone marrow-derived cells in 
tumors. In addition, it might be involved in strengthening the adhesion of infiltrating cells within 
the proliferating tumor endothelium. 
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Figure 13: Circulating SDF-1α (ELISA) 
A) Serum samples from healthy mice (n=9) and s.c. tumor-bearing mice (n=21) was assayed for 
circulating SDF-1α by ELISA. No difference was observed in the circulating SDF-1α levels 
between the two groups. 
B) Circulating SDF-1α was compared in the female (triangle) and male (circle) mice in both 
healthy (filled) and s.c. tumor-bearing (open) groups. Data not significant by two-way ANOVA 
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B: The Role of E-selectin and SDF-1α in the In Vitro Adhesion of Bone Marrow-derived 
Lineage-negative Cells to Tumors 
Rationale: 
 The second aim of this research project was to evaluate the role of SDF-1α and E-selectin 
as a cell adhesion molecule on tumor-derived cells. It is widely accepted that SDF-1α acted as a 
chemoattractant for CXCR4+ endothelial and bone marrow-derived cells. We hypothesized that 
SDF-1α was associated with tumor endothelium and acted as a potential cell adhesion molecule, 
and circulating bone marrow-derived endothelial progenitors that localized to tumors could 
bound to tumor endothelium-associated SDF-1α and incorporated into the proliferating blood 
vessel, thereby contributing to the growth of tumors.  In the previous chapter, it was 
demonstrated that metastatic tumors had elevated levels of SDF-1α compared to naïve tissue 
samples. In addition, it was illustrated that in situ SDF-1α co-localized with the tumor 
endothelium. In this chapter, using in vitro assays, we tested if SDF-1α mediated the adhesion of 
bone marrow-derived cells to tumors. The role of E-selectin in this interaction was also 
evaluated. 
The first part of this chapter describes the three cell populations used for in vitro adhesion 
experiments: murine lineage-negative bone marrow cells (Lin¯  BMC), Dissociated LLCaB 
Tumor Cells (DTC) and control dermal fibroblasts. Because endothelial progenitors (EPC) are a 
subset of Lin¯  BMC and constitute a tiny proportion of total bone marrow cells, the use of Lin¯  
BMC for adhesion experiments was thought to be most practical. DTC were chosen for in vitro 
adhesion assays because they represented the heterogeneous cell populations in tumors more 
accurately than any one cell-line.  Results of in vitro assays to evaluate the adhesion of Lin¯  
BMC to monolayers of DTC and other control cell types (LLCaB, bEnd.3, VEC, and 3T3-L1) 
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are subsequently presented. LLCaB was used to measure of Lin¯  BMC to tumor cells. bEnd.3 
(mouse brain tumor endothelioma) cell line shares properties with activated endothelium, and 
was used as a surrogate for tumor endothelial cells. Primary cultures of vascular endothelial cell 
(VEC) were used as a negative control (resting endothelial cells). The pre-adipocyte cell line 
3T3-L1 was a negative control for non-specific adhesion. In addition, the adhesion of control 
dermal fibroblast cells to DTC and bEnd.3 monolayers was also evaluated. Finally, to assess the 
roles of E-selectin and SDF-1α in the binding of Lin¯  BMC to various cell monolayers, we 
attempted to inhibit adhesion by blocking CXCR4 (a receptor for SDF-1α) and E-selectin.  
Results: 
 Isolation and Characterization of Lineage-negative BMC  
 Bone marrow cells are comprised of lineage-negative (pluripotent) cells and lineage-
committed cells, i.e. cells that are committed to a specific cell lineage such as erythrocytes, 
monocytes, macrophages, dendritic, natural killer, and B- and T-cells.  The Lin¯  BMC were 
isolated by immunomagnetic depletion of lineage-committed cells from intact bone marrow 
(Figure 4) that was harvested from femurs and tibias of wild-type C57Bl/6 or EGFP-transgenic 
(C57Bl/6-Tg(ACTbEGFP)10sb/J) mice. The Lin¯  BMC was found to constitute 3-5% of the 
intact BMC and contained only about 5% lineage-committed cells after negative purification.  
Intact BMC and Lin¯  BMC were assayed for the expression of a variety of growth factor ligands 
and receptors (Figure 14A). 
    Lin¯  BMC that express cKit and Sca1 (also known as LSK cells) comprise an enriched 
population of EPC (115;120). Intact BMC were indirectly labeled with FITC-labeled lineage 
panel antibodies, anti-cKit-APC, and anti-Sca1-PE. To quantitate the percentage of LSK cells, 
the FITC¯  BMC were gated and evaluated for cells positive for both red (Sca1+) and blue (cKit+) 
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fluorescence. An average of 42±12 % (n=7) and 19±4 % (n=6) Lin¯  BMC expressed cKit and 
Sca1 respectively. However, only 3-9% of Lin¯  BMC expressed both cKit and Sca1. As 
reported, Lin¯  BMC constituted 3-5% of total BMC and Sca1+cKit+ (SK) were 3-9% of Lin¯  
BMC, thus the Lin¯ Sca1+cKit+ (LSK) subset was calculated to constitute only about 0.3% of 
intact BMC.  
 The expression of several proteins that defined specific cell populations on intact and 
Lin¯  BMC were compared: 1) stem/progenitor cells (cKit and Sca-1), 2) cells expressing E-
selectin ligands (Lamp-1 and CD43), 3) cells expressing chemokine receptors (CXCR4, 
CXCR2), 4) cells expressing receptors for vascular endothelial growth factors (VEGFR1 and 
VEGFR2), and 5) endothelial cells (VCAM, CD31 and CD34) (Figure 14B). Lin¯  BMC were 
enriched for cells of endothelial cell lineage and for cells that expressed cognate 
ligands/receptors for E-selectin and CXCR4. Lin¯  BMC contained significantly enriched 
populations of CD31+, LAMP1+, CXCR4+, cKit+, and cKit+Sca1+ cells compared to intact BMC. 
Although, only about 10% of Lin¯  BMC were VEGFR2+, almost 35 % of the Lin¯  BMC 
expressed VEGFR1. VEGFR1 is reported to be closely related to VEGFR2, and shared common 
and specific ligands, and regulated angiogenesis (9).  The Lin¯ Sca1+cKit+ (LSK) cells that 
expressed VEGFR2+ have been reported to be EPC. Our data showed that almost 90% of LSK-
BMC expressed VEGFR2 (Figure 15), suggesting that LSK cells were predominantly endothelial 
progenitors.  Moreover, approximately 85% LSK cells were also CXCR4+ (Figure 15, data from 
one experiment).  These data indicated that Lin¯  BMC were enriched for Sca1+cKit+ progenitors, 
and that LSK-BMC predominantly contained endothelial progenitors, and expressed CXCR4. 
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Figure 14: Characterization of Lineage-negative BMC 
A) Magnetic depletion of lineage-committed cells from total bone marrow cells was used to 
enrich the lineage-negative (Lin¯ ) BMC. After the depletion protocol, approximately 95% BMC 
were Lin¯  BMC. Lin¯  BMC were double labeled with anti-cKit-APC and anti-Sca-1-PE 
antibodies.  The green box in the dot-plot in the upper right quadrant side shows the LSK cells, 
that is, the Sca1+cKit+ (SK) cells of Lin¯  BMC population. Lin¯  BMC were also labeled with 
PE-conjugated antibodies for E-selectin ligands (LAMP1 and CD43) and SDF-1α receptor 
(CXCR4) and analyzed by flow cytometry.  
B) Expression of cell surface proteins in intact BMC and Lin¯  BMC were incubated with PE-
conjugated antibodies and analyzed by flow cytometry (* p <0.05 Intact BMC vs. Lin¯  BMC by 
2-tailed Student’s t-test ). 
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Figure 15: Lin¯  Sca1+cKit+ BMC are highly Enriched for Endothelial Progenitor Cells 
Lin¯  BMC isolated by immunomagnetic depletion of lineage-committed bone marrow cells were 
incubated with anti-cKit-APC, anti-Sca1-PE/FITC, and anti-CD31-FITC, anti-VEGFR2-PE or 
anti-CXCR4-PE and analyzed by three-color flow cytometry. LSK subset was significantly 
enriched for VEGFR2+ cells, and expressed CXCR4.
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 Characterization of Cultured Dissociated-LLCaB Tumors 
Subcutaneous tumors (average tumor volume 1081±456 mm3, average days post cell 
injection 23±3) were harvested and dissociated, as described, and adherent cell cultured.  These 
adherent cells were designated as Dissociated Tumor Cells (DTC).  
 Confluent adherent DTC cultures were collected over time in culture using Trypsin-
EDTA and monitored for the of tumor endothelial cell markers E-selectin and VEGFR2 by flow 
cytometry. Cell surface levels of both E-selectin and VEGFR2 gradually increased over time, 
peaked by day 9-15 of culture, and then declined (Figure 16A). Similar results were obtained 
from all DTC cultures evaluated (n=4).   
DTC cultures were analyzed for the expression of SDF-1α by quantitative RT-PCR; 
expression of SDF-1α gene transcript was compared to the expression of endogenous control 
Beta-2 microglobulin (β2M). As graphically represented in Figure 16B, SDF-1α was expressed 
at moderate levels and the expression of both SDF-1α (n=16, average Ct = 28.7 ± 2.99) and β2M 
(n=16, average Ct = 16.4 ± 1.0) was consistent in all DTC cultures over time. Some of the 
samples (n=7) with Ctβ2M = 24.2 ± 4.7 were excluded from the analysis; high Ctβ2M was most 
likely due sub-optimal quality of RNA and/or cDNA.  SDF-1α gene transcript was detected at 
higher levels in both VEC (n=6; CtSDF-1α = 24.3 ± 5.6, Ctβ2M = 16.7 ± 2.5) and bEnd. 3 (n=5; 
CtSDF-1α = 20.5 ±1.3, Ctβ2M = 17.7 ± 0.6) cultures compared to DTC. Using 2-∆∆Ct method for 
calculating relative gene expression, we observed that bEnd.3 and VEC expressed 4X and 1X 
folds higher levels SDF-1α, compared to calibrator 3T3-L1 cells. Additionally, SDF-1α mRNA 
in DTC was calculated to be 0.01X that in 3T3-L1 cells.   
The association of SDF-1α protein with DTC was analyzed by immunohistochemical 
staining of DTC cultures in chamber slides. Cell cultures were fixed, incubated with unlabeled 
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anti-E-selectin and anti-SDF-1α, followed by additions of FITC- or PE-labeled secondary 
antibodies. DAPI was used to stain the cell nuclei. Some wells received only isotype-matched 
control antibodies and/or secondary antibodies to test for non-specific staining. Overall, 
compared to control wells, a substantial staining was observed on DTC with anti-SDF-1α and E-
selectin antibodies (Figure 16C). Cells positive for E-selectin were most likely tumor endothelial 
cells. SDF-1α was observed to be associated with numerous E-selectin expressing endothelial 
cells, in agreement with our hypothesis.   
 Isolation and Characterization of Control Cell Type (Dermal Fibroblast) 
 Fibroblasts were isolated from dorsal and ventral trunk skins of 1-3 day-old mouse pups. 
The cell surface and total expression of LAMP1, CD43, and CXCR4 by dermal fibroblasts was 
evaluated by flow cytometry using five separate cell preparations (Figure 17). Only LAMP1 was 
detected on the cell surface. More than 70% of dermal fibroblasts appeared to have intracellular 
reserves of LAMP1 and CD43, as evaluated by total staining of permeabilized cells. However, 
CXCR4 expression was not detected on the cell surface or within the cells in these cultured 
dermal fibroblasts (Figure 17 A and B). 
  Adhesion Assay and Quantitation of Adhered Cells 
 Confluent monolayer cultures of 3T3-L1, VEC, bEnd.3, LLCaB and DTC in 24- or 12-
well plates were used for the adhesion assays. Lin¯  BMC (0.5 × 105 or 1 × 105) isolated from 
adult EGFP-transgenic mice were added to the above mentioned cell cultures. EGFP-Lin¯  BMC 
were used because these cells fluoresced green and could be visualized and enumerated by 
fluorescence microscopy and flow cytometry. The non-adherent cells were washed after 30 min.  
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Figure 16: Characterization of Dissociated Tumor Cell Culture 
A) DTC cultures were analyzed over time for expression of E-selectin and VEGFR2 by flow 
cytometry. The number of cells positive for E-selectin and VEGFR2 increased in culture by 9-12 
days and then started declining in all DTC cultures tested. Similar results were observed in four 
separate experiments.     
B) SDF-1α gene transcript expression in DTC from six different tumors was evaluated by 
quantitative RT-PCR in duplicate (n=1 for days 2, 5 and 7, and n=3 days 4, 6, 9, 13, and 14).  
Beta-2-microglobulin (β2M) was used as the endogenous control (qRT-PCR).  SDF-1α 
expression was reasonably consistent over time and between different DTC cultures.  
C) Representative photomicrographs of DTC cultured in chamber slides that were stained with 
FITC-labeled E-selectin (green) and PE-labeled SDF-1α (red) or isotype controls.  DAPI (blue), 
a nuclear stain, was used to delineate cells. Cells that stained for both E-selectin and SDF-1α are 
yellow. The arrowhead indicated where SDF-1α staining appears membrane-associated.
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Figure 17: Characterization of Dermal Fibroblasts 
A) Representative histogram overlay from flow cytometric analysis of cell surface and total 
protein expression by murine dermal fibroblasts (n=4). Only LAMP1 was detected on the cell 
surface of 46% dermal fibroblasts. 73% dermal fibroblasts had intracellular reserves of CD43. 
No CXCR4 was detected in these cells.  
B)  Average percentage of dermal fibroblasts positive for the expression of cell surface and total 
LAMP1, CD43, and CXCR4 from five separate cell preparations (Average of five separate 
assays). 
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All plates were observed on an inverted fluorescent microscope and representative photographs 
were obtained (Figure 18A). Next, cell monolayers and adherent BMC were harvested using 
trypsin-EDTA and EGFP-Lin¯  BMC were enumerated by manual counting on an upright 
fluorescent microscope using a hemocytometer. Additionally, cell suspensions were also 
analyzed by flow cytometry (Figure 18B).  These assays were performed twice.  
 During adhesion experiments, a separate tube containing 0.5 × 105 or 1 × 105 EGFP-Lin¯  
BMC was set aside as a control (i.e. not added to culture wells) to determine the accuracy of the 
two methods used to enumerate adherent fluorescent cells. This control tube was treated the 
same with respect to washes, and centrifugation and enumeration, as all other cell cultures.  The 
manual counting method using fluorescent microscopy, in 3 experiments, ranged from 55-143% 
(i.e. control cells that were counted under white light on a phase contrast microscope could be 
visualized under fluorescent light).  This was most likely because the fluorescent light intensity 
on the microscope was set so that the hemocytometer grid could be visualized; thus dimmer 
EGFP-cells were not apparent.  This problem was exacerbated by the small size of Lin¯  BMC.  
It was not practical to set the light intensity to a setting that enabled visualization of even dim 
EGFP cells, because either the grid was not visible or non-specific autofluorescence of non-
EGFP cells in experimental samples would then hinder enumeration of EGFP-cells. When the 
control tube of EGFP-Lin¯  BMC was analyzed by flow cytometry, only 36% (range of 23-51% 
in 5 assays) of cells were detected. The low efficiency with the flow cytometer was apparently 
because EGFP-Lin¯  BMC has cells with varying fluorescent intensity and small cell size. In 
addition, there was a significant overlap in the fluorescence between EGFP-Lin¯  BMC and the 
autofluorescence of the non-fluorescent adherent cells. 
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 Adhesion of Lin¯  BMC and Lin¯  Sca1+cKit+ (LSK) BMC 
 More EGFP-Lin¯  BMC adhered to DTC cultures than to other cell types (Figures 18). 
Data was evaluated as the total number and percent Lin¯  BMC that adhered to cultured cells. 
The adhesion assays was conducted in either 12-well or 24-well format, and although different, 
but proportional, numbers of EGFP-Lin¯  BMC were added to all plates. Thus, reporting the data 
as the percentage of Lin¯  BMC adhered was most favorable. Greatest percentage of Lin¯  BMC 
adhered to DTC cultures compared to other cell types assayed (Figure 18 A and B).  
 The Lin¯  BMC contained progenitors of many different cell types. As mentioned earlier, 
endothelial progenitor cells (EPC) are a subset of Lin¯  BMC that expressed both cKit and Sca1 
(also known as LSK cells). To quantitate the number of adherent LSK cells, the cells harvested 
from adhesion assays were incubated with anti-cKit-APC and anti-Sca1-PE antibodies. Samples 
were analyzed by three-color flow cytometry by gating on the green EGFP-Lin¯  BMC. 
Although, significantly fewer Lin¯  BMC adhered to the surrogate tumor endothelial cell line 
(bEnd.3), the average percentage of Sca1+cKit+ (SK) cells that bound to bEnd.3 cells was 2.4-
times higher than the %SK that bound to DTC (data not shown). Additionally, 1.6-times greater 
%SK adhered to VEC compared to DTC (data not shown). This suggested that the LSK 
population preferentially bound to activated endothelial cells. Because the percent Sca1+cKit+ 
(SK) cells in Lin¯  BMC varied between experiments, reporting the data as the percentage of 
LSK cells adhered to the total LSK cells in each Lin¯  BMC isolation was optimum.  The %LSK 
cells adhered was a ratio of total LSK cells adhered (%SK × Total EGFP-Lin¯  BMC adhered per 
well) to total LSK cells incubated with adherent monolayers in each well (%SK × Total EGFP-
Lin¯  BMC added per well). Overall, a significantly higher percentage of LSK subset adhered to 
DTC cultures compared to other cell types (Figure 18C).  
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Figure 18: Analysis of Adhesion of Lin¯  BMC to Different Cell Types 
A) EGFP-Lin¯  BMC were added to confluent cell cultures (DTC, LLCaB, bEnd.3, VEC and 
3T3-L1) or blank plates for about 30 min. The non-adherent EGFP-Lin¯  BMC were washed and 
adhesion was reviewed on fluorescent microscope. Representative photomicrographs from 
adhesion assay showed that significantly greater number of EGFP-Lin¯  BMC adhered to DTC 
cultures compared to other cell types.  
B) EGFP-Lin¯  BMC, in cell suspensions from adhesion assays, were enumerated manually, and 
by flow cytometric analysis. A significantly higher percentage of Lin¯  BMC adhered to DTC 
cultured compared to other cell types. Average data from two separate assays. 
C) Percentage of Sca1+cKit+ in adhered Lin¯  BMC, i.e. LSK cells, were evaluated by three-color 
flow cytometry. %LSK cells adhered was calculated as (%SK × Total EGFP-Lin¯  BMC adhered 
per well) / (%SK × Total EGFP-Lin¯  BMC added per well). By FACS analysis, a significantly 
greater %LSK cells was observed to adhere to DTC cultured compared to other cell types. When 
data was compared based on manual enumeration, no difference was detected between the 
adhesion of LSK cells to DTC, LLCaB and bEnd.3. Average data from two separate assays. 
P-value < 0.0001 by one-way ANOVA; Post-hoc Dunnett’s test comparing adhesion to each 
cell-type to adhesion to DTC * p <0.05 and *** p <0.001. 
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 Role of CXCR4 and E-selectin in Adhesion of Lin¯  BMC and LSK Cells 
 The role of CXCR4 and SDF-1α in the adhesion of Lin¯  BMC and LSK subset to DTC 
cultures was evaluated in the presence of two CXCR4-blocking agents: AMD3100 and anti-
CXCR4 antibody (Figure 19).  AMD3100 (Plerixafor) is a bicyclic compound that is a specific 
antagonist for CXCR4 (272-274).  
 Lin¯  BMC were incubated with 0.001, 0.01, 0.1, or 1µM AMD3100 for 15 min prior to 
adding these cells to adherent monolayers of different cell cultures. Viability of Lin¯  BMC 
incubated in different concentrations of AMD3100 was evaluated at the end of each assay by 
Trypan Blue exclusion assay. AMD3100 did not affect the viability of cells at any of the above-
mentioned concentrations (data not shown). There was a significant decrease in the number of 
Lin¯  BMC and LSK cells that adhered to DTC cultures in the presence of AMD3100 at all 
concentrations tested (Figures 19 A and B). Similarly, a significant decrease was observed in the 
adhesion of total number of Lin¯  BMC and %LSK cells to DTC in the presence of anti-CXCR4 
antibody (Ab) at 12.5 µg/ml and anti-E-selectin Ab at 25 µg/ml (Figures 19 C-F). Overall, there 
was maximum decrease of 60, 50, and 30% in the adhesion of the total number of Lin¯  BMC to 
DTC in the presence of AMD3100, anti-CXCR4 Ab, and anti-E-selectin Ab (Figures 19 A, C 
and E). The total number of LSK cells that adhered to DTC also decreased in the presence of 
AMD3100, anti-CXCR4, and anti-E-selectin by 40, 50, and 30% respectively (Figure 19 B, D 
and F).  
 Adhesion of Lin¯  BMC to bEnd.3 cells in the presence of AMD3100 was evaluated. 
There was only a modest decrease in adhesion of Lin¯  BMC to bEnd.3 (Figure 20A).  
Nonetheless, the percentage of LSK cells that adhered to bEnd.3 in presence of AMD3100 
decreased considerably. When this data was extrapolated to calculate the total number of LSK 
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cells that adhered to bEnd.3, 82% fewer LSK cells had adhered to bEnd.3 monolayers in the 
presence of all concentrations of AMD3100 tested (Figure 20B). The binding of Lin¯  BMC and 
LSK cells to LLCaB tumor cell monolayers in the presence of AMD3100 was comparable to 
control wells with media only or to isotype-matched antibody (Figure 20 C and D).  
The adhesion of control cell type (EGFP-dermal fibroblasts) with DTC and bEnd.3 
monolayers in the absence and presence of AMD3100 was evaluated in 2-3 separate assays. A 
significant number of dermal fibroblasts adhered to both DTC and bEnd.3 cell cultures, but this 
adhesion was relatively less compared to the adhered Lin¯  BMC. Furthermore, this adhesion was 
not mediated by the interaction of SDF-1α and CXCR4 (Figure 21 A and B).   
Synopsis:  
 These data demonstrated that DTC cultures expressed SDF-1α and E-selectin. The in 
vitro adhesion assays suggested that Lin¯  BMC cell preferentially bound to cultures of 
dissociated tumor cell. In addition, LSK cells preferentially appeared to adhere to cells of 
endothelial lineage. This adhesion was mediated by the interaction of CXCR4 on Lin¯  
BMC/LSK cells and SDF-1α associated with the cell monolayers. E-selectin also appeared to be 
instrumental in the adhesion of Lin¯  BMC and LSK cell. To our knowledge, this is the first 
report showing that SDF-1α acted as an adhesion molecule in vitro on tumor-derived cells.
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Figure 19: Investigation of Blocking Adhesion of Lin¯  BMC to Confluent DTC Cultures  
EGFP-Lin¯  BMC were incubated in increasing concentrations of AMD3100 or media only 
before adding to the DTC monolayers. Adhesion of EGFP-Lin¯  BMC and LSK cells was 
evaluated by flow cytometry.  
A) A significant decrease was observed in the % Lin¯  BMC adhered to DTC in presence of 
increasing concentrations of AMD3100 (Average of 3 separate assays). P-value <0.05 by one-
way ANOVA; Post-hoc Dunnett’s test comparing each treatment to media control * p<0.05 in 
individual assays 
B) A significant decrease in %LSK subset that adhered to DTC cultures was observed at all 
AMD3100 concentrations tested (Average from 2 separate assays). P-value =0.01 by one-way 
ANOVA; Post-hoc Dunnett’s test comparing each treatment to media control * p<0.05 in 
individual assays. 
C-D) EGFP-Lin¯  BMC were incubated with media only, isotype-matched Ab (Ig) or anti-
CXCR4 Ab only before addition to DTC monolayers. Approximately 50% decrease in adhesion 
of Lin¯  BMC (C) and % LSK population (D) was observed in the presence of anti-CXCR4 Ab at 
12.5 µg/mL (Average data from 3 separate experiments). P-value <0.0001 by Students t-test 
compared to isotype-matched control antibody.  
E-F) DTC cultures were incubated with unlabeled anti-E-selectin Ab, isotype-matched Ab (Ig) or 
media only before addition of EGFP-Lin¯  BMC. About 30% inhibition in adhesion of Lin¯  
BMC (E) and LSK cells (F) was observed in the presence of 25 µg/mL anti-E-selectin Ab. 
(Average data from 2 separate experiments). P-value <0.001 by Students t-test to isotype-
matched control antibody. 
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Figure 20: Study of Blocking Adhesion of Lin¯  BMC to bEnd.3 and LLCaB Monolayers 
A) EGFP-Lin¯  BMC were incubated with media only or different concentrations of AMD3100 
before adding to bEnd.3 monolayers. P-value = ns by one-way ANOVA, Average of 2 assays.  
B) The total number of LSK cells that adhered to bEnd.3 in the presence of AMD3100 decreased 
up to 80%. P-value <0.001 by one-way ANOVA; Post-hoc Dunnett’s test comparing each 
treatment to media control *** p<0.0001, Average of 4 assays. 
C-D) EGFP-Lin¯  BMC were incubated in media only or different concentrations of AMD3100 
were added to LLCaB monolayers.  No significant difference was observed in the adhesion of 
Lin¯  BMC or LSK cells to LLCaB monolayers. P-value = ns by one-way ANOVA. 
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Figure 21: Evaluation of Dermal Fibroblast Adhesion to DTC and bEnd.3 Monolayers 
EGFP-dermal fibroblasts were pretreated with increasing concentrations of AMD3100 before 
incubating with cultured DTC or bEnd.3.  EGFP-dermal fibroblasts adhesion was quantitated by 
flow cytometry.  
A) AMD3100 treatment did not affect the adhesion of dermal fibroblasts with DTC cultures 
(Average data from 3 assays). 
B) No significant difference was observed in the adhesion of dermal fibroblasts with bEnd.3 
cells in presence of AMD3100 (Representative data from 2 assays). 
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C: Real-time PCR to Determine the Transgene Copy Number and to Quantitate the 
Biolocalization of Adoptively-transferred EGFP-Transgenic Cells 
Rationale: 
 The third aim of this project was to evaluate the in vivo localization of Lin¯  BMC in 
adoptive transfer experiments in the previously described metastatic model. In past, our 
laboratory assessed the biolocalization of adoptively-transferred vascular endothelial cells (VEC) 
in this same model. In these experiments, mice with metastatic disease were injected with EGFP-
VEC, euthanized 24-72 hours later, and the harvested pulmonary and hepatic tumors and other 
major organs were frozen in OCT. Tissue sections were evaluated by fluorescent microscopy.  
Although EGFP-VEC were specifically observed in metastatic tissue, (Figure 22) this analysis 
was severely compromised by tissue autofluorescence and tissue artifacts. Often fluorescent cell-
like structures were visible in sections from mice that did not receive any EGFP-VEC (data not 
shown). This prompted the development of an alternate, objective, and accurate method for 
quantitation of tissue-localized EGFP-cells.  
 Quantitative real-time PCR (qPCR) methodology has not been widely utilized to 
quantitate egfp-transgene-bearing cells in biodistribution studies.  A qPCR assay was developed 
to quantitate egfp-transgene in the genomic DNA isolated from various tissues in this syngeneic  
murine tumor model.  The development and standardization of the qPCR methodology is 
discussed in this chapter. 
Results: 
 Accurate Quantitation of Genomic DNA  
 DNA was extracted from tissue as described in the Materials and Methods section. In the 
initial qPCR experiments, the amount of DNA used for qPCR was determined  
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Figure 22: Biolocalization of Adoptively-transferred EGFP-VEC in Mice with Metastatic 
Disease  
Tissue sections from control mice (+/- EGFP-VEC), and mice with metastatic disease (+/- 
EGFP-VEC) were visualized on a fluorescent microscope. EGFP-VEC are visible as a bright 
punctuate pattern, specifically in metastatic lungs from mice that were injected with EGFP-VEC 
(Lungs 7, 8 and 9) compared to lungs from healthy mice that received EGFP-VEC (Lungs 4, 5 
and 6). No EGFP-VEC were detected in heart, spleen, or kidney by microscopy. 
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spectrophotometrically (OD260).  Beta-actin (β-actin) was used as an endogenous control for 
qPCR. Consistently higher β-actin cycle threshold (Ct) values were observed in both C57Bl/6 
wild-type and EGFP-transgenic mice with genomic DNA (gDNA) isolated from liver tissue 
compared to lung tissue (25.3± 0.2 vs. 23.6± 0.2, respectively; n=9, p<0.0001).  Liver samples 
from transgenic mice also exhibited higher Ct values for the egfp-transgene, corresponding to a 
2-fold difference in EGFP copy number between lung and liver.  It was hypothesized that gDNA 
from liver samples may have a high degree of contamination by proteins or organic compounds, 
undetected by OD260/280 ratios(267) , which were comparable for DNA isolated from lung and 
liver samples. Thus, a SYBR green-based 96-well assay was used to determine the gDNA 
concentrations accurately (268). The concentration of gDNA was calculated based on the 
standard curve built using serial dilutions of DNA of known concentration.  After diluting the 
gDNA, the isolates were analyzed by agarose gel and SYBR Green fluorescence and results 
indicated that the amount of gDNA in liver samples was 27% of that indicated by 
spectrophotometric measurement (Figure 23).  No significant differences were observed in lung 
DNA concentrations determined by the two methods.  The SYBR Green method was thus the 
optimal method for gDNA quantitation. 
 Plasmid Standard Curve for Absolute Quantitation of EGFP-transgene in  
 qPCR Assay 
 In the initial qPCR assays, plasmid pEGFP-N3 (Figure 24A) dilutions were prepared in 
nuclease-free water. However, these standard curves showed significant variation between assays 
(Figure 24B). Since a very low amount (picogram-attogram) of plasmid was used for the 
standard curve, the inconsistency was probably due to the plasmid sticking to the polypropylene 
plastic tube. This was overcome by preparing the plasmid (pEGFP-N3) dilutions in carrier DNA,  
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Figure 23: Comparison between Spectrophotometric Method and SYBR-green Assay to 
Quantitate Genomic DNA Concentration 
A) Genomic DNA (250 ng based on OD260) from liver (lanes 1-5) and lung (lanes 6-10) tissue of 
five different mice shows significant difference in band intensity on agarose gel. Lane 11 shows 
the 1 Kb Plus DNA ladder. 
 B) The concentration of genomic DNA (100 ng based on OD260) from liver and lung were 
measured spectrophotometrically (OD260) and using the 96-well SYBR-Green assay. Mean 
concentration of gDNA by SYBR-green fluorescent assay (Liver = 26.5±1.37, Lung = 
96.6±20.3).    
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which was genomic DNA isolated from either lung or liver of C57Bl/6 wild-type mice. This, 
subsequently, gave standard curves that were consistent between assays (Figure 23C). When the 
plasmid was diluted in carrier DNA from lung or liver, no significant difference in amplification 
was observed (data not shown). 
 EGFP-Transgene Copy Number 
 To understand how the egfp-transgene copy number from experimental samples 
correlated to the number of transplanted EGFP-cells in biolocalization studies, the egfp-
transgene copy number in the genome of C57Bl/6-Tg(ActbEGFP)10sb/J mice was determined.  
When the pEGFP-N3 plasmid was used to construct a standard curve, TaqMan® qPCR detected 
as few as two copies of the egfp-transgene; this assay was repeated with high reproducibility. 
qPCR analysis of DNA from hemizygous ActbEGFP- transgenic mice was subsequently 
repeated using 100 ng gDNA template as determined by SYBR Green.  No egfp amplification 
was observed with gDNA from lungs and livers of C57Bl/6 wild-type mice (negative controls) 
included in each assay.  Replicates were consistent, the Ct values and copy number determinants 
did not differ significantly between lung and liver samples (Table 8).  Overall, gDNA (100 ng) 
from hemizygous mice was found to contain about 33,300 copies of the transgene, which 
corresponded to two copies of the egfp-transgene per cell. Previously, another group had 
determined that the egfp-transgene was inserted at a single site in the mouse genome of C57Bl/6-
Tg(ACTbEGFP)10sb/J mice by FISH analysis (http://kumikae01.gen-info.osaka-
u.ac.jp/tg/TGFISHresult1.cfm). However, transgenic mice often have tandem copies of the 
transgene at one insertion site (270). Thus, the hemizygous C57Bl/6-Tg(ACTbEGFP)10sb/J 
(ActbEGFP) mice have two copies of egfp-transgene inserted in tandem. This method compared  
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Figure 24: Standardization of Plasmid Standard Curve 
A) Plasmid pEGFP-N3 containing the egfp-transgene 
B) Representative standard curve from five separate experiments using plasmid dilutions 
prepared in nuclease free water resulted in erratic standard curve 
C) Representative standard curve from seven separate experiments prepared by diluting the 
plasmid in carrier DNA (genomic DNA from lung or liver DNA from C57Bl/7 mouse) were 
consistently reproducible and were used for making standard curves in all subsequently assays.
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Table 8: Two copies of EGFP-transgene per cell calculated from genomic DNA from the 
hemizygous mouse strain C57Bl/6-Tg(ACTbEGFP)10sb/J 
 
 
 
 
 
 
 
 
 
 
 
 
* Tissue samples from five different transgenic mice 
**  Average Ct values from duplicate samples assayed in two separate experiments (n=4) 
*** EGFP copy number based on average standard curve equation from two assays (y =-3.4x + 
40.3) 
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favorably with the 2-∆∆Ct qPCR method for determining transgene copy number, especially when 
a transgenic animal with a known copy number was unavailable for comparison. 
 In one series, we analyzed DNA (lung, liver, and VEC) from the ActbEGFP-transgenic 
mice along with DNA from the homozygous transgenic C57Bl/6Tg(UBC_GFP)30/Scha/J strain 
(UbqEGFP).  Using β-actin as endogenous control and the 2-∆∆Ct method, we found that both 
strains contained the same number of copies of the transgene (Figure 25).  Thus, UbqEGFP-
transgenic mice have a single transgene at a single insertion site per haploid cell and thus had 
two copies per diploid (somatic) cell.  Although the homozygous C57Bl/6-
Tg(ACTbEGFP)10sb/J (ActbEGFP+)-transgenic mice die within the first month of birth, we 
bred these mice to confirm the egfp-copy number. qPCR results show that these mice have four 
copies of the egfp-transgene compared to two copies in hemizygous ActbEGFP-transgenic strain 
(Figure 3B).  Thus, the egfp-transgene copy number in both hemizygous C57Bl/6-
Tg(ACTbEGFP)10sb/J and homozygous C57Bl/6Tg(UBC_GFP)30/Scha/J mouse strains was 
calculated to be two. 
 Association between Manual Cell Count and qPCR to Enumerate Tissue-Localized 
 EGFP-Transgenic Cells 
 As stated above, using fluorescent microscopy, systemically administered EGFP-VEC 
were visualized in metastases, but were not detected in healthy organs.  However, high tissue 
autofluorescence often prohibited the analysis of specimens, particularly in lung tissue.  For the 
development of the qPCR assay to quantitate tissue localized EGFP-cells, three control groups: 
(1) healthy, (2) metastases-bearing mice not injected with EGFP-VEC, and (3) healthy mice 
injected with EGFP-VEC, were used along with test group: metastases-bearing mice injected  
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Figure 25: EGFP Copy Number in Transgenic Mouse Strains  
Egfp-transgene copy number in hemizygous C57Bl/6-Tg(ActbEGFP)10sb/J (n=4) was 
calculated using the plasmid stand curve in qPCR assays. The egfp-transgene copy number in 
homozygous C57Bl/6-Tg(ActbEGFP)10sb/J (n=5) and C57BL/6-Tg(UBC-GFP)30Scha/J (Ub-
EGFP) (n=3) were calculated by 2-∆∆Ct methods. 
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with EGFP-VEC. EGFP-VEC were manually enumerated by examining 10 µm liver sections by 
fluorescent microscopy (an average of 21 sections examined/group). No EGFP-VEC were found 
in liver sections from control groups 1 and 2 (healthy and metastases-bearing mice not injected  
with EGFP-VEC).  A few apparent EGFP-VEC were detected in liver sections from a single 
mouse in control group 3 (healthy mice injected with EGFP-VEC) (Figure 26 A and B).  In 
contrast, a significant number of EGFP-VEC were detected in metastases-bearing mice injected 
with EGFP-VEC (33±7 EGFP-VEC/mm2 vs. 3±5 in controls, p<0.001).   In order to compare 
directly with manual enumeration, liver tissue was scraped from the same slides enumerated 
(Figure 26A) and gDNA was extracted and analyzed by qPCR.  Replicates within each assay 
were consistent (average Ct standard deviation=0.24).  The transgene was undetected in livers 
from control groups.  In contrast, EGFP was detected in 100% (4/4) of metastatic liver tissue 
from mice injected with EGFP-VEC.   A Pearson correlation coefficient of 0.81 indicated a 
strong positive correlation between the two methods (275), although the actual number of EGFP-
VEC per section differed (Figure 26C).  Quantitative differences were most likely due to a 
culmination of things: underestimation by PCR, poor DNA recovery from the slides (170 ng per 
section), and pooling of sections causing dilution of transgene signal. 
 Due to the low overall number of tumor-localized VEC in the former experiment, intra-
tumor (i.t.) injection of EGFP-VEC into subcutaneous (s.c.) tumor model was used for further 
assay validation.  C57Bl/6 mice bearing approximately 150 mm3 s.c. LLCaB tumors were 
injected i.t. with saline (n=4) or EGFP-VEC (n=8).  Tumors were harvested 2 hours later and 
alternating 10 µm sections were assayed for EGFP-VEC by manual enumeration or qPCR. A 
total of 39-77 sections were assayed per tumor.  The average values per section for every 80 µm 
segment of tissue (5 sections for qPCR and 3 intervening sections for microscopy) were plotted  
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Figure 26: Localization and Enumeration of EGFP-VEC to Liver Metastases 
A)  Representative fluorescent microscopy pictures of 10 µm liver sections from: 1) normal 
animal not injected with EGFP-VEC (n= 5); 2) normal animal injected with EGFP-VEC (n=5); 
3-6) four metastases-bearing animals that received EGFP-VEC.  
B) Manual enumeration of EGFP-VEC in liver metastases compared to control group 3 (healthy 
mice injected with EGFP-VEC) suggests that VEC specifically localized to tumor-bearing tissue. 
C) Correlation of manual enumeration and qPCR.  PCR analysis of tissue sections scraped from 
a subset of slides from normal mice injected with EGFP-VEC and metastases-bearing animals 
that received EGFP-VEC that were previously enumerated manually. Although DNA recovery 
was low, these results correlated strongly with EGFP-VEC enumeration determined by manual 
counting (Pearson correlation ρ = 0.81).   
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for all tumors in all animals.  Alternating 10 µm s.c. tumor sections were analyzed by fluorescent 
microscopy and qPCR as described above.  PCR values were converted to the number of EGFP-
VEC per section as described in Figure 7B.  EGFP-VEC were detected, by both microscopy and 
PCR, in all eight s.c. tumors injected with EGFP-VEC.  qPCR quantitation again correlated with 
enumeration by manual cell count, both when assayed sections from all tumors were plotted 
(positive Pearson correlation of 0.61; Figure 27A) and when average EGFP-VEC per section per 
mouse were compared (strong positive Pearson correlation ρ = 0.82; Figure 27B). Although 85% 
of the sections from saline-injected tumors showed bright green apparent cell-like structures by 
microscopy, no egfp amplification was detected by qPCR in any saline control sample assayed.   
This was also true in some sections from EGFP-VEC-injected tumors. 
 All s.c. tumor sections were further analyzed by optical Z-stacks using confocal 
microscopy. Confocal microscopy was used to distinguish EGFP-VEC from artifactual 
fluorescence.  Four 100 µm2 areas of s.c. tumor sections, each containing an apparent fluorescent 
cell, were randomly selected and corresponding Z-stacks containing ten 1 µm optical sections 
were generated.  Average intensities from 4 sections were plotted, starting at the tissue surface 
(confocal Z-stack section #1) through each descending 1 µm plane to confocal Z stack section 
#10.  The average mean and maximum fluorescent intensities of sections of tumors injected with 
EGFP-VEC (n=8) were elevated throughout and were significantly higher than saline controls 
(n=4).   The fluorescence intensity of each section as well as four 100 µm2 areas per tumor, each 
containing an apparent fluorescent cell, was measured.  Blinded analysis showed that the mean 
and maximum fluorescence intensity of sections (data not shown) and cell-like structures (Figure 
27C) were significantly higher for tumors injected with EGFP-VEC compared to saline-injected 
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tumors (p<0.005).  Fluorescent signals apparent by conventional microscopy (on a single plane) 
were thus sometimes due to tissue artifacts, not EGFP-VEC, leading to false positive results.   
The biolocalization of adoptively-transferred EGFP-VEC in the metastatic model was 
analyzed by qPCR (Figure 28). The egfp-transgene was specifically detected in significantly  
higher quantities in lung and liver compared to other organs from mice with metastatic disease 
that were injected with EGFP-VEC. This data substantiated our earlier findings using fluorescent 
microscopy (Figure 22). 
 In conclusion, the qPCR assay for the egfp-transgene described here enabled the rapid, 
objective, and accurate quantitation of biolocalized transgenic cells and was superior to the 
microscopic examination of histological specimens.   
 Modification of qPCR Method to Assay Large Number of Samples 
 To increase the sensitivity of the qPCR assay to detect the egfp-transgene, five 50 µm 
thick tissue sections were collected in multiple tubes and DNA was extracted (Figure 5A). This 
generated several DNA samples per tissue and thus the qPCR assay was modified for a high 
throughput 384-well plate format. The qPCR assay efficiently translated from a 96-well plate 
format where reaction volume was 25 µl to a 384-well format where the reaction volume was 20 
µl, using 100 ng DNA as template (Figure 29A and B). The CtEGFP and Ctβ-actin were comparable 
between assays for the negative control DNA from C57Bl/6 mice (Blk 1-3, n=3), positive control 
DNA from Actb EGFP-transgenic mice (ActbEGFP 1-3, n=3), and test DNA samples from mice 
with metastatic disease injected with EGFP-VEC (n=12).  
 To increase the amount of genomic DNA to be assayed in 20 µl qPCR reaction a dose-
response experiment was conducted using 100, 200, 400, and 600 ng DNA. Although egfp 
amplification was proportional to increasing amounts of DNA extracted from EGFP-transgenic  
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Figure 27: Comparison of Manual Enumeration and qPCR Method to Quantitate Tissue-
Localized EGFP-Transgenic Cells 
A) A positive correlation (Pearson correlation ρ = 0.61; range 0.2-1.0) was observed between the 
two methods i.e. manual enumeration and qPCR for quantitation of EGFP-VEC.    
B) The overall average values per section per tumor plotted for each animal.  There was a 
strongly positive correlation (Pearson correlation coefficient ρ = 0.82) between the two methods.   
C) Confocal microscopy analysis was used to distinguish EGFP-VEC from artifactual 
fluorescence.  The average mean and maximum fluorescent intensities of sections of tumors 
injected with EGFP-VEC (n=8) were elevated throughout the section and were significantly 
higher than saline controls (n=4).  
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Figure 28: Quantitation by qPCR of Biolocalization of Systemically Injected EGFP-VEC in 
Mice with Metastatic Disease 
DNA from lung and liver metastases and other major organs from control groups (Healthy mice 
not injected with EGFP-VEC, Mice with metastases not injected with EGFP-VEC and healthy 
mice injected with EGFP-VEC), and experimental group (mice with metastases injected with 
EGFP-VEC) were analyzed for egfp-transgene by qPCR. The specific localization of EGFP-
VEC was predominantly detected in the lung metastases.
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mice (Figure 29C, black filled), the amplification efficiency for experimental DNA samples did 
not increase proportionally when more than 200 ng DNA was used (Figure 29C, open triangles). 
Thus, subsequent qPCR assays were run using 200 ng DNA in 20 µl reactions in 384-well format 
on AB7900.  
Synopsis:  
 These data suggested that the qPCR methodology offered specific, objective, and rapid 
quantitation of EGFP-transgenic cells. This qPCR-based quantitation was uncomplicated by 
tissue autofluorescence. This method should be readily transferable to other in vivo models to 
quantitate the biolocalization of transplanted transgenic cells. 
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Figure 29: Modification of qPCR Assay for High-Throughput 384-Well Analysis. 
A-B) The two graphs compare the qPCR assays in 25 µl reaction mix in 96-well (filled circles 
and squares) format and the qPCR assays in 20 µl reaction mix in 384-well format (open circles 
and squares) using 100 ng genomic DNA.  In the first graph (A) shows the Ct values 
corresponding to β-actin amplification (squares) in negative (Blk 1-3) and positive (ActbEGFP 
1-3) control samples. Amplification of egfp-transgene (circles) was not detected in the negative 
control samples. The second graph (B) shows the Ct values corresponding to β-actin and egfp 
amplification in DNA from metastatic mice injected with EGFP-VEC. The values on the x-axis 
represent the identification number for each mouse. The Ct values between the 25 µl and 20 µl 
reactions are similar. 
C) The qPCR amplification efficiency was compared to the increasing amount of genomic DNA 
in 20 µl qPCR reaction. The average fold-change in egfp-transgene detection was not 
proportional to the amounts of genomic DNA when more than 200 ng DNA from experimental 
tissue was used (table of right and open triangles in the graph). The egfp amplification appeared 
more proportional for DNA extracted from EGFP-transgenic mice (filled box in the graph).  
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D: The Role of E-selectin and SDF-1α in the Biolocalization of Bone Marrow-Derived Cells 
to Tumors 
Rationale: 
 The hypothesis for this research project was that SDF-1α associated with tumor 
endothelium, was an important mediator for biolocalization and adhesion of bone marrow-
derived endothelial progenitors (EPC) to LLCaB tumors. Bone marrow-derived lineage-negative 
cells (Lin¯  BMC) which are enriched for EPC (125;126) were selected for the in vitro adhesion 
assay. For the in vivo experiments, dermal fibroblasts (from a non-endothelial lineage) were used 
as control cells to evaluate if biodistribution of the systemically administered cells was specific 
for endothelial progenitors (i.e. Lin¯  BMC). This chapter describes the biolocalization of dermal 
fibroblasts and Lin¯  BMC to s.c. and metastatic LLCaB tumors. 
Results: 
 In vivo Biolocalization of Lin¯  BMC and Dermal Fibroblast 
The in vivo experiments were conducted as described in the Methods and Materials 
sections, and as schematically represented in Figures 5 and 6. Briefly, mice with either s.c. 
tumors or metastatic disease were systemically injected with Lin¯  BMC or dermal fibroblasts 
that were isolated from EGFP-transgenic mice. As diagrammatically represented in Figure  
8B, 50 µm-thick sections of the tissue harvested from the in vivo experiments were collected (5 
per individual tube) and genomic DNA was extracted, quantified, and used for qPCR. From each 
tube, 200 ng of DNA was assayed for the egfp-transgene in duplicate.  
 The data set was obtained from three separate qPCR assays run in 384-well plate format. 
Cycle threshold (Ct) values greater than 37 appeared unreliable and were occasionally detected 
in negative controls, and thus were deemed negative. Overall data obtained from in vivo 
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experiments is summarized in box-and-whisker plots in Figures 30-31 A and C, and 32A 
(GraphPad Prism 5.0 software). The box-plot rectangle graphically depicted Q1 and Q3 
quartiles, the line within the box-plot indicated the median value, and the I-bar (“whiskers”) 
extended to the minimum and maximum values in the data set. Box-plots are programmed to 
identify outlier cutoff or fences according to Tukey’s rule; outliers thus detected were excluded 
from data set prior to analysis. Higher Ct values represented fewer copies of egfp-transgene. As 
described in the previous chapter, Ct values were translated into egfp-transgene numbers based 
on the plasmid standard curve in individual plates. It must be noted that PCR amplification is 
exponential and a difference of one Ct is equal to a 2X difference in gene copy number. The total 
amount of DNA extracted and the total number of egfp-transgene detected per tube per tissue 
block was calculated and used to derive a single value and reported as egfp-transgene per 
microgram per tissue. These values were used for one-way ANOVA and post-hoc Dunnett’s 
analysis for determining statistical difference between groups and tissues. For statistical tests, it 
was assumed that the data set was unpaired, non-parametric and lacked Gaussian distribution. 
  Subcutaneous Tumor Model 
 Mice with small s.c. tumors (average tumor volume = 200 ± 43 mm3) were injected with 
5 × 105 EGFP-Lin¯  BMC (n=7), EGFP dermal fibroblasts (n=5), or media (n=3). There was no 
significant difference in the in vivo tumor growth curves from the three groups (data not shown). 
Animals were euthanized 72 hours post injection and s.c. tumors and the other major organs 
were frozen in OCT. Each s.c. tumor was frozen in two tissue blocks; one block was completely 
sectioned for analysis. DNA from an average of eight tubes per tumor from each group was 
analyzed. Egfp-transgene amplification was not observed in any DNA samples from tumors from 
three control mice that were injected with media only (Figure 30 A and C). Egfp-transgene 
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amplification in tumor DNA from mice injected with fibroblasts (n=5) was weak and erratic. 
None of the tumor DNA samples tested from two of these mice showed amplification for egfp-
transgene and were deemed negative.  The remaining three mice in the fibroblast group had only 
1 or 2 samples that were deemed weakly positive (4/25 tubes, Ct = 38.7- 45.5).  
 Similarly, the egfp-transgene was not detected in any of the tumor DNA samples from 4 
of the 7 mice that were injected with Lin¯  BMC. Weak and erratic amplification was observed in 
2 mice in this group (DNA from 4/16 samples had detectable egfp-transgene amplification Ct = 
37.2- 46.9). However, the majority of samples from one tumor in this group had substantial egfp-
transgene amplification (DNA from 7/10 tubes were positive Ct 34.7-36.96; Figure 30A). When 
data was averaged for all tumor samples in each group, a higher number of total egfp-transgene 
was detected in the group that was injected with Lin¯  BMC, but this difference was statistically 
insignificant (Figure 30B).   
 All major organs from the mouse that showed the highest biolocalization of Lin¯  BMC to 
s.c. tumors were assayed for expression of the egfp-transgene (Figure 30C). When CtEGFP were 
transformed to the total number of egfp-transgene per µg DNA, substantially higher values were 
detected in all of these organs (Figure 30D). Thus, although higher number of Lin¯  BMC 
compared to fibroblasts localized to s.c. tumors at 72 hours, the Lin¯  BMC did not preferentially 
or specifically localize to s.c. tumors.   
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Figure 30: Biolocalization of EGFP-Lin¯  BMC in Subcutaneous Tumor Model 
DNA from tissue samples from s.c. tumor-bearing mice that were injected with media, EGFP 
fibroblasts or EGFP-Lin¯  BMC were analyzed for egfp-transgene by qPCR.  
A) Cycle threshold (Ct) values for egfp-transgene amplification for all positive samples from all 
mice are plotted. Egfp-transgene amplification was detected in 1 of 7 tumors from the group that 
were injected with EGFP-Lin¯  BMC. No egfp amplification was observed in any tumors from 
mice injected with media or EGFP-dermal fibroblast. The reported n represents the number of 
tubes of DNA positive for egfp-amplification / total number of DNA tubes assayed. 
B) The egfp-transgene was detected in s.c. tumors in the group of mice injected with Lin¯  BMC. 
C) CtEGFP for all positive samples from the one positive s.c. tumor and other major organs for the 
same mouse are plotted. Compared to s.c. tumor, more egfp-transgene amplification was 
observed in the other major organs from the one positive mouse injected with EGFP-Lin¯  BMC. 
D) Higher amounts of egfp-transgene per organ were detected in the lungs, livers, hearts, spleens, 
and kidneys when compared to the s.c. tumor in the mouse that had the most EGFP-Lin¯  BMC. 
  
 
168
 
Me
dia
 
(n=
0/1
0)
Fib
ro
bla
st 
(n=
0/1
6)
Lin
-
 
BM
C (
n=
7/2
0)
30
32
34
36
38
40
S.C. Tumor-Bearing Mice Injected with EGFP-transgenic Cells
(Positive Samples / Total Samples)
Cy
cl
e 
Th
re
sh
o
ld
 
(C
t)
eg
fp
-
tr
an
sg
en
e
Me
dia
 
(n=
3)
Fib
ro
bla
st 
(n=
5)
Lin
-
 
BM
C (
n=
7)
0
5
10
15
20
25
30
35
S.C. Tumor-Bearing Mice Injected with EGFP-transgenic Cells
(Mice in each Group)
EG
FP
-
Tr
an
sg
en
e 
pe
r
µµ µµ
g 
DN
A
+
/- 
SE
M
SC
 
Tu
m
or
 
(n=
7/1
0)
Lu
ng
 
NV
M 
(n=
9/1
0)
Liv
er
 
NV
M 
 
(n=
10
/10
)
He
ar
t(n=
8/9
)
Sp
lee
n 
(n=
10
/10
)
Kid
ne
y (n
=
9/1
0)
30
32
34
36
38
40
*** *** ***
***
***
Tissues from Mouse Injected with Lin - BMC
Cy
cl
e 
Th
re
sh
o
ld
 
(C
t)
eg
fp
-
tr
an
sg
en
e
SC
 
Tu
m
or
Lu
ng
 
NV
M 
Liv
er
 
NV
M 
He
ar
t
Sp
lee
n 
Kid
ne
y 
0
50
100
150
200
500
1000
1500
2000
Tissues from Mouse  Injected with Lin - BMC
EG
FP
-
Tr
an
sg
en
e 
pe
r
µµ µµ
g 
DN
A
+
/- 
SE
M
A B
C D
 
 
 
 
 
 
  
 
169
 Metastatic Tumor Model                                                                                                
Mice with metastatic disease were injected i.v. with 5 × 105 EGFP-Lin¯  BMC (n=4 mice) 
and were euthanized at 48-72 hours post-injection. The biolocalization of EGFP-Lin¯  BMC in 
metastatic lung/liver tumors (n=7 metastases), as well as other control organs (heart, spleen, and 
kidney, n=4 mice) were analyzed by qPCR. Two mice with metastatic disease were injected i.v. 
with 5 × 105 EGFP dermal fibroblast as controls. These mice were euthanized at 24 hours after 
EGFP dermal fibroblast injection due to their moribund condition. The lung/liver with visible 
metastases (n=4 metastases) were evaluated for biolocalization of EGFP dermal fibroblasts by 
qPCR.  
 The control group injected with dermal fibroblasts had a significantly higher median 
CtEGFP and lower number of egfp-transgene per mg of tissue weight compared to mice with 
metastatic disease that were injected with EGFP-Lin¯  BMC  (Figure 31 A and B). A total of 37 
tubes of DNA from 4 metastatic lesions from n = 2 mice and 80 tubes of DNA from 7 metastatic 
lesions from n = 4 mice were evaluated from mice with metastatic disease injected with dermal 
fibroblasts or EGFP-Lin¯  BMC, respectively.  In addition, all four mice injected with Lin¯  BMC 
had median CtEGFP in metastases was significantly lower compared to other organs analyzed 
(Figure 31C). This translated to the detection of significantly greater numbers of EGFP-Lin¯  
BMC in metastatic lesions compared to lungs/livers with ‘no visible metastases’ (NVM), hearts 
and spleens, but not kidneys (Figure 31 D and E).   
 Data was also analyzed as total egfp-transgene per tissue based on DNA isolated from 
individual samples. This analysis indicated that significantly higher numbers of EGFP-Lin¯  
BMC were detected in metastases compared to dermal fibroblasts and all other major organs 
(data not shown).  
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Figure 31: Biolocalization of EGFP-Lin¯  BMC in Metastatic Tumor Model 
Mice with metastatic disease were injected with EGFP-Lin¯  BMC or EGFP fibroblasts. DNA 
isolated in multiple tubes from tissues blocks containing lung/liver metastases, lung/liver tissue 
with no visible metastases or other organs was analyzed for egfp-transgene by qPCR. 
 A) Cycle threshold values (Ct). Significantly lower median CtEGFP was observed in mice with 
metastases injected with EGFP-Lin¯  BMC (Ct range 27.4-37) compared to mice with metastases 
that received dermal fibroblasts (Ct range 27-36.9); lower Ct values indicated higher amounts of 
egfp-transgene.         n = positive samples / total samples analyzed per group. 
B) A significantly higher number of egfp-transgene per mg tissue wet-weight was calculated in 
metastases from the mice injected with EGFP-Lin¯  BMC compared to metastases from mice 
injected with dermal fibroblasts. 
C) Cycle threshold values (Ct). Mean CtEGFP for metastatic tissues was significantly lower than 
CtEGFP from lung/liver tissues with no visible metastases (NVM, Ct range 28.7-36.8), hearts (Ct 
range 30.1-36.4) and spleen (Ct range 36.9-32.1), but not kidney (Ct range 27.6-33.4) in the 
group of mice injected with Lin¯  BMC (3 days after injection). P-value <0.0001 by one-way 
ANOVA; Post-hoc Dunnett’s test compared to metastases *** p<0.0001. 
D) Significantly greater number of egfp-transgene per mg tissue wet-weight were detected in 
metastatic tissues compared to adjacent tissues with no visible metastases (NVM) in mice 
injected with Lin¯  BMC. Two-tailed unpaired Student’s t-test ** p<0.01. 
E) Compared to metastases, significantly lower amounts of egfp-transgene per µg DNA were 
detected in hearts and spleens. P-value = 0.001 by one-way ANOVA; Post-hoc Dunnett’s test 
compared to metastases ** p<0.001.
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The relationship between EGFP-Lin¯  BMC homing (EGFP-Lin¯  BMC per metastases per mm3) 
and metastatic tumor volumes (Average metastatic tumor volume = 24 ± 25 mm3) was also 
evaluated. Overall, an inverse correlation was apparent between biolocalization of EGFP-Lin¯  
BMC and metastatic tumor volumes by Spearman’s correlation (ρ = -0.59), however the P-value 
for this analysis was not significant. 
 In a subsequent experiment, a total of 10 metastatic lesions from 4 mice were evaluated 
for long-term (7 days post EGFP-Lin¯  BMC administration) retention of Lin¯  BMC in 
metastases. DNA from an average of 11 tubes per metastatic lesion was assayed by qPCR for 
egfp-transgene. All tubes showed amplification of egfp-transgene with Ct ranging from 23 to 
35.5. Overall, twice as many EGFP-Lin¯  BMC were detected in metastases on day 7 compared 
day 3 after EGFP-Lin¯  BMC administration; however, this difference was not statistically 
significant (Figure 32). Nonetheless, Lin¯  BMC appeared to be retained long-term in metastatic 
lesions. 
Synopsis:  
  These in vivo experiments have demonstrated that a substantial number of Lin¯  BMC 
localized to metastatic tumors compared to s.c. tumors and other non-metastatic tissues and 
organs. In addition, a significantly greater number of CXCR4+ Lin¯  BMC localized to metastatic 
tissues compared to CXCR4¯  dermal fibroblasts. The metastases expressed significantly elevated 
levels of SDF-1α compared to s.c. tumors. Thus, the data en bloc suggested that the 
biolocalization of Lin¯  BMC to metastases was most likely due to the interaction of tissue-
derived SDF-1α and the CXCR4+ Lin¯  BMC.  
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Figure 32: Long-term Retention of EGFP-Lin¯  BMC in Metastatic Tumors 
Mice with metastases were euthanized 3 and 7 days after injecting EGFP-Lin¯  BMC. Multiple 
tubes of DNA from metastatic lung/liver tissue sections from frozen tissue blocks were analyzed 
for egfp-transgene by qPCR. 
 A) Cycle threshold values (Ct). No significant difference in median CtEGFP was observed 
between the 3-day (Ct range 27.4-37) and 7-day (Ct range 23-35.5) groups. The reported n 
indicates positive samples / total samples analyzed per group. 
B) EGFP-transgene per µg DNA in metastatic lesions was higher on day 7 compared to day 3 
after intravenous injection of EGFP-Lin¯  BMC, indicating cell retention and/or replication. 
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CHAPTER IV:  MODEL 
  A suggested model for an SDF-1α-mediated mechanism of tumor biolocalization and 
adhesion of bone marrow-derived progenitors is shown in Figure 33.  This is based on our 
accumulated data in a mouse model and the use of systemically-administered, adoptively-
transferred bone marrow-derived EPC as surrogates for in vivo-mobilized EPC during tumor 
vasculogenesis.   
 In vitro and in vivo experiments have shown that both E-selectin and SDF-1α were 
expressed in LLCaB subcutaneous and metastatic tumors. E-selectin was selectively expressed in 
tumor endothelium, but not in normal healthy tissue.  SDF-1α was significantly upregulated in 
metastatic tumors compared to normal tissues and orthotopic subcutaneous tumors.  SDF-1α 
protein levels in tumors were most likely regulated by hypoxia, necrosis, and proteases. SDF-1α 
was not only found dispersed through out the extracellular matrix, but also found to be associated 
with tumor endothelium suggesting its possible role as a cell adhesion molecule. The association 
of SDF-1α with the ECM and cell membranes was most likely via heparan sulphates.  In vitro 
adhesion assays demonstrated that Lin¯  BMC and endothelial progenitors (Lin¯ Sca1+cKit+ BMC) 
adhered to the tumor-derived cells, and that their adhesion to tumor-derived cells was mediated 
by the interaction of SDF-1α and CXCR4.  A significantly greater number of Lin¯  BMC 
localized to metastases compared to adjacent healthy tissues and organs and subcutaneous 
tumors.  Thus, it appeared that SDF-1α was one of the permissive triggers of tumor 
vasculogenesis that regulated the recruitment and adhesion of BMC to tumors.   
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Figure 33: SDF-1α-Mediated Mechanism for Tumor Biolocalization and Adhesion of 
Lineage-negative BMC  
Greater numbers of adoptively-transferred CXCR4+Lin¯  BMC localized to LLCaB metastases 
(mouse on right), which had significantly elevated levels of SDF-1α protein, compared to 
LLCaB subcutaneous tumors (mouse on left) and adjacent healthier tissues. SDF-1α was 
associated with the extracellular matrix (ECM) and with tumor endothelium (EC) and this 
adhesion most likely occurred via heparan sulphates.  In vitro assays demonstrated that the 
adhesion of Lin¯  BMC and endothelial progenitor to tumor endothelial cells was mediated by the 
interaction of SDF-1α and CXCR4. Together these data suggested in our model that tumor-
derived SDF-1α bound to tumor endothelial cells may recruit and facilitate adhesion of 
circulating bone marrow-derived CXCR4+ progenitor cells to SDF-1α-rich tumors. 
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CHAPTER V: DISCUSSION 
 The formation of new blood vessels by angiogenesis and/or vasculogenesis is 
predominantly observed in embryonic development, and vascularization in healthy adults is 
observed during the menstrual cycle, pregnancy, and wound healing. It was in the early 1970’s 
that it was first demonstrated that tumor growth was angiogenesis-dependent. Dr. Judah Folkman 
proposed that targeting the developing tumor vasculature would be a valuable intervention in 
controlling tumor growth and cancer progression. In addition, it was suggested that specific 
targeting of the tumor vasculature would have advantages such as easy accessibility, specificity, 
and low toxicity, overcome limitations like drug resistance of tumor cell, and be applicable to a 
wide array of tumors. Lal et al. were the first to report the implantation and survival of 
systemically injected endothelial cells (EC) within tumors (31). Subsequently, Zwiebel et al. 
reported a significant reduction in metastatic burden by systemic administration of EC that were 
genetically modified to overexpress the cytotoxic cytokine IL-2 (89). This initial account opened 
the door for potential EC-mediated therapeutic strategies: the use of EC to deliver specific 
treatment to tumors. This approach has not been vigorously pursued, due to setbacks in clinical 
gene therapy and limited availability of syngeneic endothelial cells. However, other anti-
angiogenic strategies targeting specific steps in tumor vascularization have been established as 
important in restricting cancer progression, and are being developed as new approaches in cancer 
therapy (4;5). 
In 1997, Asahara’s group isolated a unique cell fraction from peripheral blood 
mononuclear cells mobilized from bone marrow (BM) that possessed properties similar to that of 
an embryonic angioblast; these were designated endothelial progenitor cells (EPC). This group 
demonstrated that in vitro, EPC proliferated and/or migrated in response to angiogenic growth 
  
 
179
factors and differentiated into mature EC, and in vivo were mobilized in response to ischemic 
injury and contributed to the re-vascularization of ischemic tissue (48;49). This led to the 
exploration of the role of BM-derived EPC in tumor vascularization (vasculogenesis). At the 
advent of this dissertation research, in 2005, EPC-mediated tumor vascularization was a novel 
concept with only a handful of reports with inconsistent findings (Table 1). Lyden et al. were the 
first to report the recruitment of hematopoietic and circulating endothelial precursor cells (CEPs) 
and their importance in tumor growth. They reported that BMC-mediated tumor vascularization 
was driven by vascular endothelial growth factor (VEGF), and that blocking the mobilization of 
both VEGFR2+ CEPs and VEGFR1+ bone marrow-derived cells was necessary to completely 
ablate tumor growth (197). On the contrary, Vajkoczy had et al. reported that P- and E-selectin 
and their ligand PSGL-1 mediated the localization and incorporation of embryonic endothelial 
progenitors to tumor vasculature (51). Later, in 2004 Wei et al. demonstrated that systemically-
injected embryonic EPC that were transfected with a suicide construct led to improvement in the 
survival of mice that received the substrate for the suicide gene (78).  
Early reports suggested that, like the mature endothelial cells, endothelial progenitors 
might be important in tumor vascularization and tumor targeting. Thus, understanding the 
mechanism by which EPC contributed to the process of vascularization could help in developing 
drugs to control vasculogenesis and arrest tumor growth. Additionally, genetically modified EPC 
could be developed as a therapeutic Trojan horse to specifically deliver therapy to tumors.   
In 2005, we proposed that SDF-1α was important in recruitment and adhesion of bone 
marrow-derived progenitors to tumors. Since then there have been about 20 reports that have 
demonstrated the tumor-localization of EPC from adult bone marrow and the role of hypoxia-
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induced proteins. Five of these reports have demonstrated the role of SDF-1α in tumor 
vasculogenesis.   
The metastatic tumor model was characterized in the first part of this dissertation. The 
LLCaB cell line was suitable for use in immunocompetent C57Bl/6 mice and was syngeneic to 
the host. Additionally, previous in vivo experiments in our laboratory showed that the LLCaB 
cell line, compared to the parental cell line LLC1 and LLCC3 subclone, developed primary 
tumors more rapidly and produced larger metastases. Subcutaneous (s.c.) tumor resection was 
used to promote development of metastatic tumor cells seeded in the lungs and livers. Although 
lungs appeared to be the predominant site of metastases, liver metastases were frequently 
observed. This was in agreement with the clinically observation that lung tumors metastasized to 
livers. In addition, we have demonstrated that the primary tumor volumes and the number of 
days after surgical excision of s.c. tumors were critical for consistent development of metastases 
(Figure 9).  These data were in alignment with earlier studies and the current concept of tumor 
development in the human population. The larger primary tumors gave rise to a greater number 
of metastases, which developed rapidly after primary tumor removal. In contrast, the smaller 
primary tumors led to fewer metastases and took a longer time to develop. Ohizumi et al. 
observed similar relationship between the frequency of metastases and the primary tumor 
volumes in 1987 (276;277). Their model was similar to ours, although they used a different and 
apparently more aggressive Lewis lung tumor subclone, injected it intramuscularly in the hind 
limb, and studied the metastatic development without resection of the primary tumors. These 
data suggested that the LLCaB tumor model was a clinically relevant murine model. 
The expression of E-selectin and SDF-1α in s.c. and metastatic tumors was evaluated by 
RT-PCR, ELISA and immunohistochemistry in Chapter III A. E-selectin was specifically 
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expressed on activated endothelium in tumors and absent from healthy control tissue, supporting 
our and others earlier findings (Figure 10). In contrast to E-selectin, SDF-1α protein was 
detected at basal levels in healthy control lung and liver samples. This observation was in 
agreement with other published reports (249;278).  Although, no difference in the amounts of 
SDF-1α protein in s.c. tumors and healthy control samples was observed, SDF-1α protein was 
significantly elevated in metastases (Figure 11). In addition, smaller tumors appeared to express 
higher amounts of SDF-1α protein per milligrams of total protein compared to the larger tumors. 
These data might imply that SDF-1α was critical in the early phases of tumor development and 
was replaced by other growth factors, as the tumor progressed. However, even when comparably 
sized tumors were compared, the s.c. tumor had significantly lower expression of SDF-1α 
protein. This could suggest that the expression of SDF-1α was influenced by the physiologic 
location of tumors. It was also possible that SDF-1α expression was dependent to the nature of 
tumor initiation (growth of tumor cell bolus in s.c. tumors in heterotopic environment versus 
proliferations of localized single tumor cell to produce metastases in orthotopic environment). In 
addition, this could be attributed to the difference in the ratio of blood vasculature to tumor cells 
in larger tumors compared to smaller tumors. There are several reports that have associated 
elevated levels of SDF-1α with the more aggressive and advanced phenotype in glioma (279), 
colorectal cancer (280), and pituitary adenoma (281). It must be noted that LLCaB is an 
aggressive adenocarcinoma cell line, and that tumor size must not be confused with tumor 
biology/stage. Nevertheless, to our knowledge this is the first report that describes a relationship 
between tumor size and SDF-1α protein expression. 
 Substantial levels of sdf-1α gene transcripts were detected in s.c. tumors and metastases, 
but these were significantly less than sdf-1α transcripts in healthy tissues. The inconsistency in 
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the levels of sdf-1α gene transcript and SDF-1α protein could be attributed to the fact that 
regulation of SDF-1α expression occurs primarily at the protein level.  Sdf-1α mRNA has been 
reported to have a long half-life (282;282). The half-life of SDF-1α protein in circulation has 
been demonstrated to be less than one minute (246), its half-life in tissue is not known.  
It has been reported that the association of secreted SDF-1α with proteoglycans like 
heparan sulfate in extracellular matrix protected SDF-1α protein from degradation by proteases 
such as dipeptidyl peptidase IV (246;247). Dipeptidyl peptidase IV (DPP IV/CD26) is thought to 
be important in tumor biology (283;284). Human DPP IV has been shown to be ubiquitously 
expressed in epithelial and endothelial cells (285), and certain tumor cells (286-288). It must be 
noted that proteolytic enzymes are plentiful in necrotic areas of tumor (289), and that necrosis 
increases with tumor size. Most subcutaneous tumors are considerably larger than metastases, 
contain larger areas of necrosis, and contain greater amounts of certain proteases. Indeed, 
increase in dipeptidyl peptidases II and IV paralleling the increase in size of the subcutaneous 
tumors in tumor-bearing animals and in blood and solid cancers patients has been reported (290). 
Additionally, several matrix metalloproteinases (MMP) have also been reported to cleave SDF-
1α, rendering it unable to bind to CXCR4 (291). Elevated levels of MMPs have been associated 
with tumor progression (292) and shown to indirectly modulate vasculogenesis (69;293). This 
increase in necrosis and proteolytic enzymes in large tumors could have possibly resulted in the 
increased degradation of SDF-1α protein, resulting in the reduction of detectable SDF-1α protein 
in larger tumors. This data is partially supported by the fact that relatively higher amounts of sdf-
1α gene transcript were detected in s.c. tumors compared to metastases. Taken together, SDF-1α 
protein levels in tumors appear to be modulated by proteolytic enzymes, and likely correlate with 
hypoxia and/or necrosis. 
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The tumor endothelium is the first point of attachment for circulating endothelial 
progenitors (EPC) and lineage-negative bone marrow cells (Lin¯  BMC) in our model. Evaluating 
the differentially expressed/upregulated proteins on activated tumor endothelium would be 
important to understand the mechanism by which EPC/Lin¯  BMC adhered and incorporated into 
the tumor vasculature.  We hypothesized that SDF-1α was associated with the tumor-derived 
endothelial cell in vivo. By indirect immunofluorescent staining method, SDF-1α protein was 
observed throughout lung and liver sections from naïve control mice. In metastatic tissue 
sections, SDF-1α protein appeared to be concentrated within the metastatic lesions. In addition, 
SDF-1α protein was found to often colocalize with the vasculature in s.c. tumors and metastases 
(Figure 12). The association of SDF-1α with endothelial cells and extracellular matrix was most 
likely via heparan sulphates, which have been reported to be present on EC surface and ECM 
(243). Several investigators have provided evidence that SDF-1α played an important role in the 
reconstitution of bone marrow after sub-lethal radiation.  Lapidot et al. reported that SDF-1α 
adhered to bone marrow endothelium via heparan sulfate, and was critical for stem cells to be 
localized, arrested, and maintained within the marrow niche (294). E-selectin was also shown to 
be important for these events. If vasculogenesis was involved in tumor growth, the developing 
tumors would most likely need to provide a similar microenvironment for attracting the 
progenitor cells or Lin¯  BMC. Our results indicated that metastases were rich in SDF-1α, and 
that E-selectin and SDF-1α were present on tumor endothelium, thus creating a 
microenvironment for Lin¯  BMC to be recruited, retained, and incorporated into neovasculature.   
Tumor cells, stromal cells, infiltrating cells or activated endothelial cells could be the 
source of secreted SDF-1α protein that was associated with tumor endothelium. Quantitative RT-
PCR results suggested that endothelioma cells (surrogate for activated tumor endothelial cells) 
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expressed higher levels of sdf-1α gene transcripts compared to other cell types (3T3-L1 
preadipocytes, unstimulated vascular endothelial cells from healthy tissue, BMC and LLCaB 
tumor cells) tested. Overall, these data showed that SDF-1α was elevated in tumors and it was 
associated with the endothelium.  
 SDF-1α has been demonstrated to be a chemoattractant for lymphocytes and human 
CD34+ progenitors in vitro and in vivo (295;296). In addition, circulating SDF-1α has been 
implicated as a prognostic marker for cancer progression (231;297-301). However, we did not 
observe any difference in serum SDF-1α protein between healthy controls and s.c. tumor bearing 
mice (Figure 13). This is most likely due to the short half-life of circulating SDF-1α (246). We 
did not test for circulating CXCR4+ cells in naïve healthy mice and/or tumor-bearing mice, thus 
the putative role of SDF-1α in mobilizing CXCR4+ BMC in our model remains unclear.  
 Aghi et al. did not observe any increase in circulating CXCR4+ BMC in mice implanted 
with SDF-1α expressing glioma (62;302). In addition, no difference was observed in the plasma 
SDF-1α levels from mice implanted with tumors that expressed or did not express SDF-1α.  
Similarly, we have demonstrated the lack of increase in circulating serum SDF-1α in a lung 
adenocarcinoma model. It is also possible that there was indeed a transient increase in tumor-
derived SDF-1α and circulating CXCR4+ cells, and the CXCR4+ cells bound the circulating 
SDF-1α. CXCR4 has been reported to be rapidly internalized on binding SDF-1α (223), thus 
neither the increase in CXCR4+ cells nor the elevated SDF-1α levels were detected. In contrast, 
Madlambayan et al. (76) reported more than 2-fold increase in serum SDF-1α by day 7 post 
intramuscular injections of LLC tumor cells; serum SDF-1α was reported to decrease to basal 
levels by day 13 with the tumor still intact. They did not report any parallel data about change in 
circulating CXCR4+ BM-derived cells. Since most of our blood samples were collected at least 
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15 days after subcutaneous injection of LLCaB tumors, we may have missed increased serum 
levels associated with early phases of tumor development.  
One of our novel observations was that SDF-1α in serum samples from the female mice 
was consistently lower compared to the male mice. This might be due to the fact that SDF-1α is a 
target for estrogen (303). This novel observation indicating a sex-based distinction in SDF-1α 
expression might be relevant in treating estrogen-dependent malignancies.  
 In Chapter III B, a series of in vitro adhesion assays were conducted to test our 
hypothesis that SDF-1α could act as a cell-cell adhesion molecule and was instrumental to the 
association of CXCR4+ Lin¯  BMC and endothelium in tumors. Before initiating these 
experiments, the protocol to isolate Lin¯  BMC was standardized. Endothelial progenitor cells 
(EPC) have been shown to be a subset of Lin¯  Sca1+cKit+ (LSK) population. Our data showed 
that LSK cells constituted less than 0.5% of total BMC (Figure 14) and predominantly (~85%) 
contained cells with phenotype consistent with endothelial progenitor cells, i.e. Lin¯  Sca1+cKit+ 
VEGFR2+ (Figure 15). This data was consistent with a previously published report (304). 
Additionally, we observed that ~80% LSK-BMC expressed CXCR4, a receptor for SDF-1α.  
Endothelial progenitor cells (EPC) /LSK cells could have been purified by positive 
selection of Sca1+cKit+ from Lin¯  BMC using antibodies as an alternative method. However, this 
would render the LSK cells coated with anti-cKit and anti-Sca-1 antibodies, which could cause 
stearic hindrance, interfere with cell-cell adhesion and complicate the interpretation of results. 
This could also alter the in vivo biodistribution of cells. Alternatively, it would be possible to 
culture Lin¯  BMC in vitro with growth factors to promote EPC differentiation. Several groups 
have successfully cultured Lin¯  BMC and have reported the expression of endothelial cell-
specific markers on these cells. However, progenitor cell culture is expensive and difficult, there 
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is a lack of standardized protocol for culturing Lin¯  BMC, and ex vivo-expanded cells might not 
accurately reflect the in vivo biology of mobilized Lin¯  BMC.  It was also possible to use a 
chimeric mouse model for studying in vivo mobilization and biodistribution of bone marrow 
derived cells. In the chimeric mouse model, bone marrow in host mice is depleted by radiation, 
and reconstituted by transplanting intact bone marrow from a transgenic mouse strain. This 
model would prove useful for understanding the role of different BM-derived cell lineages in 
tumor development. Often transgenic BMC detected in tumors have been reported to belong to a 
committed lineage i.e. CD11b+ cells that belonged to the granulocytic lineage (71;76;77) making 
it difficult to interpret if progenitor cells localized to tumors prior to differentiation or if 
differentiated cells from bone marrow were recruited to tumors.  In contrast, the detection of 
systemically injected stem cell populations in tumors ensures the progenitor phenotype of tumor-
localized cells.  
Because of these concerns, the use of Lin¯  BMC as EPC surrogates for in vitro and in 
vivo experiments was considered most practical. Additionally, in order to develop a cell-based 
vehicle to deliver site-specific therapy, it is important that cells satisfied certain basic criteria like 
1) simple harvesting procedure, 2) tolerance to ex vivo culture, 3) low risk of non-specific 
differentiation in vitro, 4) high transfectability, 5) adequate in vivo tropism, and 6) inability to 
generate a graft versus host immune response. Thus, exploring biolocalization of syngeneic stem 
cells in an immunocompetent animal model was essential. We chose to evaluate the mechanism 
by which adoptively-transferred syngeneic Lin¯  BMC localized to orthotopic and heterotopic 
tumors in a clinically relevant immunocompetent C57Bl/6 mouse tumor model. 
As discussed earlier, SDF-1α was expressed by a variety of cell types within tumors. To 
best reproduce the heterogeneous cell population in the tumor microenvironment, we dissociated 
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LLCaB tumors and cultured them in vitro. These tumor-derived cell cultures were designated 
Dissociated Tumor Cells (DTC). Expression of E-selectin and VEGFR2 were used to determine 
the percentage of tumor endothelial cells in cultured DTC, which gradually increased, peaked 
between 9-15 days in culture, and declined thereafter (Figure 16A). We predict that LLCaB-
derived VEGF might be responsible for the stimulation and proliferation of tumor endothelial 
cells in DTC cultures. Additionally, the commercial endothelial cell growth supplement in 
culture media could be responsible for the increase in endothelial cells. The ultimate decline in 
E-selectin+ and VEGFR2+ cells was most likely due to the fact that these endothelial cells were 
capable of only limited in vitro growth. The expression of SDF-1α gene transcript in all DTC 
cultures was found to be constant by RT-PCR (Figure 16B). In addition, by immunofluorescent 
staining, SDF-1α protein was observed to be co-localized with the cell membrane of DTC. In 
addition, approximately 35% E-selectin+ SDF-1α+ cells were observed in DTC cultures 
indicating that SDF-1α bound to tumor-derived endothelial cells (Figure 16C).  
For in vitro adhesion assays, monolayers of DTC, LLCaB (tumor cell line), bEnd.3 
(endothelioma cell line), VEC (unstimulated murine cardiac vascular endothelial cells), and 3T3-
L1 (pre-adipocyte cell line) were incubated with EGFP-Lin¯  BMC. The number and percentage 
of EGFP-Lin¯  BMC that adhered to each cell type was evaluated by manual enumeration on a 
fluorescent microscope and by flow cytometry. Results indicated that Lin¯  BMC preferentially 
adhered to DTC compared to all other monolayer cultures tested (Figure 17). Three-color flow 
cytometric evaluation for adhesion of Lin¯ Sca1+cKit+ (LSK) cells revealed that, although 
sizeable percentage of LSK cells adhered to naïve endothelial and endothelioma cells, the largest 
percentage of LSK cells bound to DTC (Figure 17). Blocking E-selectin on DTC cultures 
decreased the number of adhered Lin¯  BMC and LSK cells by 30%. When CXCR4 was blocked 
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on the Lin¯  BMC by either AMD3100 or anti-CXCR4 antibody, the adhesion of Lin¯  BMC 
decreased by an average of 50%. CXCR4 blocking by AMD3100 and anti-CXCR4 antibody 
reduced the adhesion of the LSK population by approximately 30% and 60% respectively 
(Figure 18). A significant number of control cell-type, CXCR4¯  dermal fibroblast, adhered to 
DTC and bEnd.3 monolayers. However, as expected, this adhesion of CXCR4¯  dermal 
fibroblasts to DTC cultures was not influenced by the presence of AMD3100.  These 
experiments demonstrated that SDF-1α acted as an adhesion molecule for Lin¯  BMC and LSK 
cells in tumors.  
As already mentioned, a significantly high percentage of LSK cells bound to bEnd.3 
cells. In the presence of CXCR4 blocking drug AMD3100, there was an 80% decrease in the 
number of LSK cells that adhered to bEnd.3 cultures (Figure 19). These data suggested that LSK 
cells preferentially adhered to cells of endothelial lineage. The affect of blocking CXCR4 on the 
adhesion of Lin¯  BMC to unstimulated resting vascular endothelial cells was not evaluated. 
Thus, no comment can made about preferential adhesion of Lin¯  BMC and/or LSK cells to 
activated tumor endothelial cells compared to normal endothelial cells.   
The Lin¯  BMC and LSK cell adhesion to DTC was not completely inhibited in presence 
of CXCR4 or E-selectin blocking agents for most cell types tested.  It must be noted that 
blocking would only be as efficient as the percentage of cells expressing E-selectin and CXCR4. 
On average about 45% of cells in DTC cultures expressed E-selectin. Approximately 30% of 
Lin¯  BMC expressed CXCR4 and ~80% of LSK cells expressed CXCR4. LSK population and in 
presence of AMD3100 the adhesion of LSK cells to endothelioma cells decreased by 80%, 
indicating an almost complete inhibition of the interaction between CXCR4 and SDF-1α. In 
addition, CXCR7, a second receptor for SDF-1α, could be playing a role in adhesion of bone 
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marrow-derived cells to tumor-derived cells. Although, AMD3100 has been reported to bind 
CXCR7, it appears to act agonist of CXCR7 {586}. Due to the lack of a commercially available 
anti-mouse anti-CXCR7 antibody and/or CXCR7-antagonist, we have not been able to evaluate 
the role of CXCR7 in adhesion of Lin- BMC or LSK to DTC.  In addition, it was possible that E-
selectin and SDF-1α acted together in a complementary fashion. However, we did not 
simultaneously block both CXCR4 and E-selectin in the same experiment, primarily due to the 
possible stearic hindrance that could interfere in cell-cell adhesion. It is also plausible that other 
cell adhesion molecules were involved in the adhesion of Lin- BMC and/or LSK to tumors. 
Nonetheless, taken together, these data suggested that Lin¯  BMC had a tendency to adhere to 
several cell types in tumors, and both SDF-1α and E-selectin mediated this interaction with DTC.  
Finally, in Chapter IV, data from in vivo studies were reported. For in vivo experiments, 
mice transgenic for the egfp-transgene were used as donors in adoptive transfer experiments 
because: 1) post-harvest biochemical labeling of cells would not be required, 2) bright 
fluorescent signals would help in detecting tissue-localized cells, and 3) the egfp-transgene 
would be inherited by all progeny cells, thus making long-term studies more feasible. In the early 
in vivo experiments, biolocalization of vascular endothelial cells (VEC) isolated from EGFP-
transgenic mice in wild-type C57Bl/6 mice with metastatic disease was evaluated by fluorescent 
microscopy (Figure 20). Although EGFP-VEC were specifically detected in metastases, 
evaluation of tissue sections was compromised by tissue autofluorescence and artifactual 
fluorescence. This prompted the development of a qPCR method to detect the egfp-transgene to 
quantitate the tissue-localized EGFP-transgenic cells (Figure 20). Overall, this methodology was 
accurate, objective and efficient, and detected as low as two egfp-transgenes (1 cell) in 200 ng of 
genomic DNA (~35,000 cells). 
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Earlier studies in our laboratory have shown that adoptively-transferred vascular 
endothelial cells (VEC) specifically localized to primary and metastatic tumors. This homing of 
VEC to tumors was mediated by E-selectin (Storey and Verbanac, unpublished data).  It was 
proposed that Lin¯  BMC, which were enriched for EPC might localize to tumors using a similar 
mechanism, with SDF-1α playing crucial roles in their recruitment and adhesion. Additionally 
we sought to test an “irrelevant” cell type (dermal fibroblast) as a control cell to evaluate if 
tumor-localization was specific to bone marrow-derived Lin¯  BMC.  
No EGFP-dermal fibroblast were detected in any subcutaneous tumors at 72 hours after 
systemic injection. EGFP-Lin¯  BMC were detected in only 1 of 7 s.c. tumors. However, in this 
mouse greater numbers of EGFP-Lin¯  BMC were detected in normal organs like lung, liver, 
heart, spleen, and kidney, compared to the s.c. tumor. Shinde et al. (60) have reported similar 
whole body biodistribution results, based on the detection of tissue-localized radioactively-
labeled Lin¯  BMC on a gamma counter. They concluded that stem cells were recruited in low 
levels to subcutaneously implanted LLC in syngeneic animals, but did not contribute directly to 
vasculogenesis. In our study, the low biolocalization of Lin¯  BMC to s.c. tumors could also be 
attributed to the fact that cells were injected into the caudal artery instead of the caudal vein. 
However, this theory could be disputed by the fact that EGFP-Lin¯  BMC were detected in other 
organs. Additionally, in earlier experiments EGFP-VEC injected via caudal artery were 
successfully detected in s.c. tumors. 
In contrast, in the metastatic model a significantly greater number of EGFP-Lin¯  BMC 
localized to metastatic tissues compared to adjacent tissue with no visible metastatic lesions and 
other normal organs like heart, and spleen. In addition, a significantly greater number of EGFP-
Lin¯  BMC were detected in metastases compared mice injected with EGFP-dermal fibroblast. In 
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this experiment, cells were administered via the caudal vein, and the lungs would be the first 
major organ that cells would encounter. To summarize, it is possible that the disparity in EGFP-
Lin¯  BMC localization to metastases compared to s.c. tumors data is partially due to the 
physiology and anatomy of the circulatory system. It is perhaps more likely that CXCR4+ Lin¯  
BMC preferentially localize to metastases that expressed higher levels of SDF-1α protein, but 
not the heterotopically implanted primary tumors with lower SDF-1α expression. 
Although a significantly high number of EGFP-Lin¯  BMC were detected in metastatic 
lesions 48-72 hours after injection, we also detected a substantial number of EGFP-Lin¯  BMC in 
other major organs that did not have visible metastases, particularly in kidneys (Figure 30 and 
31). Detection of EGFP-Lin¯  BMC in kidney samples could be because kidneys receive about 
20% of the total cardiac output (305;306) and are involved in blood clearance function. When 
Shinde et al. systemically injected stem cells into tumor-bearing mice, they did not detect any 
cells in the kidneys at 24 hours post-injection but identified about 5% of the injected cells at 72 
hours post-injection (60), suggesting that the increase of Lin¯  BMC in kidneys could be due to 
blood clearance. A time-course study must be conducted to evaluate the non-specific retention of 
Lin¯  BMC in healthy tissue. We are currently analyzing normal organs from the experiment 
where tissue samples were collected 7 days after administration of Lin¯  BMC. 
Bone marrow is one of the tissues that we have not evaluated for localized Lin¯  BMC 
after adoptive transfer. Bone marrow localization of adoptively-transferred BMC has been 
reported in many radiation chimera models, however Xie et al. have demonstrated that the 
transplanted BMC did not localize to the hematopoietic stem cell niche in bone marrow in mice 
whose bone marrow was not depleted by irradiation (304). 
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 The calculated total number of EGFP-cells detected from all organs analyzed from each 
mouse exceeded the number of EGFP-Lin¯  BMC that was injected. This could be due to the 
highly proliferative nature of stem cells. Murine stem cells have been reported to be have a 
doubling time that ranges from 12 to 41 hours (307;307-309;309). Thus, in 72 hours the cell 
number could multiply at least 2-64 fold. In a subsequent study, just completed, mice with 
metastatic disease were injected with EGFP-Lin¯  BMC, and tumor-localization of adoptively-
transferred cells was evaluated 7 days later. In this group, the number of egfp-transgenes/µg 
DNA detected at 7 day was ~3X greater than that detected by 3 day (Figure 32). This increase in 
number of Lin¯  BMC at 7 day indicates retained and/or proliferating cells.    
While this dissertation was in preparation, Madlambayan et al. published a similar report 
showing that BM-derived stem and progenitor cells contributed to neovasculogenesis, and that 
“SDF-1α was a permissive trigger for BM recruitment to sites of neovascularization” (76). Their 
studies were conducted in a single mouse model with multiple neovascularization (Ischemic 
retinal injury, Lewis lung carcinoma, and B16 melanomas tumors). Although, this model was 
intriguing, it must be noted that tumor is a systemic disease and could potentially influence the 
BM-mediated ischemic repair and tumor growth in such a dual model system, and/or create 
competing sites. Nonetheless, they illustrated that the greatest BMC homing was detected in 
ischemic retinas, compared to intra-muscular Lewis lung carcinoma and B16 melanomas. This 
BMC recruitment was demonstrated to be dependent on site-specific expression of SDF-1α and 
CD133+CXCR4+ myeloid progenitor cells were reported to directly participate in new blood 
vessel formation. The abrogation of BM-derived neo-vascularization in heterotopic LLC and 
retinopathy by blocking SDF-1α activity with neutralizing antibodies was also demonstrated by 
immunohistochemistry. Thus, they concluded that active sites, which expressed SDF-1α, were 
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prone to BM involvement and underwent vasculogenesis whereas vascularization was mediated 
by a non-BM-derived mechanism in the other sites.  
Our results reiterate similar findings.  We observed that tumor localization of Lin¯  BMC 
was greater in mice with only metastatic lesions (with high SDF-1α levels), than in mice bearing 
only primary subcutaneous tumors. A greater number of Lin¯  BMC localized to metastatic 
tissues compared to adjacent tissue with no visible metastatic lesion and other normal organs like 
heart, spleen, and kidney. Moreover, significantly fewer CXCR4¯  EGFP-dermal fibroblasts 
localized to the metastases. Furthermore, data from in vitro experiments showed that adhesion of 
Lin¯  BMC and endothelial progenitors to the tumor microenvironment was mediated by SDF-1α. 
Thus, it appears that SDF-1α might be a key regulator in facilitating adhesion and retention of 
Lin¯  BMC in metastases.  
A 2010 report by Kioi et al. demonstrated that irradiation caused a HIF-1-dependent 
increase in SDF-1α expression, and influx of bone marrow-derived cells in murine glioblastomas 
(77). This mechanism was shown to be responsible for tumor recurrence. CD11b+Tie2+ bone 
marrow-derived cells, also known as Tie2-expressing monocytes (TEM), were the predominantly 
detected cells in tumors and tumor vasculature. Endothelial progenitors were not involved in 
tumor vasculogenesis, and there was no difference in tumor recurrence in the presence of 
VEGFR2-blocking antibody treatment. However, pharmacological inhibition of HIF-1 or SDF-
1α/CXCR4 interaction prevented the influx of bone marrow-derived CD11b+ myelomonocytes, 
inhibited post-radiation vascularization, and abrogated tumor re-growth. Similarly, Ahn et al. 
had reported earlier that tumor-infiltrating bone marrow cells were predominantly MMP9-
expressing CD11b+ and contributed to vasculogenesis. Genetic ablation of MMP-9 reduced 
tumor growth and vascularization in B16 melanoma, Lewis lung, and mammary carcinoma 
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models (69). Our data showed the biolocalization of bone marrow-derived cells that were 
depleted of lineage-committed cells, including CD11b+ cells. Nonetheless, it is possible that 
lineage-negative progenitors could differentiate into CD11b+ cells and participate in 
vasculogenesis in mechanism similar to that described by Kioi and Ahn.  
In summary, this research was conducted in a clinically relevant metastatic murine 
model. Quantitative PCR assay was used to objectively enumerate the biodistribution of 
transgenic cells and it enabled comprehensive analysis of tissue samples. A distinction of our 
study is the use of dermal fibroblast cells as a control cell type in the in vitro and the in vivo 
experiments. As fibroblasts are considerably more adherent compared to bone marrow-derived 
cells, they acted as a more stringent control. We have also addressed the mechanistic interaction 
between the bone marrow-derived cells and tumor cells in a series of in vitro assays, which 
appears to corroborate with in vivo data. Nonetheless, interpretation of results from the in vivo 
experiments was limited due to the use of heterogeneous lineage-negative bone marrow and 
small sample sizes. In addition, experiments with in vivo blocking of CXCR4 remain to be 
performed. Subsequently, the phenotype of the tumor-localized lineage-negative BMC needs to 
be analyzed. Additionally, evaluation of the incorporation of these adoptively-transferred bone 
marrow cells into the developing tumor blood vessels will help understand their role in 
vascularization, and analysis of proliferation markers would help in evaluating their long-term 
retention potential. 
 
CHAPTER VI: SIGNIFICANCE 
The mechanism by which tumor cells colonize, vascularize, and metastasize must be 
understood to aid in the design of effective anti-cancer therapies. It is also important to identify 
the proteins that might participate in this process. Moreover, evaluating these mechanisms in a 
model that mimics clinical scenario is essential. We have shown that the murine LLCaB tumor 
model recapitulated human cancer development closely. A novel tumor size-specific role for 
SDF-1α has been proposed in this dissertation. If SDF-1α was important for the development of 
vascularized metastases, early intervention to block SDF-1α could prove to be an effective 
therapy in controlling tumor proliferation. In addition, there is a growing body of evidence that 
bone marrow-derived cells might be recruited to tumors in a SDF-1α-modulated manner. Results 
from our group and others suggest that SDF-1α could be an important trigger for a tumor-
recruited endothelial progenitor-mediated “angiogenic switch”. Inhibiting the tumor localization 
of BM-derived cells could be utilized to restrict tumor proliferation and this strategy could be 
developed into a cancer-restricting therapy. As with the current anti-angiogenic strategies found 
to be effective clinically to date, strategies to block vasculogenesis via SDF-1α/CXCR4 targeting 
are almost certain to be used as adjuvant therapy to standard chemotherapy or hormonal therapy 
drugs that directly target the tumor cells. 
Understanding the phenotype of progenitor cells that preferentially localize to specific 
tumor types and techniques to efficiently deplete these cells could be used as anti-cancer 
treatments.   If CXCR4+Lin¯  BMC preferentially localized to SDF-1α-expressing tumors, then 
these cells could be used to deliver specific therapy to tumors that are otherwise inaccessible. In 
addition, the interaction between SDF-1α in certain organs and CXCR4+ tumor cells has been 
revealed crucial for organ-specific metastasis in animal models. Currently there are two clinical 
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trials evaluating the role of SDF-1α/CXCR4 in cancer patients; both these trials are investigating 
the role of SDF-1α/CXCR4 in the metastatic process. Nonetheless, with the emerging 
multifaceted functions of SDF-1α in tumor biology it appears that inhibition of SDF-1α could be 
used to not only restrict the metastatic process per se, but to tumor vasculogenesis and 
angiogenesis.   
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